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Abstract 	
 Described originally in plants, disease tolerance is a defense 
strategy against infection, which protects the host by sustaining 
homeostasis without exerting a direct negative impact on pathogens. 
This is enforced by a myriad of stress and damage responses 
conferring tissue damage control and preventing “damage to 
functions and structures”, fully operational in animals, including flies, 
mice and humans.  
Production of cytotoxic levels of reactive oxygen species (ROS) is 
a common resistance mechanism against infection as it mediates 
pathogen killing. However, there is a clear trade-off in the activation 
of this defense strategy in that ROS can lead to oxidative stress in 
host parenchymal cells, eventually leading to programmed cell 
death, tissue dysfunction and damage. The stress response to 
oxidative insults is mastered by the transcription factor Nuclear 
Factor E2-Related Factor-2 (NRF2). Under homeostasis, NRF2 
binds to the Kelch-like ECH-associated protein 1 (KEAP1), a redox 
sensor constitutively associated with the Cul3–Rbx1 E3 ubiquitin 
ligase complex, which ubiquitinates and targets Nrf2 for degradation 
by the 26s proteasome. Oxidative stress impairs KEAP1 binding to 
the Cul3–Rbx1 complex, sparing NRF2 from degradation and 
allowing for the de novo synthetized NRF2 to undergo nuclear 
translocation. Inside the nucleus, this transcription factor binds to 
Antioxidant Responsive Elements (AREs), promoting the 
transcription of genes encoding for cytoprotective proteins mediating 
metabolic adaptation and detoxification, allowing the return to 
homeostasis. 
Bloodstream infections are associated with varying levels of 
hemolysis and therefore with the generation of extracellular 
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hemoglobin, which releases its heme prosthetic groups upon 
oxidation. When released from extracellular oxidized hemoglobin, 
labile heme can sensitize parenchyma cells to undergo programmed 
cell death in response to a variety of inflammatory agonists, such as 
Tumor Necrosis Factor (TNF). This deleterious effect is driven to a 
large extent by the generation of ROS, leading to mitochondrial 
dysfunction and programmed cell death. As a consequence, 
released Damage Associated Molecular Patterns (DAMPs) from 
damaged tissues sustain inflammation and cellular stress. Many of 
these pathogenic effects are countered by the stress-response 
regulated by NRF2 and involve the expression of a variety of effector 
genes, including the heme-catabolizing enzyme HO-1 (Heme 
Oxygenase-1) and the iron sequestering protein Ferritin Heavy 
Chain (FtH), which are essential to establish disease tolerance to 
bloodstream infections. 
In this PhD thesis we hypothesized that the mechanism via which 
the stress-response regulated by NRF2 confers tissue damage 
control and establishes disease tolerance to bloodstream infections 
involves the inhibition of programmed cell death by necroptosis. 
Here, we demonstrate that NRF2 is activated in response to labile 
heme both in vivo and in vitro, and protects parenchyma cells from 
undergoing necroptosis triggered by heme and TNF. This protective 
effect is mediated by a mechanism preserving mitochondrial function 
downstream of the signal transduction pathway comprising 
Receptor-Interacting serine/threonine-Protein Kinase 1 (RIPK1), 
Receptor-Interacting serine/threonine-Protein Kinase 3 (RIPK3), 
Mixed lineage kinase domain like pseudokinase (MLKL) and 
Phosphoglycerate Mutase Family Member 5 (PGAM5). In the 
specific case of Plasmodium infection, this cytoprotective effect also 
targets the participation of Cyclophilin D (CYPD), presumably on the 
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regulation of the mitochondrial permeability transition pore (MPTP) 
leading to necrosis.  
Our work demonstrates that NRF2 is essential to confer tissue 
damage control and establish disease tolerance to bloodstream 
infectious diseases associated with hemolysis, such as malaria and 
sepsis. We propose that manipulation of signal transduction 
pathways that modulate the cellular redox status might unravel a 
general mechanism for tissue damage control and disease tolerance 
in different inflammation models accompanied by the accumulation 
of labile heme. 
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Sumário 	
 Descrita originalmente em plantas, a tolerância à doença é uma 
estratégia de defesa contra infecções que protege o hospedeiro 
através da manutenção da homeostasia sem exercer qualquer efeito 
negativo directo nos agentes patogénicos. Esta estratégia é 
reforçada por uma miríade de respostas ao stress e dano, 
conferindo controlo de danos no tecido e prevenindo “danos a 
funções e estruturas”, encontrando-se integralmente operacional em 
animais, incluindo moscas, ratinhos e humanos. 
 A produção de níveis citotóxicos de espécies reactivas de 
oxigénio  é uma estratégia comummente utilizada como parte de um 
mecanismo de resistência contra infecções, na medida em que 
contribui para a morte do agente patogénico. Porém, existe um claro 
trade-off na activação desta estratégia de defesa uma vez que as 
espécies reactivas de oxigénio induzem stress oxidativo, culminando 
na disfunção e dano tecidular. A resposta a stress induzida por 
agentes pro-oxidantes é regulada pelo factor de transcrição Nuclear 
Factor E2-Related Factor-2 (NRF2). Em condições de homeostasia, 
esta proteína liga-se ao Kelch-like ECH-associated protein 1 
(KEAP1), um sensor redox constitutivamente associado ao 
complexo Cul3–Rbx1 E3 ubiquitin ligase, levando à ubiquitinação do 
NRF2 e ao seu direccionamento para degradação pelo proteasoma 
26s. O stress oxidativo impede a ligação do KEAP1 ao complexo 
Cul3–Rbx1 e permite que o NRF2 sintetizado de novo seja 
translocado para o núcleo. Uma vez no núcleo, o NRF2 liga-se ao 
um grupo de promotores denominados Elementos de Resposta 
Antioxidante, promovendo a transcrição de genes codificantes para 
proteínas citoprotectoras responsáveis pela adaptação metabólica e 
detoxificação do sistema, promovendo o retorno à homeostasia.  
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 Infecções da corrente sanguínea estão associadas a diferentes 
graus de hemólise e, por conseguinte, à acumulação de 
hemoglobina no meio extracelular, o que promove a sua oxidação e 
libertação dos seus grupos prostéticos (heme). Quando libertado da 
hemoglobina extracelular oxidada, o heme lábil pode induzir a morte 
celular programada de células do parênquima, quando na presença 
de agonistas inflamatórios como o Tumor Necrosis Factor (TNF). 
Este efeito deletério é promovido maioritariamente pela geração de 
espécies reactivas de oxigénio, o que leva à disfunção mitocondrial 
e morte celular programada. Como consequência, a libertação de 
Damage Associated Molecular Patterns (DAMPs) dos tecidos 
lesados sustém a inflamação e stress celular. 
 Os efeitos deletérios do heme lábil são contrabalançados pela 
resposta ao stress mediada por NRF2, envolvendo a expressão de 
genes efectores incluindo o gene que codifica para HO-1 (Heme 
Oxygenase-1) e para a proteína sequestradora de ferro FtH (Ferritin 
Heavy Chain), cujas funções foram já associadas ao 
estabelecimento de tolerância à doença em infecções da corrente 
sanguínea. 
 A nossa hipótese neste trabalho é que o mecanismo através do 
qual a resposta a stress mediada por NRF2 confere controlo de 
danos no tecido e estabelece tolerância a infecções da corrente 
sanguínea envolve a inibição da morte celular programada, 
particularmente através da via de necroptose. Os nossos resultados 
demonstram que o NRF2 é activado em resposta ao heme lábil 
tanto in vivo como in vitro e protege as células parênquimais de 
sofrerem necroptose em resposta ao efeito sinergístico do heme 
com o TNF. O nosso trabalho revela que a protecção conferida pelo 
NRF2 assenta num mecanismo que preserva a função mitocondrial 
downstream à via de sinalização que inclui as proteínas Receptor-
Interacting serine/threonine-Protein Kinase 1 (RIPK1), Receptor-
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Interacting serine/threonine-Protein Kinase 3 (RIPK3), Mixed lineage 
kinase domain like pseudokinase (MLKL) e Phosphoglycerate 
Mutase Family Member 5 (PGAM5). No caso específico da infecção 
causada por Plasmodium, o efeito citoprotector do NRF2 também 
tem como alvo a proteína Cyclophilin D (CYPD) e, presumivelmente, 
a modulação da transição de permeabilidade mitocondrial (MPTP) e 
a indução de necrose.  
 O nosso trabalho demonstra que o NRF2 é essencial para o 
controlo de danos no tecido e para estabelecer tolerância à doença 
no contexto de infecções da corrente sanguínea associadas a 
hemólise, como a malária e a sépsis. Assim, propomos que a 
manipulação das vias de transdução de sinal que modulam o estado 
redox das células poderá deslindar um mecanismo geral de controlo 
de danos no tecido e tolerância à doença em diferentes modelos de 
inflamação associados a condições de hemólise.  
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Chapter 1: 
Introduction 
 
 
 
 
 
 
 
 
“In the face of such hopelessness as our eventual, 
unavoidable death, there is little sense in not at least 
trying to accomplish all of your wildest dreams in life.” 
(Kevin Smith) 
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1.1. Inflammation and the breakdown of homeostasis 
 It was more than 200 years ago, in the 19th century, when the 
idea of a stable internal environment first arose. Claude Bernard 
coined the term milieu interieur referring to biological processes 
present in all living beings, which maintain steady states despite 
variations in the external environment1. This concept was further 
explored by Walter Cannon, who crafted the term homeostasis as 
the equilibrium or stability in biological systems via maintenance of 
key physiological variables by feedback mechanisms2. Cannon 
classified any living being as an open system with automatic reactive 
mechanisms used to correct large fluctuations, thus maintaining 
each homeostatic category within narrow and constant limits2. 
 The steadiness of the internal milieu is constantly subjected to 
different threats while the organism interacts with its environment. As 
such, organisms evolved adaptive responses to exogenous cues 
such as microbes or allergens and endogenous signals like the ones 
produced by stressed, damaged or malfunctioning tissues3. 
Inflammation refers to the adaptive responses which aim primarily at 
identifying and eliminating the source of insult, followed by repair of 
the damage caused in this process, as a means to reestablish an 
homeostatic state4. In the particular case of infection, i.e., invasion of 
an organism by a disease-causing microbe, the physiological 
purpose of inflammation is to defend the host by neutralizing and 
eliminating pathogens while triggering a tissue repair program to 
ultimately restore homeostasis3.  
 
1.2. Host defense strategies against infection 
 It is traditionally thought in the field of immunology that the best 
approach for a host to counter infection is by neutralizing, killing 
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and/or eliminating the infectious agent. This host defense strategy, 
commonly known as resistance to infection, aims at protecting the 
host by activating a number of immune-mediated mechanisms that 
act directly on invading microorganisms5.  
 The negative impact of infectious diseases is countered, not only 
by the host´s capacity to limit pathogen burden, but also by its ability 
to tolerate the presence of pathogens, limiting their deleterious effect 
on host tissues6. This defense strategy that protects the infected host 
without interfering directly with the pathogen is named disease 
tolerance and is recognized as a distinct evolutionarily conserved 
mechanism in host-microbe interactions5. 
 Immune driven resistance mechanisms likely coevolved with 
disease tolerance mechanisms, acting in a concerted manner to limit 
disease severity and maintain host homeostasis. Resistance carries 
a significant trade off as it can impose collateral damage to the host 
tissues (immunopathology), eventually increasing host morbidity 
and/or mortality. As such, disease tolerance plays a major role in 
counteracting the negative impact of host immunity as well as the 
direct deleterious effects of pathogens in host tissues5,7 (Figure 1.1). 
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Figure 1.1. Disease tolerance to infection acts in two distinct 
ways.  
Both pathogens and the immune response to infection can damage host 
tissues. Disease tolerance mechanisms protect the host from these two 
different forms of stress (Adapted from Medzhitov et al., 2012).  
 
 
1.2.1. Disease tolerance and tissue damage control 
 Disease tolerance relies on tissue damage control mechanisms 
that encompass stress and damage responses, which act in a 
concerted manner to preserve the functional integrity of host tissues, 
thus preventing the collapse of homeostasis8. 
 
Figure 1.2. Tissue damage control in host-microbe 
interactions.  
Two major classes of molecules can initiate inflammation: PAMPs and 
DAMPs. The later include mitochondrial components, heme, DNA, histones 
or other DNA binding proteins such as HMGB1, released to the extracellular 
space due to cytotoxicity imposed directly by pathogens (through toxins, for 
example) and/or by inflammatory mediators (immunopathology). This 
causes different types of stress to parenchyma cells, eventually leading to 
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programmed cell death and tissue damage, culminating in host death. 
Tissue damage fosters further DAMP release, which sustains the 
inflammatory response. This positive forward pathologic loop is mitigated by 
the activation of specific stress and damage responses that confer tissue 
damage control via metabolic adaptation, cytoprotection and repair as part 
of a disease tolerance strategy. 
 
 Inflammatory responses to infection are initiated and perpetrated 
through the recognition of pathogen-derived molecules [Pathogen 
Associated Molecular Patterns (PAMPs)] or molecules derived from 
damaged or dead host cells [Damage Associated Molecular Patterns 
(DAMPs)] by pattern recognition receptors (PRR)9 (Figure1.2). 
These correspond to intracellular components such as nuclear and 
mitochondrial DNA, purine nucleotides (i.e., ATP, UTP), High-
Mobility Group Box 1 (HMGB1) and mitochondrial N-formyl peptides, 
released upon plasma membrane disintegration, typical of necrotic 
cell death10. DAMP release induces an inflammatory response, 
which imposes stress to parenchyma cells, i.e., host cells that do not 
exert a direct negative impact on pathogens7 (Figure 1.2). This is 
countered by the activation of specific stress and damage responses 
that confer tissue damage control by providing metabolic adaptation, 
cytoprotection and repair of damaged cells and tissues, as part of a 
disease tolerance strategy against infection (Figure 1.2)7. 
 
1.2.2. Stress responses underlying tissue damage control 
 Stress responses are triggered by sensors that respond to 
environmental cues whose variations can interfere with cellular 
homeostasis via, for example, deregulation of redox status, 
osmolarity, oxygen tension and metabolite concentration, among 
others8. The outcome of stress responses is metabolic adaptation, 
which allows the maintenance of core cellular processes at the 
expense of accessory ones, assuring cellular, tissue and organ 
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function under different types of stress8. This is achieved through the 
expression of immediate-early response genes regulated by specific 
transcription factors known as master regulators of stress 
responses8. In this section, I emphasize the association between the 
oxidative stress response orchestrated by NRF2, the main focus of 
this thesis, and other stress responses, mainly in the context of 
disease tolerance to infection. 
 
The oxidative stress response  
 Oxidative stress resulting from the accumulation of Reactive 
Oxygen Species (ROS) has been widely implicated in the 
pathogenesis of infectious diseases11,12. ROS are compounds that 
have chemically reactive oxygen-containing functional groups with of 
one or more unpaired electrons, which renders these compounds 
highly unstable13. In the context of infection, innate immune cells 
produce ROS as part of a resistance strategy promoting the 
elimination of pathogens. However, the generation of these highly 
reactive compounds leads to oxidative stress on host cells, 
eventually leading to tissue damage, organ dysfunction and 
disease5. 
 Oxidative stress is countered by the activation of an adaptive 
cellular response pathway induced by the transcription factor NRF2 
and leading to the expression of a battery of genes with anti-oxidant 
and detoxifying properties14,15,16. Consistent with this notion, levels of 
ROS in NRF2-deficient cells are elevated when compared to wild-
type cells17. This difference becomes even more significant upon 
exposure to pro-oxidants18 and is directly linked to impaired 
activation of antioxidant programs countering the deleterious effects 
of ROS19. One of the mechanisms via which NRF2 protects against 
oxidative stress involves the expression of both catalytic and 
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regulatory subunits of γ-glutamyl cysteine ligase, the enzyme 
catalyzing the rate-limiting step in glutathione biosynthesis20. 
Glutathione is an evolutionarily conserved antioxidant, which in its 
reduced form (GSH) prevents ROS-mediated damage to cellular 
components, such as caused by the accumulation of free radicals, 
peroxides, lipid peroxides or heavy metals21. Moreover, the xCT 
subunit of xc-, the system that imports cystine into cells, i.e. a 
precursor of glutathione, is also a transcriptional target for NRF220. 
GSH levels are maintained by glutathione reductase 122, another 
transcriptional target for NRF2 that reduces oxidized glutathione 
(GSSG) to GSH using reducing equivalents from Nicotinamide 
Adenine Dinucleotide Phosphate (NADPH). Together, these data 
probably explain why levels of GSH are lower in NRF2-deficient cells 
as compared to wild type cells, while intracellular GSH accumulates 
following NRF2 activation23,24.  
 NRF2 also regulates the expression of thioredoxin (TRX1)23,25 and 
sulfiredoxin (SRXN1)26, essential proteins for the reduction of 
oxidized thiol groups16. Additionally, NADPH-generating enzymes 
such as Glucose-6-Phosphate Dehydrogenase (G6PD) and drug 
metabolizing enzymes that require NADPH as a cofactor, namely 
NAD(P)H Quinone Dehydrogenase 1 (NQO1) and thioredoxin 
reductase 1 (TXNRD1) are also regulated by NRF227,28.  
Upon infection, engagement of PRRs by PAMPs activates NRF2 
in innate immune cells such as monocytes/macrophages (Mø). For 
instance, lipopolysaccharide (LPS) recognition by Toll-Like Receptor 
4 (TLR4) triggers the transcription/expression of the inducible form of 
nitric oxide synthase (iNOS/NOS2), via a mechanism involving the 
adaptor molecule Myeloid differentiation primary response gene 88 
(Myd88) and the transcription factor nuclear factor kappa B (NF-
κB)29. The TLR4–MyD88–NF-κB signal transduction pathway also 
triggers the transcription/expression of the phagocytic NADPH 
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oxidase (NOX2/gp91phox), leading to the generation of intracellular 
superoxide (O2.−) anions30. The NO produced through iNOS activity 
reacts with O2− and produces peroxinitrate (ONNO−) anions, which 
targets several thiol-based (S-H) redox systems, including reactive 
cysteines in the Kelch-like ECH-associated protein 1 (KEAP1)16,31,32 
(Figure 1.3), an adaptor for the cullin (Cul)3– RING (really interesting 
new gene)-box protein (Rbx)1 ubiquitin ligase complex16. This 
protein acts as a repressor of NRF2 activation under homeostasis, 
as it constitutively targets this transcription factor for proteolytic 
degradation by the 26s proteasome16 (Figure 1.3).  
Upon oxidative stress, some of the reactive cysteines of KEAP1, 
(Cys151) are targeted by ONNO−, generating thiol oxidation products 
and ultimately forming disulfide (S-S) bonds33. These alter the 
tertiary structure of Keap1, inhibiting its ubiquitin ligase activity and 
hence NRF2 ubiquitination/degradation16,31,32. The newly transcribed 
NRF2 undergoes nuclear translocation and binds to small 
musculoaponeurotic fibrosarcoma (sMaf) transcription factors, 
including MafF, MafG and MafK34, driving the transcription of NRF2-
responsive genes containing AREs in their promoter16 (Figure 1.3).  
It is now clear that other E3 ubiquitin ligase complexes contribute 
to integrate NRF2 activation within different forms of cellular stress16. 
These include the Skp1 (S-phase kinase-associated protein 1)–
Cul1–F-box (SCF)–β-transducin repeats-containing proteins (β-
TrCP) complex (SCFβ-TrCP)35, which recognizes the Neh6 (NRF2-
ECH homology 6) domain of NRF2 when phosphorylated by the 
Glycogen Synthase Kinase 3β (GSK3β)35. NRF2 phosphorylation at 
the Neh6 domain allows for coupling of different forms of stress 
sensed by GSK3β with NRF2 ubiquitination by the SCFβ-TrCP 
complex and its degradation by the 26s proteasome16,35 (Figure 1.3). 
The HMG (high mobility group)-coA reductase degradation 1 (HRD1) 
E3 ubiquitin–protein ligase involved in endoplasmic reticulum-
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associated protein degradation (ERAD) also controls NRF2 
activation36. Hrd1 targets the Nhe4–5 domain of NRF2 for 
ubiquitination and degradation by the 26s proteasome36 (Figure 1.3). 
How Hrd1 acts in the context of other components of the 
endoplasmic reticulum stress response, such as the protein kinase 
RNA-like ER kinase 1 (PERK1)37, to regulate NRF2 is not clear.  
It is worth noting that NRF2 activity is controlled to a large extent 
by its rate of transcription/expression (Figure 1.3). This is regulated 
by several transcription factors including NF-κB16 and NRF2 itself, as 
well as clock components that impose a circadian control to NRF2 
activity38 (Figure 1.3). Presumably, this is required to sustain NRF2-
dependent gene expression. 
 
Figure 1.3. Control of NRF2 activation by different E3 
ubiquitin ligase complexes.  
When no longer targeted for degradation by E3 ubiquitin ligase complexes, 
NRF2 activity is controlled mainly by its rate of transcription, with newly 
transcribed NRF2 regulating gene expression. It is the Keap1–Cul3–Rbx1, 
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Hrd1 E3 ubiquitin ligase and SCFβ-TrCP complexes, however that 
underlies the stress responsive nature of NRF2 activity (From Soares & 
Ribeiro, 2015). 	
 Upon infection, NRF2 acts in different cellular components to 
modulate both resistance and tolerance to specific pathogens 
(Figure 1.4). Perhaps the best demonstration that NRF2 modulates 
host resistance to infection is provided by the observation that 
deletion of Nrf2 in mice increases viral clearance upon Marburg virus 
infection39. This effect is mediated by the Marburg virus encoded 
VP24 protein, which binds the Kelch domain of Keap1 and inhibits 
the ubiquitin ligase activity of the Keap1–Cul3–Rbx1 complex, hence 
inducing NRF2 activation39,40. Several other observations are 
consistent with the notion that viruses induce host NRF2 activation in 
vitro, as suggested for Kaposi’s sarcoma-associated herpes virus41, 
as well as for Influenza42,43 and Dengue44 viruses. However, the 
pathophysiologic relevance of these observations remains to be 
elucidated. Conversely, viruses such as hepatitis C virus, down-
regulate NRF2 activation via a mechanism impairing its nuclear 
import through delocalization of sMaf proteins45. The impact of this 
phenomenon to the outcome of hepatitis C virus infection is also not 
clear. 
 Intracellular bacteria also modulate NRF2 activation, as 
demonstrated for Salmonella typhimurium infection in Mø46. NRF2 
activation enforces the transcription/expression of Ferroportin-1 
(Fpn-1), an iron exporter that decreases iron cellular content46. This 
limits Salmonella access to iron, restraining the proliferation of this 
intracellular pathogen46. Whether NRF2 acts under pathophysiologic 
conditions to promote resistance to Salmonella infection is likely, but 
this remains to be formally demonstrated. Furthermore, 
pharmacologic induction of NRF2 by sulforaphane promotes 
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resistance to Pseudomonas aeruginosa47 as well as to Plasmodium 
infection in mice48.  			
	
 
 
 
Figure 1.4. Outcomes of NRF2 activation.  
Upon infection , activation of NRF2 in cellular components of the immune 
system acts in an immunoregulatory manner, modulating resistance to 
infection. Activation of NRF2 in parenchyma tissues provides tissue 
damage control and disease tolerance to infection. Control of NRF2 
activation is illustrated in the context of a generic E3 ubiquitin ligase 
complex, detailed under Figure 1.3 (From Soares & Ribeiro, 2015). 		
 The NRF2 signal transduction pathway was co-opted to confer 
tissue damage control and disease tolerance to systemic 
infections15. This is particularly important for Plasmodium infection 
(the causative agent of malaria), where the blood stage of the 
disease is associated with hemolysis and consequent accumulation 
of extracellular hemoglobin in plasma49. Upon oxidation, extracellular 
hemoglobin releases its heme prosthetic groups, a structure 
composed of a tetrapyrrole ring surrounding a single iron (Fe) atom, 
leading to the unfettered generation of ROS49.  
 ROS and contributes to oxidative stress and cellular damage to 
host parenchyma tissues, eventually compromising host 
homeostasis and driving the pathogenesis of severe forms of 
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malaria49. The pathophysiologic relevance of this pathway is 
highlighted by the finding that mutations in the β-chain of hemoglobin 
(sickle hemoglobin) establish disease tolerance to the blood stage of 
Plasmodium infection via a mechanism that relies on the induction of 
NRF2-dependent HO-1 expression50. This enzyme catalyzes the 
degradation of heme via cleavage of its protoporphyrin IX ring, giving 
rise to biliverdin, then converted to the salutary antioxidant bilirubin, 
the cytoprotective CO and equimolar amounts of labile Fe2+ 51. 
Whether this cytoprotective mechanism explains how sickle 
hemoglobin protects humans from malaria remains to be 
established, but is likely to be the case based on recent evidence 
from a human cohort52. 
 Similarly, nitric oxide (NO) suppresses the pathogenesis of severe 
forms of malaria through a mechanism involving the induction of HO-
1 via NRF2 and establishing disease tolerance to malaria53. This 
protective effect arises via NO-driven NRF2 activation53, presumably 
through mechanisms targeting Keap1 at Cys15116,54. NRF2 
activation induces heme catabolism by HO-1, generating CO55, a 
gasotransmitter shown to establish disease tolerance to malaria53. 
This occurs via the binding of CO to the prosthetic heme group of 
cell free hemoglobin, preventing heme from participating in the 
pathogenesis of Plasmodium infection50,53,56.  
 Presumably, the mechanism via which NRF2 confers tissue 
damage control and establishes disease tolerance to malaria also 
involves the expression of Ferritin Heavy Chain (FtH). This regulator 
of iron metabolism is also regulated at a transcriptional level via the 
activation of NRF257,58 and was demonstrated to play a crucial role in 
the establishment of disease tolerance to malaria59. 
 There is circumstantial evidence to suggest that NRF2 confers 
disease tolerance to systemic infections, other than malaria. Namely, 
NRF2 is protective against endotoxic shock60, severe sepsis 
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triggered by polymicrobial infection60 and lung injury induced by 
Staphylococcus aureus infection61 in mice. These salutary effects 
have been associated mainly with immunoregulation, although there 
is no clear evidence demonstrating a role for NRF2 in the modulation 
of pathogen load under these specific experimental settings60.  
 In my thesis I demonstrate that NRF2 prevents the lethal outcome 
of malaria and polymicrobial sepsis in mice, without interfering with 
pathogen load. This shows that NRF2 does confer disease tolerance 
to infection via the induction of tissue damage control mechanisms 
when activated in parenchyma cells or presumably acting as an 
immunoregulatory transcription factor in innate immune cells, 
although this remains to be fully established. 	
NRF2 and the hypoxia stress response 
 Hypoxia refers to a pathophysiological condition in tissues where 
the O2 concentration is lower than homeostatic levels (normoxia) due 
to either failure in delivery or use of O262. Alterations in O2 tension 
modulate cell function by affecting intracellular NADPH levels, 
protein kinases, ion channels and antioxidant defenses63. The 
transcription factor Hypoxia Inducible Factor 1 alpha (HIF-1α) is the 
master regulator of the hypoxia stress response, leading to most 
changes in gene expression that allow adaptation to prolonged low 
oxygen tension64. 
 Hypoxia is sensed by the prolyl hydroxylase (PHD2), which uses 
O2 to hydroxylate two proline residues in HIF-1α65. This promotes the 
recruitment of the E3 ubiquitin ligase von Hippel–Lindau (VHL/Cul3), 
ubiquitinating and targeting HIF-1α for proteolytic degradation by the 
26s proteasome pathway65. PHD2 activity is inhibited when O2 
pressure decreases below physiologic levels, releasing HIF-1α from 
VHL and allowing its nuclear translocation and binding to DNA 
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Hypoxia-Responsive Elements (HRE) in the promoters of effector 
genes regulating metabolic adaptation to hypoxia65 (Figure 1.5). 
 One hallmark of hypoxia is the increased generation of ROS, 
presumably due to the shut down of the mitochondrial electron 
transport chain (ETC) as a consequence of the low O2 concentration 
reaching the mitochondria65. Several lines of evidence have 
demonstrated that mitochondrial ROS are essential to mount a 
hypoxic response66. For instance, the activity of the hypoxia sensor 
PHD is highly sensitive to iron redox state and ROS accumulation, 
which has a profound effect on the activation of HIF-1α67 (Figure 
1.5). As such, NRF2-dependent modulation of intracellular redox 
status impacts on the hypoxia stress response to insure return to 
homeostasis under low O2 conditions67. In the context of cancer, 
NRF2 depletion was shown sufficient to decrease HIF-1α at the post-
translational level, suggesting a role of NRF2 in the regulation of 
PHD proteins68 (Figure 1.5). Additionally, NQO1, encoded by a 
downstream target gene of NRF2, interacts physically with HIF-1α, 
leading to its stabilization by decreasing the interaction with PHDs69 
(Figure 1.5).  
 Inflammation can trigger hypoxia, leading to exacerbated 
generation of ROS and oxidative stress, countered by the concerted 
action of the transcription factors HIF-1α and NRF270 (Figure 1.5), as 
suggested for experimental models of inflammation such as alcohol-
induced liver injury70 and liver transplantation following ischemia 
reperfusion injury (IRI)71.  
 Determining the molecular mechanisms via which the NRF2 and 
HIF-1α-mediated pathways communicate might provide new insights 
into tissue damage control mechanisms, namely under the disease 
tolerance strategy in the context of infection. 
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Figure 1.5. HIF-1α  and NRF2 mediate the stress response to 
pathophysiological O2 levels.  
Low O2 levels (hypoxia) lead to ROS production and inactivation of PHD, 
allowing the induction of HIF-1α. Both hypoxia and redox unbalance trigger 
HIF-1α stabilization and nuclear translocation. NRF2 counters ROS 
production/accumulation and PHD activity, impacting on HIF-1α stabilization 
and activation. The expression of NQO1 downstream of NRF2 activation 
leads to HIF-1α stabilization via direct interaction with NQO1 and the 
induction of the hypoxia stress response. The NRF2-dependent response 
ameliorates inflammation and provides cytoprotection.  
 
 
NRF2 and the metabolic stress response 
 Infection can decrease mitochondrial ATP output and reduce its 
availability, compromising host homeostasis72. The stress response 
pathway orchestrated by the 5' Adenosine Monophosphate-activated 
Protein Kinase (AMPK) regulates cellular energy status by sensing 
increases in the ratios of Adenosine Monophosphate (AMP) to 
Adenosine Triphosphate (ATP) and Adenosine Diphosphate (ADP) 
to ATP (Figure 1.6)72. Cellular AMP, ADP and ATP concentrations 
are maintained by different mechanisms regulating ATP production 
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and consumption in the mitochondria72. When cellular ATP 
concentration decreases, the ADP:ATP ratio increases72. This is 
sensed by AMPK, which orchestrates a cellular adaptive response 
promoting catabolic pathways generating ATP while switching off 
ATP consumption72 (Figure 1.6). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.6. AMPK and NRF2 protect against metabolic 
imbalance.  
The generation of ROS either due to abnormal levels of glucose 
(hyperglycemia) or other metabolic stresses leads to mitochondrial 
dysfunction and decrease in ATP production. This signals to AMPK, which 
in turn converts ADP in ATP to replenish the pool of ATP. AMPK activates 
the transcription factor Forkhead box class O (FOXO) that translocates to 
the nucleus where it induces the expression of the cytoprotective gene 
Glutathione S-transferase Mu 1 (Gstm1), a gene which expression has 
been also shown to depend on Nrf2. The activation of AMPK induces NRF2 
nuclear translocation and downstream HO-1 expression and cytoprotection. 
AMPK phosphorylates GSK3β, inactivating its repressor activity on NRF2 
and promoting the antioxidant signal transduction pathway. GSK3β 
phosphorylation by AMPK protects mitochondria by blocking MPTP 
formation and ROS production. Whether this protection is dependent on 
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NRF2 via release from GSK3β-mediated degradation remains to be 
elucidated. 
 
There is circumstantial evidence proposing a link between the 
metabolic and the oxidative stress response. For instance, AMPK 
activation inhibits GSK3β thus promoting NRF2 activation and 
downstream expression of NRF2-regulated genes preventing 
mitochondrial dysfunction through repression of mitochondrial 
permeability transition pore (MPTP) and ROS production35,73 (Figure 
1.6). Moreover, pharmacologic AMPK agonists also induce NRF2 
activation and downstream expression of NRF2-regulated genes 
such as HO-174, while inhibition of AMPK blocks NRF2-dependent 
HO-1 expression, presumably via NRF2 inhibition74. Finally, 
transgenic expression of a constitutive active form of AMPK triggers 
NRF2 activation and HO-1 expression in endothelial cells75 (Figure 
1.6). Therefore, it is likely that AMPK, when induced in host 
parenchyma cells, synergizes with NRF2 to confer some level of 
tissue damage control and disease tolerance to infection but this 
remains to be demonstrated experimentally.  
 
NRF2 and the osmotic stress response 
 Mammalian cells evolved adaptive mechanisms to compensate 
for increases in extracellular osmolarity, i.e., the number of solute 
molecules per solution volume or solution weight76. At the cellular 
level, semipermeable membranes mediate the separation of two 
solutions with distinct compositions76. Thus, the ability to regulate 
and preserve different intracellular and extracellular solute 
microenvironments is crucial in maintaining cellular and tissue 
homeostasis76.  
 Variations in cellular volume and intracellular concentrations of 
inorganic ions/macromolecules lead to osmotic stress, through a 
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mechanism involving the aquaporin ‘water channels’ (AQP) and 
solute carrier channels (SLC)76. Prolonged osmotic stress is sensed 
by the protein kinase A-anchoring protein 13 or Brx, which activates 
Mitogen-Activated Protein Kinases (MAPK) 76. These kinases include 
the p38 MAPK that targets the transcription factor Nuclear Factor of 
Activated T Cells 5 (NFAT5), known to be the master regulator of the 
osmotic stress response76. Phosphorylated NFAT5 dimerizes and 
translocates to the nucleus where it binds to Osmotic-Response 
Elements (ORE) in the promoters of osmoregulatory genes76 (Figure 
1.7). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.7. NRF2 as a player in the osmotic stress response. 
Osmotic stress is caused by variations in cellular volume and intracellular 
concentrations of inorganic ions/macromolecules via the AQP and SLC 
channels. This is sensed by Brx, which activates MAPK targeting NFAT5 for 
phosphorylation, dimerization and nuclear translocation, where it binds to 
OREs. Other toxic stimuli activate MAPK and PI3k/Akt, or interaction of 
NFAT5 with Sirt1, leading to NRF2 stabilization, nuclear translocation and 
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binding to ORE, where it mediates transcription of cytoprotective genes and 
blocks cell death.  
 
 
 The osmotic stress response orchestrated by NFAT5 has been 
previously linked to infection such as the one caused by Leishmania 
major, as it strengthens the antimicrobial barrier function of the skin 
and promotes host defense77. Moreover, the cytoprotective response 
mediated by NFAT5 was shown to operate in parenchyma cells 
during sepsis, providing tissue damage control to the kidney78.  
 The oxidative response pathway controlled by NRF2 was shown 
to interact with the osmotic stress response79. Namely, Curcumin, a 
natural polyphenolic compound that induces NRF2 activation, 
upregulates the expression of aldose reductase via NRF2-dependent 
mechanism involving the ORE in the aldose reductase promoter79 
(Figure 1.7). The cytoprotective effect of NFAT5 promotes the 
SIRT1/NRF2 pathway leading to up-regulation of NRF2-regulated 
genes, including Superoxide Dismutase (SOD), Catalase (Cat), GSH 
and HMOX1, all of which counter the induction of programmed cell 
death80 81 82 (Figure 1.7).  
 To which extent NRF2 contributes directly to the maintenance of 
osmotic homeostasis downstream of NFAT5 activation to provide 
tissue damage control and disease tolerance still remains to be 
demonstrated. 
 
1.2.3. Damage responses underlying tissue damage control: 
The role of NRF2 
 Damage responses are triggered by sensors that recognize 
specific macromolecular or organelle damage, acting downstream of 
stress responses presumably as a second layer of tissue damage 
control mechanisms enforcing disease tolerance. Damage 
responses induce repair mechanisms as a means to restore cellular 
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integrity and ultimately tissue function8. Here I focus on the 
connection between the oxidative stress response orchestrated by 
NRF2 and damage responses, mainly in the context of disease 
tolerance to infection. 
 
NRF2, the heat shock response (HSR) and the unfolded protein 
response (UPR) 
 Accumulation of misfolded proteins either in the cytosol or the 
endoplasmic reticulum (ER) is a form of macromolecular damage 
associated with different types of stress8. This leads to the activation 
of two distinct damage responses: the heat-shock response (HSR) in 
the cytosol and the unfolded protein response (UPR) in the ER8.  
 The heat shock response is a biological process activated in 
conditions leading to denaturation of proteins through a specific 
program orchestrated at the transcriptional level via activation of 
Heat Shock Factors (HSF) leading to the expression of a series of 
effector Heat Shock Proteins (HSP)83. One of the protective effects 
of HSPs comes from their ability to block TNF-dependent 
programmed cell death by apoptosis through a mechanism that 
relies on the activation of HSF84,, presumably explaining why HSF 
counters endotoxic shock85. Of note, initiation of apoptotic programs 
blocks further HSF activation and HSP expression86.  
Disruption of Hsf1 gene was shown to increase mortality and 
exaggerate TNF production during endotoxemia85 and Listeria 
monocytogenes infection87. These data demonstrate that HSF1 is 
needed to prevent the overproduction of TNF and subsequent death 
due to septic shock that can result following high-dose challenge 
with bacterial pathogens85,87.  
Several studies suggest that HSF1 plays an important role in 
countering cellular oxidative stress/damage. Namely, HSF1 has 
been reported to maintain GSH cellular levels and prevent oxidative 
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damage to mitochondria88 (Figure 1.8). Moreover, HSF1 and NRF2 
interact functionally to control the expression of chaperones, 
antioxidant and drug metabolizing enzymes, proteins involved in 
repair of damaged macromolecules, maintenance of cell structure as 
well as in redox and intermediary metabolism89. Presumably, this is 
explained by the fact that NRF2 and HSF1 share transcriptional 
target genes encoding proteins regulating iron metabolism and 
oxidative stress, including the heme catabolizing enzyme HO-1 
(initially named HSP32)90,91, Transferrin Receptor (TR)92, HSP7093 
and the nucleoporin p6294,95. It is possible that NRF2 and HSF1 are 
to some extent redundant90 (Figure 1.8), compensating for each 
other’s absence, as illustrated  for the regulation of HSP70 
expression or HO-196. These observations suggest that NRF2 and 
HSF1 engage in crosstalk for cytoprotection, responding to a variety 
of stress stimuli associated with infection. 
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Figure 1.8. Crosstalk between the oxidative stress response, 
the heat shock response and the unfolded protein response. 
The accumulation of misfolded proteins as consequence of oxidative stress 
activates HSPs in the cytoplasm. In parallel, ROS production induces 
NRF2. The genetic programs activated by NRF2 and HSF-1 afford 
cytoprotection through the upregulation of detoxifying enzymes that prevent 
cell death, presumably as part of a disease tolerance strategy. The 
induction of NRF2 upon oxidative stress to the ER is most likely part of the 
UPR, as an important mechanism contributing to tissue damage control. 
The accumulation of ROS leads to the accumulation of partially/non-
properly folded proteins in the ER. This in turn triggers the activation of the 
UPR, which relies on the expression of Xbp1 where its unspliced form 
(Xbp1u) activates NRF2 and the oxidative stress response. The spliced 
form of Xbp1 (XBP1s) leads to upregulation of Hrd1, a repressor of NRF2.  
 	
The oxidative environment of the ER favors correct protein folding 
guaranteed by specific enzymes that maintain redox homeostasis98. 
Perturbations in this fine tuned redox balance, such as those caused 
by external cues, trigger the UPR. This highlights the importance of 
oxidative stress responses in maintenance of ER homeostasis98 
(Figure 1.8). In support of this notion, the UPR modulates NRF2 
activation via different mechanisms37: On one hand, the non-spliced 
form of X-box-binding protein 1 (XPB1u) activates NRF2 to induce 
the expression of HO-199; On the other hand, its spliced form 
(XBP1s) encodes for a transcription factor that modulates the 
expression of ERAD-associated E3 ubiquitin-protein ligase (Hrd1)100, 
which interacts directly with NRF2 to inhibit its activation36, 
presumably acting as a negative feed back loop avoiding the 
sustained activation of NRF2 (Figure 1.8).  
The UPR has been clearly demonstrated to have a role in tissue 
damage control and disease tolerance, as it is required to sustain 
epithelial barrier integrity and prevent colitis101. Moreover, ER stress 
was implicated in vitro in Pseudomonas aeruginosa infection of 
human primary bronchial epithelial cells through the cytoprotective 
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induction of heme-regulated eIF2α kinase (HRI), activated by high 
levels of ROS102. In Caenorhabditis elegans, Xbp1 is protective 
against P. aeruginosa infection by providing tissue damage control, 
without interfering with bacterial load103. Although NRF2 and the 
UPR play a role in providing disease tolerance it is still not clear what 
are the mechanisms through which these pathways act in a 
concerted manner to confer tissue damage control in the context of 
infection. 
 
NRF2 and the DNA damage response (DDR) 
 Recognition of DNA damage sites and activation of repair 
programs are crucial to avoid the accumulation of mutations and 
maintain genome integrity and stability104. Different classes of 
pathogens105 are important triggers for genomic instability, a well 
established hallmark of cancer106, and damage responses such as 
the one orchestrated by ataxia telangiectasia mutated protein kinase 
(ATM) play a crucial role in sensing and repairing this type of insult107 
(Figure 1.9).  
Sub-toxic levels of DNA damage inflicted by pharmacological 
agents which activate the response orchestrated by ATM provide a 
robust protection against severe polymicrobial sepsis in mice108. 
Here, ATM plays a cytoprotective role via a disease tolerance 
strategy by providing tissue damage control through activation of the 
autophagy damage response in the lung epithelium, without 
interfering with bacterial counts108 (Figure 1.9).  
Establishing a link between the DNA damage response and the 
oxidative stress response is the data showing that administration of 
dexamethasone, a glucocorticoid used for treatment of Ataxia 
Telangiectasia (A-T), improves redox state in A-T lymphoblastoid cell 
lines by promoting an NRF2-mediated antioxidant response109. This 
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suggests a role for NRF2 in cytoprotection against DNA damage 
compensating for the absence of ATM (Figure 1.9). Moreover, ATM 
activation and subsequent DNA repair were identified as 
downstream targets of HO-1 through generation of CO, suggesting a 
putative role of NRF2 in inducing the DDR110. In the context of high 
oxidative stress caused by heme toxicity in a model of hemolytic 
inflammatory diseases, the absence of ATM leads to NRF2 
activation, suggesting that ATM might act in parallel with NRF2 as 
part of the antioxidant stress response (Rita Carlos et al., 
unpublished observation) (Figure 1.9). 
Taken together, these data suggest a putative connection 
between the oxidative stress response modulated by NRF2 and the 
DDR dependent on ATM as regulators of tissue damage control, 
although the mechanisms through which these proteins interact still 
remains uncharacterized. 
 
 
 
 
 
 
 
 
 
 
 
 
 		
 
Figure 1.9. Crosstalk between the oxidative stress response 
and the DNA damage response. 
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ROS production, for example in the context of infection, leads to oxidative 
stress, activating NRF2. Concomitantly, it might cause damage to DNA 
through the generation of DNA base lesions that often lead to DNA breaks. 
These breaks are sensed by ATM, which activates a protective program 
(DDR) relying on the activation of DNA damage mechanisms, on the 
induction of autophagy and possibly NRF2 activation (grey arrow). The 
absence of ATM (grey box) is sufficient to activate NRF2. The NRF2 
dependent response induces the expression of HO-1, which through CO 
production activates ATM. Whether ATM acts in parallel or to compensate 
the absence of NRF2 in the amelioration of ROS production/accumulation 
still remains to be understood. 
 
NRF2 and the lipid damage response 
 Oxidative damage to lipids, or lipid peroxidation, is associated 
with a self-propagated oxidative chain reaction catalyzed by divalent 
metals, such as the iron contained inside the lipophilic ring of 
heme111 (Figure 1.10). Labile (‘loosely coordinated’, ‘redox-active’) 
iron in the cytosol, mitochondrial matrix and lysosomes can catalyze 
the formation free radicals via Fenton reaction112 (Figure 1.10) and 
trigger ferroptosis, an iron-dependent form of programmed cell death 
elicited by lipid peroxidation and reverted by lipophilic antioxidants113. 
Of note, the Fenton Reaction will be analyzed in detail on Section 
1.3. 
Members of the Glutathione Peroxidase (GPX) family of oxido-
reductase enzymes play a crucial role in the detoxification of 
oxidized macromolecules by reducing ROS to water and oxygen 
utilizing glutathione as the reducing agent114. GPX4 is the only 
member of the GPX family that interacts with cell membranes and 
prevents uncontrolled peroxidation of phospholipids and ultimately 
cell death115 (Figure 1.10). This might presumably explain why GPX4 
confers tissue damage control upon Salmonella typhimurium 
infection114. GPX4 levels are significantly decreased in Salmonella 
typhimurium infection and inversely correlate with the rate of 
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neutrophil migration across mucosal surfaces, which impose a 
certain level of tissue damage. Moreover, overexpression of GPX4 in 
vitro decreases Salmonella typhimurium-induced neutrophil 
migration, ameliorating immunopathology114. The salutary effect 
provided by GPX4 depends on cystine supply for glutathione 
biosynthesis116, which has been shown to depend on NRF216,27. 
Recent studies have identified the NRF2-dependent gene 
expression as a downstream event to GPX4 specific deletion in the 
liver (Figure 1.10)117 and that it plays a central role in protecting 
hepatocellular carcinoma cells against ferroptosis, a specific type of 
programmed necrosis triggered by lipid peroxidation and GPX4 
depletion118. Moreover, liver specific NRF2 activation increases the 
expression of GPX427.  
Additionally, GPX4 was shown to be activated by Hepatitis C 
Virus in human liver biopsies as a strategy to ameliorate lipid 
peroxidation and allow viral spread119. Together, these data suggest 
that the activation of NRF2 counters lipid peroxidation via a 
mechanism involving GPX4 and conferring cytoprotection against 
ferroptosis118. Whether the salutary effect of GPX4 as a lipophilic 
antioxidant against lipid peroxidation is directly related to the 
antioxidant nature of NRF2 activity in the context of infection remains 
to be further elucidated.  
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Figure 1.10. Crosstalk between the oxidative stress response 
and the damage response against lipid peroxidation.  
The damage response to lipid peroxidation caused by ROS is orchestrated 
by GPX4, the enzyme that converts a hydroperoxide group (LOOH) into a 
hydroxyl group (ROH) and water, using GSH as a substrate. NRF2 induces 
the uptake of cystine leading to GPX4 detoxifying activity. NRF2 activation 
upon ROS production in the lipid fraction leads to Gpx4 and Hmox-1 
expression. HO-1 produces bilirubin, a powerful lipophilic antioxidant, as by-
product of heme catabolism. Both bilirubin and GPX4 act on the lipid 
fraction as antioxidant molecules, conferring cytoprotection. Absence of 
GPX4 (grey box) induces the activation of NRF2 and downstream 
cytoprotective response.  
 
NRF2 and autophagy  
 Autophagy is a tightly regulated damage response in which the 
cell self-digests its own components in response to multiple forms of 
cellular stress including nutrient or growth factor deprivation, 
hypoxia, ROS, DNA damage, protein aggregates, damaged 
organelles or intracellular pathogens120. This self-degradation 
process not only provides nutrients to maintain vital cellular functions 
during fasting but can also avoid the accumulation of damaged 
organelles, misfolded proteins or invading microorganisms 
(xenophagy). As such, autophagy constitutes a major protective 
mechanism that ensures cell survival integrating cues from different 
upstream stress responses121.  
Autophagy is protective against many infectious diseases120, a 
salutary effect associated mainly with resistance to infection via 
xenophagy120.  More recently, however, this damage response has 
been shown to provide tissue damage control and establish disease 
tolerance in septic mice through its concerted action with the ATM-
dependent DNA damage response108.  
The autophagy pathway has been functionally linked to the NRF2-
dependent oxidative stress response. Namely, autophagy leads to 
the sequestration of Keap1-p62 complexes in autophagosomes, 
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resulting in lysosomal-mediated degradation of Keap1 and NRF2 
activation94. Blocking autophagy leads to the accumulation of p62 
and its binding to KEAP1, inducing prolonged NRF2 activation94. As 
such, p62 accumulation induces NRF2 in autophagy-deficient mouse 
livers, presumably and counter intuitively, the major cause of 
hepatotoxicity in autophagy-impaired livers94. 
Interestingly, NRF2 mediates the induction of p62-containing 
aggresome-like induced structures in response to TLR4 engagement 
by LPS, promoting autophagy. Similarly, heme treatment was shown 
to induce the formation of p62 containing aggresome-like induced 
structures, activating NRF2 and conferring cytoprotection against 
heme122. Presumably, this generates a positive feedback loop in 
which NRF2 induces p62 aggregation, which in turn amplifies NRF2 
activation. Whether the formation of aggresome-like induced 
structures in response to heme depends on signaling through TLR4 
similarly to LPS and what is the mechanism via which NRF2 is 
protective remains to be established. 
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Figure 1.11. Crosstalk between the oxidative stress response 
and the autophagy damage response.  
ROS production following recognition and elimination of pathogens, for 
example, induces protein oxidation on different organelles. Namely, 
oxidative damage to mitochondria interferes with its function and leads to 
increased ROS production, as these organelles are the major source of 
ROS in the cell. Mitochondria quality control mechanisms activate the 
autophagy pathway leading to its removal and destruction. NRF2 induction, 
as a response to oxidative stress, activates mitophagy to remove the 
source of ROS and the expression of p62, which stabilizes NRF2 in 
autophagy-deficient mice and induces mitophagy. In this context (dashed 
grey box), the increased levels of p62 results in the induction the 
expression of various cytoprotective enzymes, via NRF2 stabilization.  
 
 Exacerbated mitochondrial ROS production impairs mitochondrial 
function, leading to its elimination through a process called 
mitophagy123 (Figure 1.11). This negative feedback regulation loop 
removes the source of stress and prevents oxidative damage124.  
 NRF2 was suggested to have a role in redox-sensitive mitophagy 
in a model of Staphylococcus aureus-induced sepsis, as it increases 
autophagy of mitochondrial cargo in the lungs125. Furthermore, p62-
mediated mitophagy inducer (PMI) upregulates p62 via stabilization 
of NRF2 and stimulates mitophagy126 (Figure 1.11). In vivo using a 
model of diabetic kidney disease, it was shown that mitochondrial 
ROS promote tubular injury and that mitophagy promoted by NRF2 
is protective against this type of insult127. Recently, Tomatidine, a 
natural compound known to inhibit age-related skeletal muscle 
atrophy in mice was described to have a beneficial role in C. 
elegans128. In this study, the authors have demonstrated that mild 
mitochondrial ROS production activates the NRF2 pathway, leading 
to salutary higher levels of mitophagy and prolonged lifespan128. 
These data argue that redox quality control programs might be 
targeted through NRF2 activation and consequent elimination as a 
means to modulate ROS levels and protect against tissue damage. 
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1.3. NRF2 in cellular redox homeostasis 
 The mechanisms involved in the maintenance of ROS-sensitive 
physiological functions is called redox biology129.	Under homeostatic 
conditions, ROS are powerful signaling molecules, contributing to the 
maintenance of core physiological processes (Figure 1.12)130. These 
molecules include free radicals such as the superoxide anion (O2-) 
and the hydroxyl radical (•OH) and oxidants such as hydrogen 
peroxide (H2O2) (Figure 1.12)131. The O2- produced both by NADPH 
oxidases and mitochondria is rapidly converted into hydrogen 
peroxide (H2O2) by compartment-specific SODs. In the presence of 
highly reactive ferrous iron (Fe2+), H2O2 is converted to hydroxyl 
radicals (•OH), ferric iron (Fe3+) and the hydroxide anion (OH-), the 
so-called Fenton Reaction. Hydroxyl radicals are extremely powerful 
in oxidizing DNA, proteins and lipids, leading to oxidative stress131 
(Figure 1.12). 	
 Oxidative stress refers to the consequences of elevated 
intracellular levels of ROS in lipids, proteins and DNA (Figure 
1.12)130 and is linked to a plethora of pathologies such as 
neurodegenerative diseases, cancer, chronic inflammation or 
autoimmunity132,133.	Oxidative stress elicits an adaptive response that 
ensures return to the normal cellular redox status134. The first line of 
defense is provided by enzymes that inactivate ROS, such as SOD 
and Catalase (Cat), which reduce O2 to H2O2 and convert two 
molecules of H2O2 into two molecules of H2O and O2, respectively135 
(Figure 1.12).  
 Antioxidants are the second line of defense against oxidative 
stress (Figure 1.12). These are small molecules with redox-active 
properties that prevent ROS formation or remove ROS directly like 
bilirubin or GSH (direct antioxidants) or act indirectly like NRF2, via 
the induction of cytoprotective genes that recycle and/or generate 
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direct antioxidants135. Modulation of NRF2 activity may be 
advantageous over direct antioxidants for two reasons: First, the 
induction of detoxifying enzymes is a natural process and the 
expression of these genes will be held only when and where is 
needed, leaving signaling processes mediated by ROS intact; 
Second, the antioxidant effect is prolonged because proteins have a 
longer half-life than small molecule activators136. Additionally, 
antioxidants can be classified based on their source: the 
endogenous that are produced by the cells such as GSH and 
Catalase or the exogenous, which are obtained through diet, such as 
ascorbate135.  
 
1.3.1. NRF2 , NADPH oxidases and mitochondria 
 ROS levels are determined their rate of production, either as the 
main product or as a by-product of catalytic reactions as well as by 
the rate of ROS elimination by different antioxidant mechanisms137.  
 One of the main sources of ROS are NADPH oxidases, a family 
of multi-subunit enzymes that transfers electrons across biological 
membranes (Figure 1.13)138. NADPH oxidases were initially 
discovered due to their involvement on the generation of the 
oxidative burst associated with bacterial clearance by phagocytes138. 
There are several NADPH oxidase isoforms that include NOX1-5 
and DUOX1 and 2, which sole role appears to generate ROS in 
different cell types138. Activation of NRF2 in response to the ROS 
generated via NADPH oxidases139 counters the expression of the 
catalytic subunits NOX2 and NOX4137, thus acting in a negative feed 
back loop for the maintenance of cellular redox homeostasis (Figure 
1.13).  
 Mitochondria are the other main source of cellular ROS generated 
as a natural by-product of oxidative phosphorylation through the 
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electron transport chain140 (Figure 1.12). NRF2 also counters the 
production of mitochondrial ROS141, acting as a negative feed back 
loop to maintain mitochondrial redox homeostasis. NRF2 regulates 
both substrate availability for mitochondrial respiration and 
mitochondrial ROS production141, therefore acting as a crucial 
mechanism maintaining overall cellular redox homeostasis140.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.12. The role of NRF2 in cellular redox state.  
Intracellular superoxide (O2-) is primarily produced by the oxidation of 
NADPH by NAPH oxidase enzymes (NOXs) or by electron leak from 
aerobic respiration in mitochondria. Superoxide is rapidly converted into 
hydrogen peroxide (H2O2) by compartment-specific superoxide dismutases 
(SODs). H2O2 is capable of oxidizing cysteine residues on proteins to 
initiate signaling processes. Alternatively, H2O2 may be converted to H2O by 
cellular antioxidant proteins, such as catalase (Cat). In the presence of 
ferrous iron (Fe2+), H2O2 is converted through Fenton Reaction into highly 
reactive hydroxyl radicals (•OH), which irreversibly damage cellular 
macromolecules. This reaction also produces hydroxide anions (OH-) and 
ferric iron (Fe3+) that, in the presence of O2-, provides the substrate for 
Fenton Reaction (Fe2+) sustaining oxidative stress. NRF2 (pink rectangles) 
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counters cellular oxidative stress at different levels. (Adapted from Schieber 
M & Chandel NS, Current Biology 2014) 
 
1.3.2. NRF2 and mitochondrial quality control 
 Mitochondrial membrane potential (Δѱm) can be disrupted by 
diverse pathological states and have negative consequences for 
mitochondrial integrity and cellular homeostasis142. ROS-induced 
ROS release (RIRR) in the mitochondria143 can trigger MPTP 
opening143 and the collapse of Δѱm with increased ROS generation 
by the electron transport chain (ETC). Presumably, cytosol ROS 
production potentiates mitochondria RIRR, acting as a positive 
feedback mechanism potentially leading to mitochondrial and cellular 
injury143.  
 Being the Δѱm a universal indicator of mitochondrial health and 
cellular redox state, any given insult changing its amplitude has deep 
consequences in cellular and tissue homeostasis144. NRF2 activation 
was shown to increase the Δѱm as well as the availability of 
substrates for respiration and ATP production145. Concordantly, 
constitutive activation of NRF2 in cells lacking the NRF2 repressor 
Keap1 is associated with higher rate of mitochondrial respiration, 
suggesting that NRF2 activation promotes mitochondrial oxidative 
phosphorylation and, hence, increased ROS production137. This is 
countered by NRF2-dependent gene expression, including the 
uncoupling protein 3 (UCP3), which increases the mitochondrial 
inner membrane proton conductance, decreasing superoxide 
production146. 
 Activation of NRF2 has been linked to mitophagy, a regulated 
process driving the degradation and recycling of dysfunctional 
mitochondria142. This is supported by the observation that 
constitutive activation of NRF2 in cells lacking the NRF2 repressor 
Keap1 increase LC3 (an autophagossome marker) recruitment to 
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mitochondria126. Similarly, treatment with the autophagy and NRF2 
inducer PMI in Keap1-knockdown or Keap1-/- cells (NRF2 over-
activation) causes an increase in LC3 recruitment to mitochondria, 
which does not occur in Nrf2-/- cells126. Furthermore, induction of 
mitophagy with the uncoupling agent FCCP activates NRF2147. 
 NRF2 has been shown to upregulate p62, a protein that facilitates 
the recruitment of damaged mitochondria to the phagophore147. A 
very recent study has strengthened the link between NRF2 and 
mitophagy demonstrating that MitoQ, a mitochondria targeted 
antioxidant induces mitophagy via NRF2 signaling, exerting 
beneficial effects on tubular injury caused by diabetic kidney 
disease148.  
 In order to maintain cellular homeostasis, the removal of 
damaged mitochondria by mitophagy needs to be carefully regulated 
and counter-balanced by the biogenesis of new mitochondria149. 
Concordantly, it has been reported that NRF2 contributes to 
maintenance of liver mitochondria150 and that several proteins 
involved in mitochondrial biogenesis are transcriptionally regulated 
by NRF2151.  
 In sum, the tightly regulated processes that underlie mitochondrial 
quality control through mitophagy and mitochondrial biogenesis rely 
to some extent on the activation of NRF2. 
 
1.3.3. NRF2 and mitochondrial homeostasis during infection 
 Activation of NRF2 contributes to maintain mitochondrial 
homeostasis and function during infection140. For example, endotoxic 
shock triggers cardiac oxidative damage, consequently damaging 
mitochondrial DNA (mtDNA) and decreasing its copy number, 
impairing mitochondrial gene transcription and protein expression152. 
On the other hand, expression of genes involved in mitochondrial 
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biogenesis is increased in response to oxidative stress with 
mitochondrial oxidative damage being necessary to trigger 
mitochondrial biogenesis153.  
 The murine model of experimental sepsis is perhaps the model of 
infection in which the NRF2-dependent regulation of mitochondrial 
biogenesis has been more extensively investigated. For instance, 
using E. coli peritoneal injection in mice it was demonstrated that 
NRF2, through HO-1 up-regulation, links mitochondrial biogenesis 
and anti-inflammatory response programs by inducing PGC1-α and 
Tfam, as well as TNF and Interleukin 10 (IL-10), respectively. This 
cytoprotective effect acts in vivo against E. coli-induced sepsis 
through HO-1 activity and consequent CO production, via a NRF2-
dependent mechanism154. In a model of Staphylococcus aureus-
induced peritonitis, CO induces NRF2-dependent mitochondrial 
biogenesis, accompanied by an increase in mtDNA copy number in 
the liver of septic mice155. More recently, PGC1-α was shown to be 
required not only for the induction of hepatic mitochondrial 
biogenesis, but also for mitochondrial antioxidant enzyme induction, 
namely SOD2, partnering with NRF2 in Staphylococcus aureus-
induced sepsis156. The protective effect of NRF2 in mediating the 
mitochondrial biogenesis program was corroborated in lung cells 
upon Staphylococcus aureus-induced pneumonia in mice151.  
 Together, these results indicate a clear role for NRF2 in 
preservation of overall cellular homeostasis by maintenance of 
mitochondrial integrity and number.  
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1.4. NRF2 as a cytoprotective molecule against the 
pathophysiology of hemolytic disorders 
 Heme is an evolutionarily conserved structure that acts as a 
prostethic group for a variety of hemoproteins and plays a pivotal 
role in many essential biological processes157. Heme is stored mainly 
into hemoglobin and myoglobin, which constitutes the largest pool of 
bioavailable iron in RBCs and muscle cells, respectively158. 
Endogenous heme levels are tightly regulated to prevent heme-
driven cytotoxicity while assuring its availability for incorporation into 
nascent apo-hemoproteins. This is tightly regulated through a fine 
tuned maintenance program of heme synthesis, transport and 
catabolism49.  
 Under pathophysiologic conditions, damage to RBC and muscle 
cells can result in hemoglobin and myoglobin leakage into 
circulation, driving its rapid oxidation and release of heme prosthetic 
groups159. This occurs via a process converting iron from ferrous 
(Fe2+) to ferric (Fe3+) state. The end product of this reaction is labile 
heme, i.e., redox active loosely bound to proteins or molecules other 
than its normal partners, the hemoproteins159. Circulating labile heme 
is a threat to systemic homeostasis, as it creates the potential for 
iron cytotoxicity interfering with basic cellular functions and possibility 
culminating in cell death49.  
 
1.4.1. Heme as a danger molecule 
 The cytotoxic nature of labile heme is associated with its pro-
oxidant activity, as Fe2+ catalyzes the formation of ROS via Fenton 
reaction (Figure 1.10, Figure 1.12)160. Heme degradation by HO-1 
occurs via the oxidative cleavage of the protoporphyrin IX ring, giving 
rise to biliverdin, CO and equimolar amounts of labile Fe2+ (Fig. 
1.13)51. The cytoprotective action of HO-1 resides both in the 
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degradation of toxic labile heme as well as in the release of 
cytoprotective heme degradation products: biliverdin, which is then 
converted by biliverdin reductase to bilirubin, a powerful lipid phase 
antioxidant161; and CO, an anti-inflammatory and cytoprotective 
gaseous molecule162. The highly reactive Fe2+ produced upon heme 
catabolism is captured by Ferritin, a protein with ferroxidase activity 
capable of chelating and converting iron into its non-reactive, 
reusable form (Fe3+)200 (Fig. 1.13). 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.13. Heme catabolism. 
Under hemolysis (RBC damage) or rhabdomyolysis (muscle cell damage), 
hemoglobin or myoglobin, respectively, are released into circulation and 
become oxidized, releasing its heme prosthetic groups. Labile heme is 
degraded by HO-1 releasing CO and biliverdin (converted to bilirubin by 
biliverdin reductase) as well as equimolar amounts Fe2+. This iron form 
reacts with H2O2 to form hydroxyl radicals (•OH), hydroxide ions (OH−) and 
Fe3+. Countering this process is Ferritin, which scavenges Fe2+ and 
catalyzes its oxidation to its non-reactive form (Fe3+). NRF2 modulates the 
cytoprotective effects of HO-1 and ferritin and blocks the deleterious effect 
of the hydroxyl radical. 
 
 
 Heme belongs to a class of molecules named alarmins that are 
normally intracellular and can be released, both actively by cells and 
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passively as a result of sterile trauma, ischemia or toxin/pathogen-
induced rupture159,165. Such molecules are at the interface of damage 
and repair, inducing a robust inflammatory response causing 
collateral tissue damage166,167 while promoting tissue repair, as 
illustrated for muscle168, intestinal169 and lung injuries170. 
 Systemic infections are often associated with more or less severe 
levels of hemolysis either as an active process for acquisition of host 
iron171 or as a consequence of pathogen life-cycle172. The effects of 
hemolysis can be beneficial, as extracellular hemoglobin contributes 
to pathogen clearance, presumably due to the peroxidase activity of 
heme reacting with H2O2 to oxidize molecules in microbes, as 
illustrated for bacteria173 and protozoan parasites174 (Figure 1.14). 
Moreover, labile heme released from oxidized hemoglobin 
synergizes with LPS to induce cytokine production in macrophages 
through TLR4 signaling175,166. Concordantly, LPS-primed 
macrophages by heme produce Interleukin-1 β (IL-1β) dependent on 
nucleotide-binding domain and leucine rich repeat containing family, 
pyrin domain containing 3 (NLRP3) inflammasome176. On the other 
hand, a consequence of hemolytic disorders is excessive 
erythrophagocytosis, which leads to macrophage apoptosis and 
consequently to impaired bacterial or parasite clearance177.  
 Labile heme is not only cytotoxic to pathogens, but also to host 
cells and, if not promptly mobilized via export or catabolism, it has a 
strong potential to react with any cellular membrane49,111. Heme was 
recently described to have a role in the formation aggresome-like 
induced structures both in vitro in macrophages and in vivo in a 
model of acute hemolysis (Phenylhydrazine)122. These structures 
composed of p62 aggregates containing ubiquitinated proteins are 
storage compartments whose formation is part of the antioxidant 
response to excessive ROS formation by heme122.  The formation of 
these aggresome-like induced structures is dependent on the NRF2 
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antioxidant capacity and NRF2-dependent heme degradation via 
HO-1 upregulation. Moreover, the iron released upon heme 
catabolism is sufficient to induce ALIS and, hence, FtH prevents its 
formation122.  
 The deleterious effect of labile heme is key in the process leading 
to oxidative stress, cytotoxicity, tissue damage and ultimately organ 
failure characteristic of the pathogenesis of hemolytic immune-
mediated inflammatory diseases159.  
 
1.4.2. NRF2 and heme cytotoxicity 
 Intravascular hemolysis is associated with many disorders 
ranging from genetic variation that compromise RBC homeostasis, 
such as sickle cell anemia and β-thalassemia, to infectious diseases 
like malaria or sepsis49. These hemolytic conditions have one thing 
in common – the accumulation of circulating labile heme, which acts 
as a DAMP inducing a robust pro-inflammatory response while 
acting as a pro-oxidant and cell death agonist178. 
 
Malaria  
 Malaria, the disease caused by the Plasmodium spp. protozoan is 
characterized by a transient liver stage in which the parasite 
develops inside hepatocytes, followed by a blood stage, where the 
parasite invades RBCs, causing hemolysis as a consequence of its 
replication55. All clinical manifestations of malaria occur at the blood-
stage of infection, coinciding with the release of hemoglobin from 
RBC and the accumulation of labile heme in circulation55. To what 
extent the labile heme derives from hemoglobin or from the release 
of myoglobin subsequent to muscle damage, is not clear179. Several 
lines of evidence suggest that labile heme contributes to the 
pathogenesis of infectious diseases, malaria being the most clearly 
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established49,53,176. Heme sensitizes parenchyma cells, including 
hepatocytes, to undergo TNF-dependent programmed cell death in 
vitro180. The severity of Plasmodium infection correlates with the 
accumulation of cell-free hemoglobin and labile heme in the plasma 
of mice56,59 and humans181,59, eliciting the onset of severe forms of 
malaria56,180. This cytotoxic effect is countered via heme catabolism 
by HO-1 and the production of CO, which has cytoprotective and 
anti-inflammatory effects that prevent the pathologic outcome of 
malaria50,53,56 (Figure 1.14). Heme catabolism generates labile iron, 
which is scavenged by ferritin, a multimeric protein revealed critical 
to restore homeostasis in both rodent and human malaria59 (Figure 
1.14). Interestingly, activation of NRF2 plays a crucial role in the 
induction of HO-1 and the subsequent production of CO that limits 
malaria severity50,53 (Figure 1.14). Whether NRF2 also plays a 
crucial role in the induction of ferritin during Plasmodium infection 
remains to be elucidated.  	
Sepsis 
 Sepsis develops from an exacerbated immune response to 
microbial infection that leads to tissue damage, multiple organ failure 
and, in most cases, death182. Although the mechanisms underlying 
the pathogenesis of sepsis remain poorly understood, it is now clear 
that labile heme is as a crucial pathophysiological agonist for poor 
sepsis outcome183. In vitro studies have shown a direct 
physicochemical interaction of bacterial LPS with RBC membranes, 
resulting in RBC damage and hemolysis184. In mice, cecal ligation 
and puncture (CLP), a model of experimental sepsis, is associated 
with RBC deformation (poikilocytosis), accumulation of cell-free 
hemoglobin and labile heme, as well as decreased plasma 
concentrations of haptoglobin and hemopexin, the receptors for free 
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hemoglobin and heme, respectively183. Both RBC deformations185 
and decreased hemopexin183 concentrations are found in sepsis 
patients, suggesting a conserved effect of labile heme in the 
pathogenesis of polymicrobial systemic infections (Figure 1.15).  
Moreover, these data show that significant amounts of hemoglobin 
can be released and have relevant pathological outcomes, even in 
the absence of overt hemolysis like the one occurring in malaria 
disease. Namely, deregulated plasma osmolarity186, acidosis187 and 
bacterial hemolysins188 contribute to the increase of labile heme in 
circulation, which, capable of damaging RBCs by itself, enters a 
positive-feedback loop that contributes to further heme release into 
circulation189 (Figure 1.14). Although mainly hemoglobin-derived 
heme has been linked to the pathogenesis of sepsis, 
rhabdomyolysis, a disease characterized by severe muscle damage 
and myoglobin release, was also associated with septic shock, 
suggesting a transversal role for heme in this disease, independently 
of the source, i.e. hemoglobin or myoglobin190.  
 The deleterious effects of heme in the pathogenesis of sepsis 
have been liked mainly to sensitization of parenchyma cells to TNF-
dependent programmed cell death183. More recently, heme was also 
show to block phagocytosis and migration of human and mouse 
phagocytes, by disrupting actin cytoskeletal dynamics, thus impairing 
bacterial clearance191.  
 NRF2-dependent protection against heme toxicity has been 
described in the context of sepsis as artesunate, a protective 
molecule against this pathology, enhances NRF2 activation with 
downstream HO-1 upregulation and increased activity in lung 
tissue161. Whether NRF2 and the oxidative stress response protect 
against sepsis by preventing programmed cell death in the lung still 
remains to be elucidated. 
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 Activation of NRF2 and consequent amelioration of heme toxicity 
via tissue damage control mechanisms countering oxidative stress 
may be good candidates for prevention of the pathophysiological 
effects of hemolysis in the context of polymicrobial infections. 
 
Hereditary hemolytic anemias  
A number of hereditary diseases associated with defects in RBC 
structure and function can lead to premature RBC senescence 
associated with increased erythrophagocytosis and hemoglobin 
release into circulation49.  
 The most widely studied form of hereditary hemolytic anemia is 
sickle cell disease, caused by a single point mutation in the β chain 
of hemoglobin49. This pathology is characterized by the presence of 
deformed RBCs (sickle shape) with a shortened half-life and prone 
to hemoglobin polymerization49. These defects lead to heme release 
into circulation, which can increase RBC adhesion, hemolysis, 
vascular occlusion and ultimately stroke192 (Figure 1.14). This 
causes ischemia-reperfusion injury (IRI) characterized by an 
interruption of blood supply to a given tissue followed by the abrupt 
delivery of O2 that cannot be readily used for mitochondrial electron 
transport chain193. The excess O2 is used by oxidative enzymes like 
NADPH oxidase to produce ROS, contributing to oxidative stress 
and ultimately programmed cell death49. As such, the NRF2-
dependent antioxidant response has been implicated in the context 
of IRI. Namely, mice lacking NRF2 develop severe tissue damage 
after kidney IRI injury194 whereas Keap1 hypomorphs that activate 
NRF2 constitutively are protected against this oxidative insult195. 
 More recently, the connection between NRF2 and sickle cell 
anemia was reinforced by the finding that Keap1-knockout mice, with 
constitutive activation of NRF2, are protected against oxidative 
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stress and inflammation associated with sickle cell anemia196. 
Interestingly, NRF2 does not interfere with hemolysis nor stress-
induced erythropoiesis during sickle cell disease, suggesting that this 
transcription factor protects against oxidative tissue damage and the 
consequent pathologic outcome, rather than preventing hemolysis196 
(Figure 1.14). Presumably, the protective effect exerted by NRF2 
acts via the expression of HO-1 and the subsequent production of 
CO197 198 (Figure 1.14). 
 In the context of infection, the mutated form of hemoglobin 
confers a survival advantage to human populations, when in 
heterozygozity, in highly endemic areas of Plasmodium infection50. 
This is done through constitutive expression of HO-1 via the 
activation of the NRF2 antioxidant pathway50. The CO produced 
through heme catabolism by HO-1 binds to cell-free hemoglobin, 
blocking the release of its heme prosthetic groups and countering 
the pathogenesis of severe forms of malaria50 (Figure 1.14).  
 Autoimmune hemolytic anemia is a heterogeneous autoimmune 
disorder characterized by the development of antibodies directed 
against antigens on autologous RBCs199. As such, RBC are 
eliminated at a higher rate than the rate of bone marrow 
replenishment, presumably saturating the carrying capacity of 
hemoglobin and heme transport/catabolism systems, leading to the 
accumulation of labile heme in plasma199. The chronic accumulation 
of labile heme in circulation leads to regenerative immune-mediated 
hemolytic anemia due to increased sequestration of damaged 
erythrocytes, a phenotype countered by NRF2 and the oxidative 
stress response200. Furthermore, hematological analysis revealed 
that old mice (14 weeks) lacking NRF2 have morphologically 
abnormal RBCs, which are more sensitive to H2O2-induced 
hemolysis and carry higher levels of IgG bound to it in the presence 
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of oxidative damage, suggesting that these cells are more prone to 
elimination through erythrophagocytosis200.  
 Overall, NRF2 plays a pivotal role in diseases associated with 
hemoglobin leakage from RBCs, presumably countering the 
deleterious effects of heme by limiting the generation/accumulation 
of ROS and providing tissue damage control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.14. The pathophysiology of hemolytic inflammatory 
diseases. 
Hemolytic infectious diseases such as malaria or sepsis, as well as 
genetically encoded hemolytic conditions such as sickle cell anemia or 
autoimmune hemolytic anemia are associated with the release of 
hemoglobin into circulation. Upon oxidation, extracellular hemoglobin 
releases its heme prosthetic groups, which impacts on tissue homeostasis. 
Heme signals via TLR-4 and NLRP3 inflammasome activation to promote 
inflammation. Concomitantly, heme acts directly on pathogen membranes 
by inducing ROS formation and subsequent killing. Heme degradation by 
HO-1 leads to the release of Fe2+, which is sequestered and neutralized by 
ferritin, as to avoid the production of superoxide, leading to oxidative stress. 
Heme catabolism by HO-1 also generates biliverdin, converted to bilirubin 
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by biliverdin reductase, and CO, which binds to cell-free hemoglobin and 
inhibits the release of heme. The cytoprotective effect mediated by HO-1, 
Ferritin (FtH) and by detoxifying enzymes neutralizing superoxide formation 
is dependent on NRF2. Hence, NRF2 is crucial to counter oxidative stress 
leading to tissue damage and guarantee the return to homeostasis. 
 
1.5. Oxidative stress and Programmed cell death 
 When stress and damage responses fail to sustain the functional 
outputs of parenchymal cells, tissues or organs, the default program 
shifts to programmed cell death as a means to eliminate damaged 
cells and return to homeostasis201. Cell death is an important 
biological process that contributes to the shaping of multicellular 
organisms during development as well as to maintenance of 
homeostasis in the adult. In the immune system, programmed cell 
death mechanisms play a key role in inflammation and pathogen 
defense201.  
 The notion that oxidative stress triggers programmed cell death 
emerged more than 20 years ago. By that time, it was thought that 
cells could die exclusively through one pathway – apoptosis202. 
Nowadays, growing evidence demonstrates that cells can die 
through a plethora of different pathways and that ROS are key 
players in many of them203. Despite the emerging knowledge in 
different cell death pathways and its relevance in pathological 
scenarios, in this thesis I will focus on the necroptosis pathway. 
 
1.5.1. ROS and TNF-dependent necroptosis 
 Regulated necrosis is a genetically controlled cell death process 
that results in plasma membrane permeability and leakage, 
cytoplasmic granulation as well as organelle and/or cellular swelling 
– in other words, an ordered cellular explosion204. Receptors of the 
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TNF superfamily were the first to be linked both to apoptosis and 
regulated necrosis and, although TNF-induced necrosis have been 
studied since the late 1980’s, it was only the discovery of the crucial 
role played by receptor interacting protein kinase 1 and 3 (RIPK1 
and RIPK3) in this pathway that captured the interest of the scientific 
community203. The term necroptosis arose to define a mode of 
regulated necrosis depending on both RIPK1 and RIPK3. Since 
then, different pathways of regulated necrosis have been described 
and defined based on different molecular players and the stimuli that 
“pull the necrotic trigger”203.  
 
The molecular machinery of necroptosis 
 Unlike apoptosis, which is carried out by caspases in a silent and 
in some settings anti-inflammatory fashion, necroptosis is an 
extremely turbulent form of programmed cell death from the point of 
view of the immune system205. This pathway may have been 
selected throughout evolution in the context of viral infections, as its 
lytic nature is inflammatory and promotes immunity206. Moreover, 
necroptosis is only activated when caspases are inhibited, which 
happens for example upon targeting of caspases by viral proteins, 
blocking the apoptotic pathway206.  
 Necroptosis can be activated by death receptors such as TNF 
receptor 1 (TNFR1), PRR such as TLR3 or TLR4 and interferon 
receptors207, as well as by intracellular DNA sensor such as the 
DNA-dependent activator of interferon-regulatory factors (DAI)230 . 
TNFR1-dependent necroptosis is the best-characterized pathway 
and the one I will focus on throughout this thesis. 
 While death receptors such as the TNFR can trigger programmed 
cell death, the dominant outcome of their downstream signaling 
transduction pathway is to promote cell survival207. Engagement of 
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TNFR1 leads to the formation of complex I210, composed of TNF 
receptor–associated death domain (TRADD), TNF receptor–
associated factor 2 (TRAF2), RIPK1, cellular inhibitor of apoptosis 1 
and 2 (cIAP1, cIAP2) and the linear ubiquitin chain assembly 
complex (LUBAC)203 (Figure 1.15). Complex I is essential for 
recruitment and activation of the Inhibitor of κB Kinase (IKK) 
complex203,207, which phosphorylates Inhibitor of kappa B (IκBα) 
leading to its degradation by the 26S proteasome pathway and 
subsequent nuclear translocation of NF-κB211. This results in the 
upregulation of pro-inflammatory and anti-apoptotic genes blocking 
the cytotoxic effects of TNF212,213 (Figure 1.15). Activation of NF-κB 
induces the expression of cFLIPL, a Caspase 8 heterodimer that 
prevents apoptosis by inhibiting its activation212 (Figure 1.15). Unlike 
conventional death receptors such as FAS or Tumor Necrosis 
Factor-Related Apoptosis-Inducing Ligand (TRAIL), Fas-associated 
death domain (FADD) and Caspase 8 are not recruited to TNFR1-
associated complex I214. Instead, rapid internalization of complex I is 
crucial to dock FADD and Caspase 8, the initiator caspase, forming 
a new cytoplasmic structure named complex IIa201 (Figure 1.15), 
which leads to downstream activation of effector caspases and 
culminating in apoptosis (Figure 1.15). The heterodimer cFLIPL 
inhibits Caspase 8 proapoptotic activity but maintains cleavage 
capacity of the necrosis regulators RIPK1 and RIPK3, blocking 
apoptosis and necroptosis201 (Figure 1.15). Active Caspase 8 in 
Complex IIa initiates not only the apoptotic program, but also cleaves 
and inactivates essential necroptosis mediators such as RIPK1 and 
RIPK3215 (Figure 1.15). Hence, inhibition of Caspase-8 or its 
upstream adaptor FADD primes cells for necroptosis by preserving 
the integrity of RIPK1 and RIPK3207. In fact, most necroptotic stimuli 
described to date rely on TNFR1 stimulation and simultaneous 
caspase inhibition reinforced by the inhibition of IAPs, which in turn 
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blocks NF-κB activation207,216. Stabilization of RIPK1 and recruitment 
of RIPK3 convert Complex IIa to Complex IIb or the necrosome217 
(Figure 1.15). These two kinases interact via their RIP homotypic 
interaction motif (RHIM) forming an amyloid-like complex, essential 
for recruitment and activation of the downstream RIPK3 substrate 
mixed lineage kinase domain-like (MLKL)218 (Figure 1.15). RIPK3 
phosphorylates MLKL, stimulating its oligomerization and 
translocation to organelle and plasma membranes (Figure 1.15)219. 
The mechanism through which MLKL disrupts membrane integrity is 
still controversial, but recent data indicates recruitment of NADPH 
oxidases and ROS generation as well as disruption of calcium or 
sodium ion channels219. 
 Mitochondria promote necroptosis, probably by aiding in the 
translocation of the necrosome to the mitochondria membranes. This 
process relies on the binding of MLKL to the mitochondrial 
phosphatase phosphoglycerate mutase family member 5 (PGAM5), 
which then triggers mitochondrial ROS production and mitochondrial 
damage220 (Figure 1.15). This protein has an important role in 
mitochondrial homeostasis and programmed cell death through 
impairment of mitochondrial dynamics, leading to necroptosis220 
(Figure 1.15). 
 
Necroptosis and infection 
 Because the release of DAMPs stimulates pattern recognition 
receptors such as TLRs, the explosive nature of necroptosis is 
widely accepted as part of the pathophysiology of many 
inflammatory diseases221.  
In viral infections, such as caused by Vaccinia virus, TNF induces 
RIPK1/RIPK3 activation in host tissues. Deletion of the genes 
encoding for these proteins renders cells resistant to necroptosis and 
		 49	
reduces inflammation222,223. As a trade-off, mice in which 
RIPK1/RIPK3 activation is impaired succumb to infection due to 
failure in controlling viral replication222,223.  
 In bacterial sepsis, however, TNF is a major driver of systemic 
cytokine storm, tissue damage and multiorgan failure. As such, 
impaired RIPK1/RIPK3 activation was shown to be protective against 
TNF-induced Systemic Inflammatory Response Syndrome 
(SIRS)224,225.  
 The necroptosis pathway is also implicated in the control of 
Mycobacterium infection11. One of the major protective functions of 
TNF is to promote granuloma formation, which is crucial in bacteria 
containment11. Activation of RIPK1 and RIPK3 by TNF leads to the 
accumulation of ROS and necroptosis of macrophages in these 
granulomas, allowing bacteria to be released into the growth-
permissive extracellular environment. Blocking necroptosis however, 
leads to burst of macrophages due to excessive bacterial replication 
inside these cells. As a consequence of macrophage death, bacteria 
reach the extracellular environment, where replication is 
permissive11. Hence, unlike the situation with Vaccinia virus, one can 
view Mycobacterium as a pathogen that hijacks the host necroptosis 
machinery to promote its own growth and dissemination.  
 In parasitic diseases such as malaria, the leakage of hemoglobin 
and consequent release of heme into circulation leads to 
inflammation and oxidative stress activating TNF-dependent 
programmed cell death in parenchyma cells180. Macrophages are 
also prone to heme sensitization to programmed cell death via TLR4 
signaling and autocrine TNF and ROS production, which synergize 
to induce RIPK1/RIPK3-dependent necroptosis175. Other cell types 
that are susceptible to ROS-dependent necrosis include neurons226 
and astrocytes227.  
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Besides its role in infection, activation of the RIPK1/RIPK3/MLKL 
signaling pathway is a hallmark of sterile inflammatory conditions 
such as acute and chronic alcohol exposure220 and acetaminophen 
(APAP)-induced liver injury221. Consistent with these findings, a 
recent study shows that MLKL is the trigger for necroptosis in vivo in 
human autoimmune hepatitis and in a model of inflammation-
dependent hepatitis (Concanavalin A, Con A) where it is upregulated 
and activated230. Interestingly, in this particular context, 
hepatocellular necrosis is driven by a previously unrecognized 
RIPK3-independent function of MLKL230. Additionally, RIPK3 and 
MLKL are essential players mediating hepatocyte cell death in 
samples from human patients with primary biliary cholangitis, and 
genetic ablation of RIPK3 protects mouse hepatocytes from 
oxidative stress, inflammation and necrosis231. The tissue damage 
caused by IRI in several organs was also shown to be dependent on 
the necroptosis machinery and many of these studies unravel a role 
for mitochondria as key players in TNF-dependent necroptosis232,233. 
 Together, these data highlight the role of the canonical 
necroptosis mediators RIPK3 and MLKL in promoting tissue damage 
in models of sterile inflammation, and may presumably act through a 
similar mechanism upon infection. 	
Mitochondria and the execution of necroptosis 
 Although there is some controversy as to whether mitochondria 
are required for necroptosis234, vast information pointing to these 
organelles as key players in the execution of necroptosis was 
obtained in cell lines and requires backup from both primary cells 
and in vivo data. The first evidence for involvement of ROS in 
necroptosis arose more than 10 years ago, where it was 
demonstrated that triggering the formation of the necrosome after 
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TNFR1 engagement leads to ROS production235. In adition, TNF-
mediated ROS generation dependent on RIPK1 derive from 
mitochondria236, where suppression of the mitochondrial respiratory 
chain complex I is cytoprotective237. Presumably, the complex IIb 
formed by RIPK1/RIPK3/MLKL in response to TNFR1 engagement 
triggers necroptosis via translocation to mitochondria and 
subsequent mitochondrial ROS production, activation of PGAM5 and 
mitochondrial damage234 (Figure 1.15). 
 PGAM5 regulates mitochondrial fission and mitophagy238. 
Mitochondrial fission is a result of mitochondrial stress and 
dysfunction characterized by the significant cristae remodeling, 
leading to fragmentation and disappearance of cristae membranes 
and a typical change in mitochondrial morphology to a spherical 
shape239. This is achieved via the recruitment of dynamin-related 
protein 1 (Drp1) by PGAM5, which activates Drp1 GTPase activity 
through its dephosphorylation, leading to mitochondrial 
fragmentation, an early obligatory step in necrosis execution240,271,242. 
In agreement with these findings, PGAM5 contributes to ROS 
production243 downstream of RIPK3 and MLKL243, presumably 
through Drp1 activation, which was shown to promote TNF-
dependent necroptosis243,244 (Figure 1.15).  
  MPTP is a large non-specific channel that spans in the inner 
mitochondrial membrane impairing oxidative phosphorylation and 
promoting ROS production245. This process leads to ATP depletion, 
mitochondrial swelling and rupture, culminating in necrotic cell 
death245. Cyclophilin D (CypD), a mitochondrial matrix protein 
encoded by the nuclear gene Peptidylprolyl Isomerase F (Ppif)245 is a 
critical regulator of the MPTP opening (Figure 1.16)246,247,248 and is 
involved in TNF-dependent necroptosis217,11 probably acting 
downstream from RIPK1249 but probably not RIPK3232. 
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Figure 1.15. TNF-dependent programmed cell death 
machinery.  
The membrane-associated Complex I induces NF-κB activation leading to 
cFLIPL expression, heterodimerization with caspase 8 and inhibition of both 
apoptosis and necroptosis. Active caspase 8 in Complex IIa promotes 
apoptosis and inhibits necroptosis by cleavage of RIPK1 and RIPK3. Upon 
caspase 8 inactivation (red X), RIPK1 and RIPK3 initiate Complex IIb 
(necrosome) assembly, amyloid conversion and recruitment of MLKL. This 
protein acts on the plasma membrane where it mediates membrane rupture 
with DAMP release and on mitochondria, where it signals to PGAM5, 
contributing to ROS formation and subsequent MPTP opening mediated by 
CypD. This leads to mitochondrial dysfunction and sustained ROS 
production culminating in a necrotic outcome. (Adapted from Ka-Ming Chan 
F, Luz NF & Moriwaki K, Annu. Rev. Immunol. 2015) 
 
1.6. NRF2 and TNF-dependent necroptosis 
 There are several independent lines of evidence that suggest a 
functional link between NRF2 and necroptosis and indicating that 
activation of NRF2 represses this cell death pathway. Namely, 
butylated hydroxyanisole (BHA), an NRF2 inducer, suppresses ROS 
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generation and blocks TNF-dependent necroptosis235,250, suggesting 
that this transcription factor acts as a repressor of necroptosis. 
Furthermore, exogenous GSH attenuates iron-dependent 
necrosis226, leading to the hypothesis that the mechanisms via which 
NRF2 activation counter necroptosis probably involves an increase 
in cellular glutathione142. 
 There is also a functional link between the NRF2-dependent 
antioxidant pathway and MPTP, which is closed under physiological 
conditions251. In response to pro-oxidant stimuli including ischemia-
reperfusion and cytotoxic agents, the MPTP opens irreversibly, 
eliminating mitochondrial Δѱm and ATP producing capacity251. One 
of the proteins involved in MPTP opening is GSK-3β252,253, a kinase 
that phosphorylates and inhibits NRF2 activation254,255. GSK-3β 
inhibition is cytoprotective via a mechanism involving NRF2 
activation and associated with NF-κB inhibition256. This suggests that 
inhibition of NRF2 phosphorylation by GSK-3β reduces mitochondrial 
ROS accumulation and MPTP opening, presumably ameliorating 
programmed cell death and tissue damage. 
 A key component in the necroptosis pathway that was shown to 
have a link to NRF2 is PGAM5, the protein downstream of MLKL and 
upstream of MPTP opening220. Interestingly, PGAM5 forms a ternary 
complex containing NRF2 and Keap1 that is localized to 
mitochondria, contributing to the repression of NRF2-dependent 
gene expression. Thus, PGAM5, by anchoring the Keap1-NRF2 
complex to outer membrane of mitochondria, may facilitate the 
coordination between mitochondrial function and regulation of NRF2-
dependent antioxidant gene expression257. 
 Together, these studies reveal that oxidative stress leads to 
mitochondrial damage through the activation of the necroptotic 
pathway, and that this mechanism may be countered by the 
transcriptional regulation of protective genes mediated by NRF2. 
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1.7. Thesis overview  
 The general goal of this thesis is to characterize the 
pathophysiological effects of labile heme in the context of 
inflammatory agonists leading to necroptosis and understand how 
these are countered by NRF2. We aimed at uncovering the 
protective mechanisms via which this redox sensitive transcription 
factor blocks necroptosis, confers tissue damage control and 
establishes disease tolerance to systemic infections associated with 
hemolysis. Manipulation of signal transduction pathways that 
modulate the oxidative status might unravel a general mechanism for 
tissue damage control and disease tolerance in different 
inflammation models. 
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Chapter 2: 
Results 
 
 
 
 
 
 
 
 
 
 
“However vast the darkness, we must supply our own 
light.”  
(Stanley Kubrick) 
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2.1. NRF2 is essential to establish disease tolerance to 
malaria. 
 We used a well-recognized experimental model of Plasmodium 
infection in which >90% of wild type C57BL/6 mice survive the blood 
stage of Plasmodium chabaudi chabaudi (Pcc) infection, via a 
mechanism that relies on both resistance and disease tolerance 
mechanisms1,2. Pcc infection in C57BL/6 mice was associated with 
the induction of NAD(P)H quinone dehydrogenase 1 (Nqo1) and 
glutathione s-transferase (Gst) gene expression in the liver, as 
assessed by qRT-PCR (Figure 2.1a,b). Up regulation of these genes 
was ablated in NRF2-deficient (Nrf2-/-) C57BL/6 mice, as compared 
to C57BL/6 wild-type (Nrf2+/+) controls, demonstrating that the NRF2-
dependent antioxidant pathway is activated in response to the blood 
stage of Plasmodium infection (Figure 2.1a,b,c). Expression of Heme 
oxygenase 1 (Hmox1) and Ferritin Heavy Chain (FtH) was induced 
at comparable levels in the liver of Nrf2-/- vs. Nrf2+/+ mice in response 
to Plasmodium infection (Figure 2.1c,d). This suggests that, in the 
absence of NRF2, the aforementioned genes are probably regulated 
via the induction of other transcription factors. 
 Plasmodium infection was associated with a more pronounced 
decrease in body weight (Figure 2.1e) and temperature (Figure 2.1f), 
as well as with a higher incidence of mortality (Figure 2.1g) in Nrf2-/- 
vs. Nrf2+/+ mice. Percentage of infected RBCs in circulation, 
assessed during the course of infection, was similar in Nrf2-/- vs. 
Nrf2/+/+ mice (Figure 2.1h). Together, these data demonstrate that 
Nrf2 is essential to establish disease tolerance to the blood stage of 
Plasmodium infection. 			
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Figure 2.1. NRF2 confers disease tolerance to malaria 
infection.  
(a-d) Liver Nqo1, Gst, Fth and Hmox1 mRNA levels, normalized to Arbp0, 
in non-infected Nrf2+/+ and Nrf2-/- mice (0) and in Nrf2+/+ and Nrf2-/- mice at 
days 3, 5 or 7 after Pcc infection. Data is represented as mean ± STD from 
n=4-5 mice per genotype, one experiment. One-way ANOVA. (e) 
Percentage of initial weight and (f) temperature in Pcc-infected Nrf2+/+ and 
Nrf2-/- mice, relative to non-infected controls (day 0). Data pooled from three 
independent experiments with similar trend (n=16 mice per genotype), 
represented as mean ± SEM. Mann-Whitney U Test. (g) Percent survival of 
Pcc-infected Nrf2+/+ and Nrf2-/- mice, pooled from six independent 
experiments with similar trend (n=31-32 mice per genotype). Log-Rank 
Test. (h) Percentage of infected RBC in Nrf2+/+ and Nrf2-/- mice throughout 
the course of Pcc infection, pooled from six independent experiments 
(n=27-31 mice per genotype), represented an as mean ± SEM. n.s.: non 
significant, *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 Lethality of Plasmodium infection in Nrf2-/- mice was associated 
with the development of multi-organ damage, revealed by the 
accumulation of lactate dehydrogenase (LDH, general tissue 
damage), alanine aminotransferase (ALT; liver damage), aspartate 
aminotransferase (AST; liver damage), creatinine kinase (CK; 
muscle damage) and creatinine (kidney damage) as well as urea 
(kidney damage) in the plasma (Figure 2.2).  
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Figure 2.2. NRF2 protects against multi-organ 
damage/dysfunction in malaria infection.  
Serological analysis of general tissue damage marker LDH and specific-
tissue damage markers ALT and AST (liver), CK (muscle), Urea and 
Creatinine (kidney) in Nrf2+/+ and Nrf2-/- mice before (day 0) and at days 7 
and 10 after Pcc infection. Data pooled from four independent experiments 
with similar trend (n=10-20 mice per group), represented as mean ± SEM. 
One-way ANOVA. n.s. non significant, *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 Histological analysis confirmed that Nrf2-/- mice develop more 
severe liver, kidney and heart damage, observed by the number of 
necrotic foci as a consequence of Pcc infection, when compared to 
Nrf2+/+ mice (Figure 2.3).  
 
 
Figure 2.3. NRF2 provides tissue damage control to malaria 
infection.  
Liver, kidney and heart sections stained with H&E from control (non 
infected) Nrf2+/+ and Nrf2-/- mice and collected 10 days after Pcc infection. 
Dotted lines indicate areas of hepatocyte necrosis. White arrows indicate 
kidney tubular cell necrosis and black arrows display areas of 
cardiomyocyte necrosis. Images are representative of two independent 
experiments, n=8-10 mice per genotype. Scale bar = 100µm.  
 
 Tissue damage was associated with the accumulation of DAMPs 
in the extracellular space3,4. Nrf2-/- mice display increased levels of 
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extracellular DNA, as monitored by liver intravital imaging5 (Figure 
2.4a,b) as well as detectable levels of circulating mitochondrial DNA 
in the plasma (Figure 2.4c).  
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Figure 2.4. NRF2 prevents DAMP release and oxidative 
stress in malaria infection.  
(a) Extracellular DNA (green) monitored by liver intravital microscopy 7 
days after Pcc infection and in non-infected (control) Nrf2+/+ and Nrf2-/- mice 
(red: mitochondria). Scale bar = 200 µm. (b) Quantification of liver 
extracellular DNA from two independent experiments (n=4 mice per group, 
4 different areas analyzed), represented as mean % area ± SEM. Mann 
Whitney U Test. (c) Levels of circulating mtDNA, i.e. cytochrome b (Cytb), 
mitochondrial encoded cytochrome c oxidase I and III (mt-CoI, mt-CoIII), 
and NADPH dehydrogenase (Nd1) copies in the plasma of infected Nrf2+/+ 
and Nrf2-/- mice at day 10 post-Pcc infection. Data pooled from two 
independent experiments with similar trend (n=9 mice per group), is 
represented as mean ± SEM. (d) HMGB1 levels in the plasma of non-
infected (Day 0) and infected Nrf2+/+ and Nrf2-/- mice at day 10 post-Pcc 
infection. Data pooled from two independent experiments (n=4-10 mice per 
group), represented as mean ± SEM. Mann Whitney U Test. (e) Heme 
levels in the plasma of non-infected (Day 0), or infected Nrf2+/+ and Nrf2-/- 
mice at days 7 and 10 after Pcc infection. Data from one experiment (n=4-6 
mice per group) represented as mean ± STD. Mann Whitney U Test. (f) 
GPX levels in the plasma of non-infected (Day 0) and infected Nrf2+/+ and 
Nrf2-/- mice 10 days after Pcc infection. Data from one experiment (n=4-6 
mice per group), represented as mean ± SD. Mann Whitney U Test. n.s.: 
non significant, *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 Moreover, higher levels of High Mobility Group Box 1 (HMGB1) 
(Figure 2.4d) were detected in the plasma of Nrf2-/- mice as well as 
higher concentrations of labile heme (Figure 2.4e), when compared 
to infected Nrf2+/+ mice. Additionally, infected Nrf2-/- mice display 
increased GPX activity in the plasma when compared to their wild-
type counterparts, a proxy for systemic oxidative stress6 (Figure 
2.4f).  
 We have also found higher levels of circulating cytokines IL-1b, 
IL-6, MCP-1, MIP-1α, RANTES and IL-10 in the plasma of Pcc-
infected Nrf2-/- vs Nrf2/+/+ mice (Figure 2.5).  
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Figure 2.5. NRF2 counters inflammation in malaria infection. 
Cytokine levels in the plasma of non-infected controls (day 0) and infected 
Nrf2+/+ and Nrf2-/- mice 7 days post-Pcc infection. Data is represented as 
mean ± STD from n=4-6 mice per genotype, one experiment. Mann 
Whitney U Test. *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 Overall, these observations demonstrate that the stress response 
regulated by NRF2 limits the release of DAMPs into circulation, 
presumably by controlling the systemic oxidative stress leading to 
tissue damage, organ dysfunction and necrosis upon Plasmodium 
infection, therefore limiting the extent of inflammatory cytokine 
secretion and overall inflammation. Therefore, by providing tissue 
damage control, NRF2 counters disease severity and confers 
disease tolerance to malaria infection. 
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2.2. NRF2 is essential to establish disease tolerance to 
polymicrobial sepsis. 
 As polymicrobial bloodstream infections are often associated with 
more or less severe hemolysis7,8 and NRF2 is protective in the 
context of different models of sepsis9,10, we hypothesized that the 
stress response regulated by NRF2 contributes to the establishment 
of disease tolerance to sepsis. Thus, we tested this hypothesis 
specifically for systemic polymicrobial infections leading to sepsis 
using cecal ligation and puncture (CLP) as experimental model11. 
 We have observed that most Nrf2-/- mice succumbed to CLP, 
under experimental conditions that were not lethal to Nrf2+/+ mice 
(Figure 2.6a), which is consistent with previous observations9. 
However, the survival advantage of Nrf2+/+ vs. Nrf2-/- mice was not 
associated with differences in pathogen load, as assessed 16 hours 
after CLP for aerobic and anaerobic bacteria in different organs 
(Figure 2.6b). Of note, body weight (Figure 2.6c) and temperature 
(Figure 2.6d) were similar in Nrf2-/- vs. Nrf2+/+ mice subjected to CLP. 
Finally, CLP in Nrf2+/+ mice was associated with the induction of Fth 
mRNA expression in the kidney, as assessed by qRT-PCR (Figure 
2.6e). Upregulation of this gene was ablated in NRF2-deficient (Nrf2-
/-) mice, as compared to wild-type controls, demonstrating that the 
NRF2-dependent antioxidant pathway is activated in response to 
polymicrobial sepsis. 
 Mortality of Nrf2-/- mice subjected to CLP was associated with 
organ damage, as assessed serologically (Figure 2.7a) and 
confirmed by histological analysis (Figure 2.7b), through observation 
of widespread hepatocellular degeneration. This was not apparent 
however, in the kidney, lung and heart of Nrf2-/- mice subjected to 
CLP (Figure 2.8). 
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Figure 2.6. NRF2 provides disease tolerance to polymicrobial 
sepsis.  
(a) Survival of Nrf2+/+ and Nrf2-/- mice subjected to CLP in three independent 
experiments with similar trend (n=9-11 mice per genotype). Log-Rank Test. 
(b) Colony forming units (CFU) of aerobic (Ae) and anaerobic (An) bacteria, 
16 hours after CLP in Nrf2+/+ and Nrf2-/- mice. Data pooled from two 
independent experiments (n=5-6 mice per genotype). Mann Whitney U 
Test. PC: peritoneal cavity. Percentage of initial (c) weight and (d) 
temperature in Nrf2+/+ and Nrf2-/- mice subjected to CLP, relative to non-
infected controls (day 0). Data pooled from three independent experiments 
with similar trend (n=9-11 mice per genotype), represented as mean ± 
SEM. (e) Kidney Fth mRNA levels, normalized to Arbp0, in control Nrf2+/+ 
and Nrf2-/- mice (0) and in Nrf2+/+ and Nrf2-/- mice 16 and 36h after CLP. 
Data is represented as mean ± STD from n=3-8 mice per genotype, one to 
two experiments. One-Way ANOVA. n.s.: non significant, *p< 0.05, **p< 
0.01, ***p<0.001. 
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 Accumulation of mitochondrial DNA (Figure 2.7c) and HMGB1 
(Figure 2.7d) in the plasma was higher in Nrf2-/- septic mice as 
compared to Nrf2/+/+ septic mice after CLP. 
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Figure 2.7. NRF2 confers tissue damage control in 
polymicrobial sepsis.  
(a) Serological markers of tissue damage (LDH), liver (ALT), muscle (CK) 
and kidney (Urea) in plasmas from Nrf2+/+ and Nrf2-/- mice collected before 
(Ctr.) and 16h after CLP. Data pooled from one to two independent 
experiments with similar trend (n=5-7 mice per group for CK and Urea; n=7-
10 mice per group for LDH and AST). Data represented as mean ± SEM. 
Mann-Whitney U Test. (b) H&E staining of liver sections from naïve Nrf2+/+ 
and Nrf2-/- mice (Control) and 16h after CLP. Images correspond to one 
experiment, n=5-7 mice per group. Dotted line indicates area of 
hepatocellular degeneration. Scale bar = 100µm. (c) HMGB1 concentration 
in the plasma of non-infected (Ctr.) and infected Nrf2+/+ and Nrf2-/- mice, 16h 
after CLP. Data from one experiment (n=7 mice per group) is represented 
as mean ± STD. Mann-Whitney U Test. (d) Levels of circulating mtDNA in 
the plasma of mice subjected to CLP, 16h after procedure. Data, pooled 
from two independent experiments with similar trend (n=5-10 mice per 
genotype), is represented as mean ± STD. *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
Figure 2.8. NRF2 provides tissue damage control mainly in 
the liver upon polymicrobial sepsis.  
H&E staining of kidney, lung and heart sections from non-infected (control) 
and infected Nrf2+/+ and Nrf2-/- mice, 16 hours after CLP. Images are 
representative of n=7 mice per genotype in one experiment. Scale bar = 
100 µm. 
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 There were also increased levels of circulating cytokines MCP-1, 
MIP-1β, MIP-2, RANTES or IL-10 in the plasma of Nrf2-/- mice and a 
similar trend for IL-1α, IL-1β, IL-6, MIP-1α, IL-12 and MIG (Figure 
2.9), when compared to Nrf2+/+ mice, 16 hours after being subjected 
to CLP.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.9. NRF2 counters inflammation upon polymicrobial 
sepsis.  
Cytokine levels in the plasma of non-infected (Ctr.) and 16 hours after CLP 
in Nrf2+/+ and Nrf2-/- mice. Data is represented as mean ± STD from n=3-5 
mice per genotype, one experiment. Mann Whitney U Test. n.s.: non 
significant, *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 Taken together, our data reveal that NRF2 establishes disease 
tolerance to polymicrobial infection via a tissue damage control 
mechanism limiting DAMP release and, presumably, preventing an 
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unfettered inflammatory response leading to sepsis, which is 
consistent with previous reports9.  
 
2.3. NRF2 confers tissue damage control after sterile 
hemolysis. 
 We then asked what is the contribution of heme in the 
pathophysiology of hemolytic infections and whether NRF2 activation 
is protective against sterile intravascular hemolysis. Induction of 
acute hemolysis through the administration of Phenylhidrazine (PHZ) 
was lethal to Nrf2-/- mice and not to Nrf2+/+ mice (Figure 2.10a), 
despite similar levels of hemolysis (Figure 2.10b) and heme 
accumulation in the plasma (Figure 2.10c). PHZ administration was, 
however, linked to the release of mtDNA, significantly higher in the 
plasma of Nrf2-/- mice when compared to their wild-type counterparts 
(Figure. 2.10d). Mortality of Nrf2-/- mice was not associated with a 
significant reduction of body weight (Figure. 2.10e) or temperature 
(Figure. 2.10f), when compared to Nrf2+/+ mice. 
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Figure 2.10. NRF2 protects against lethality associated with 
severe acute hemolysis.  
(a) Relative survival of Nrf2+/+ and Nrf2-/- mice subjected to acute 
intravascular hemolysis, induced by PHZ administration. Data was pooled 
from three independent experiments with similar trend (n=12 mice per 
genotype). Log-Rank Test. (b) Mean number of circulating RBC ± STD in 
the same mice as (a). (c) Heme levels in the plasma of control (Ctr.) or after 
PHZ administration, when temperature of PHZ-treated Nrf2-/- mice was 
below 27oC (around 24h after second injection). Data from one experiment 
(n=3-4 mice per group) is represented as mean ± STD. Mann-Whitney U 
Test. (d) Levels of circulating mtDNA, i.e. mitochondrial encoded 
cytochrome c oxidase III (mt-CoIII) and NADPH dehydrogenase (Nd1) 
copies in the plasma of control and infected Nrf2+/+ and Nrf2-/- mice, when 
temperature of PHZ-treated Nrf2-/- mice was below 27oC (around 24h after 
second injection). Data pooled from two independent experiments with 
similar trend (n=5-7 mice per group) is represented as mean ± SEM. Mann-
Whitney U Test. Percentage of initial (e) weight and (f) temperature in 
Nrf2+/+ and Nrf2-/- mice receiving PHZ, relative to controls (day 0). Data from 
three independent experiments with similar trend (n=12 mice per genotype) 
was pooled and is represented as mean ± SEM. n.s.: non significant,  *p< 
0.05, **p< 0.01, ***p<0.001.  
 
 
 Administration of PHZ led to severe tissue damage in liver and 
kidney from Nrf2-/- mice when compared to their wild-type 
counterparts. Deletion of NRF2 was associated with higher number 
of necrotic foci in the liver and multiple areas of tubular cell necrosis, 
completely absent in the kidney of NRF2 proficient mice. 
Interestingly, both Nrf2-/- and Nrf2+/+ mice extensively accumulate 
hemoglobin inside kidney tubular cells, but only knockout cells 
undergo necrosis followed by detachment of these cells into the 
tubule lumen (Figure 2.11).  
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Figure 2.11. NRF2 provides tissue damage control after 
acute sterile hemolysis.  
H&E staining of liver and kidney sections from control (non-treated) Nrf2+/+ 
and Nrf2-/- mice or from mice receiving the second injection of PHZ 24h 
before harvesting the organs. Images are representative of one experiment, 
4 mice per group. Black dotted line indicate areas of hepatocyte necrosis in 
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the liver and necrotic tubular cells detached to the lumen of the kidney 
tubule; red dotted line shows hemoglobin cast; white arrow points to tubular 
cells filled with hemoglobin and asterisk marks necrotic kidney tubular cells. 
Scale bar = 200 µm (liver) and 50 µm (kidney). 
 
 
 We then asked whether NRF2 acts directly to counter the 
pathogenic effects of heme, a byproduct of hemolysis. Heme 
administration to transgenic OKD48 mice, expressing a NRF2-
luciferase reporter12, was associated with induction of luciferase 
activity (Figure 2.12a,b), demonstrating that heme activates NRF2 in 
vivo. Heme administration led to increased mortality in Nrf2-/- mice 
(Figure 2.12c) and to a more pronounced loss of body weight (Figure 
2.12d) and temperature (Figure 2.12e), as compared to Nrf2+/+ mice. 
Interestingly, heme administration was associated with extracellular 
DNA accumulation in the liver of Nrf2/+/+ mice (Figure 2.12f,g).  
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Figure 2.12. NRF2 protects against the cytotoxic effects of 
labile heme.  
(a) Luciferase activity in reporter OKD48 mice, 6 hours after PBS (Control) 
or heme injection (40mg/Kg). Image is representative of 4-8 mice per group 
in two independent experiments. (b) Quantification of luciferase activity of 
mice in (a). Data is represented as mean ± STD. Mann-Whitney U Test. (c) 
Relative survival of Nrf2+/+ and Nrf2-/- mice subjected to heme 
administration. Data was pooled from three independent experiments with 
similar trend (n=12 mice per genotype). Log-Rank Test. Percentage of (d) 
initial weight and (e) temperature in Nrf2+/+ and Nrf2-/- mice receiving heme. 
Data from one experiment (n=4 mice per genotype) is represented as mean 
± STD. Mann-Whitney U Test. (f) Representative images captured by liver 
intravital microscopy showing extracellular DNA (green) and mitochondrial 
TMRM (red) in the liver of Nrf2+/+ mice receiving PBS or heme 24 hour 
before. Scale bar = 200 µM. (g) Mean % of liver extracellular DNA ± STD, 
detected by intravital microscopy. Data in (f) and (g) was pooled from two 
independent experiments (n=4 mice per group, 4 different areas analyzed). 
Mann-Whitney U Test. *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 In contrast to PHZ-induced hemolysis, antibody-induced RBC 
depletion (Figure. 2.13a) was not associated with the accumulation 
of heme in the plasma (Figure. 2.13b), with the activation of NRF2 in 
transgenic OKD48 mice (Figure. 2.13c), nor with increased mortality 
of Nrf2-/- vs. Nrf2+/+ mice (Figure. 2.13d).  
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Figure 2.13. NRF2 specifically protects against hemolysis, 
not RBC depletion. 
(a) Number of circulating RBC in Nrf2+/+ and Nrf2-/- mice receiving αRBC 
serum. Data from four independent experiments with similar trend (n=15-16 
mice per genotype) was pooled and is represented as mean ± STD. (b) 
Heme concentration in the plasma of Nrf2+/+ and Nrf2-/- mice, 4 days after 
the first administration of αRBC serum. Data from one experiment (n=3-4 
mice per genotype) is represented as mean ± STD. Mann-Whitney U Test. 
(c) Bioluminescence imaging in OKD48 reporter mice, 24h after the first 
administration of αRBC serum. Images are representative of 2-3 mice 
genotype. (d) Relative survival of Nrf2+/+ and Nrf2-/- mice receiving αRBC 
serum. Data polled from four independent experiments with similar trend 
(n= 15-16 mice per group). Log-Rank Test. n.s.: non significant, *p< 0.05, 
**p< 0.01, ***p<0.001.  
 
 
 Together, these observations highlight the role of NRF2 in 
countering the deleterious effects of labile heme generated upon 
hemolysis, by protecting against necrosis and providing tissue 
damage control in the context or not of bloodstream infections.  
 
2.4. NRF2 regulates the anti-oxidant response targeting 
the mitochondria. 
 When exposed in vitro to heme plus TNF, primary mouse 
hepatocytes increased NRF2 protein expression (Figure 2.14a), 
nuclear translocation (Figure 2.14b,c) and transcriptional activity 
(Figure 2.14d). However, while heme alone led to an augmented 
NRF2 protein expression (Figure 2.14a) and nuclear translocation 
(Figure 2.14b,c), it did not induce NRF2 transcriptional activity 
(Figure 2.14d). Moreover, TNF failed per se to induce NRF2 protein 
expression (Figure 2.14a), nuclear translocation (Figure 2.14b,c) or 
transcriptional activity (Figure 2.14d). Interestingly, our data reveals 
that heme primes hepatocytes to activate antioxidant NRF2-
dependent gene expression in response to TNF, consistent with our 
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previous observation that heme primes hepatocytes to accumulate 
ROS in response to TNF13,14,1. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.14. Heme synergizes with TNF to induce NRF2 
expression but not transcriptional activity.  
(a) NRF2 protein expression detected by western blot in whole cell lysates 
from Hepa1-6 cells not treated (-) or treated (+) with MG132, heme, TNF or 
heme and TNF. Image is representative of three independent experiments 
with similar trend. (b) NRF2 protein detected by immunofluorescence (red) 
in Hepa1-6 cells not treated or treated with heme, TNF or heme plus TNF. 
(Blue: DNA). Images are representative of three independent experiments. 
Asterisk indicates cytoplasmic NRF2 and arrowheads nuclear NRF2. Scale: 
10µm. (c) Quantification of NRF2 nuclear translocation in Hepa1-6 cells 
treated as in (a) and (b). Data represents the mean integrated density per 
cell, from five fields per treatment per experiment in three independent 
experiments ± STD. Mann-Whitney U Test. (d) NRF2 transcriptional activity 
in Hepa1-6 cells transiently transfected with an NRF2-luciferase reporter 
and treated as in (a-c). Data from two independent experiments is 
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represented as mean ± STD. Mann-Whitney U Test. *p< 0.05, **p< 0.01, 
***p<0.001.  
 
 Under experimental conditions not cytotoxic to Nrf2+/+ primary 
hepatocytes, heme and TNF induced Nrf2-/- hepatocytes to undergo 
programmed cell death (PCD) (Figure 2.15a). Cytotoxicity in Nrf2-/- 
hepatocytes was accompanied by the accumulation of high levels of 
ROS (Figure 2.15b,e), including mitochondrial superoxide (mtO2-) 
(Figure 2.15c,f) and with mitochondrial membrane (Δψm) 
hyperpolarization (Figure 2.15c,g).  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
**
0
20
40
60
Heme
TNF
-
-
+
-
-
+
+
+
C
el
l D
ea
th
 (%
) Nrf2+/+
Nrf2-/-
a
*
Heme
TNF
-
-
+
-
-
+
+
+
Nrf2+/+
Nrf2-/-
*
Heme
TNF -
+
- +
+
+
0
2
4
6*
Heme
TNF
-
-
+
-
-
+
+
+
0
2
4
6
8
- -
b
c d
0
4
8
12
16
Nrf2+/+
Nrf2-/-
Nrf2+/+
Nrf2-/-
TM
R
E
 
(F
ol
d 
in
du
ct
io
n)
R
O
S
 (D
C
FD
A
) 
(F
ol
d 
in
du
ct
io
n)
m
tO
2- 
(M
ito
S
ox
)
(F
ol
d 
in
du
ct
io
n)
fe
Pe
rc
en
t o
f M
ax
100 101 102 103
0
20
40
60
80
100
104 100 101 102 103 104
Medium
Heme
TNF
Heme +
TNF
Nrf2+/+ Nrf2-/-
0
20
40
60
80
100
100 101 102 103 104 100 101 102 103 104
ROS (CM-H2DCFDA) Mitochondrial O2 (MitoSOX)
Medium
Heme
TNF
Heme +
TNF
Nrf2+/+ Nrf2-/-
100 101 102 103 104 100 101 102 103 104
TMRE
g
P
er
ce
nt
 o
f M
ax
0
20
40
60
80
100 Medium
Heme
TNF
Heme +
TNF
Nrf2+/+ Nrf2-/-
		 90	
Figure 2.15. NRF2 protects against mitochondrial 
dysfunction, mitochondrial ROS production and cell death in 
response to heme and TNF.  
(a) Percentage of cell death in Nrf2+/+ and Nrf2-/- primary hepatocytes 
treated (+) or not (-) with heme, TNF or heme plus TNF and collected 8h 
after heme treatment. Data is represented as mean ± STD from 6 wells in 
one out of three independent experiments with similar trend. One-Way 
ANOVA. Levels of (b,e) intracellular ROS, (c,f) mitochondrial superoxide 
and (d,g) mitochondrial membrane potential in primary mouse hepatocytes, 
treated as in (a). Data in (b-d) represents the pool of four independent 
experiments with the same trend and is displayed as mean ± STD and data 
in (e-g) displays one from the four independent experiments in (b-d). One-
Way ANOVA. *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 These data show that NRF2 preserves mitochondrial integrity and 
protects against PCD in response to heme and TNF via a 
mechanism associated with reduced production/accumulation of 
mitochondrial O2-. 
 To further investigate the role of mitochondrial O2- in the induction 
of hepatocyte PCD after heme and TNF treatment, we used the 
mitochondrial O2- scavenger, MitoTempo. This mitochondria-specific 
antioxidant protected primary Nrf2-/- (Figure 2.16a) or Nrf2+/+ (Figure 
2.17a) hepatocytes from undergoing PCD in response to heme and 
TNF. This suggests that mitochondrial O2- plays a central role in the 
mechanism via which heme sensitizes hepatocytes to undergo PCD 
in response to TNF and that NRF2 is protective against the 
production and/or accumulation of mitochondrial ROS. Of note, 
MitoTempo reduced to basal levels the overall ROS production in 
Nrf2-/- (Figure 2.16b,d) or Nrf2+/+ (Figure 2.17b,c) hepatocytes 
exposed to heme and TNF. This antioxidant effect was similar to the 
one observed using the glutathione precursor N-acetyl cysteine 
(NAC) (Figure 2.16b,d; Figure 2.17b,c), a well-known general 
antioxidant, suggesting that mitochondrial O2- is the predominant 
form of ROS generated in hepatocytes exposed to heme and TNF. 
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 MitoTempo preserved mitochondrial Δψm in primary Nrf2-/- 
(Figure 2.16c,e) or Nrf2+/+ (Figure 2.17d,e) hepatocytes exposed to 
heme and TNF, to a similar extent as NAC. This demonstrates that 
the mechanism via which NRF2 supports mitochondrial integrity 
involves the repression of mitochondrial O2- 
production/accumulation, which is consistent with the notion that this 
transcription factor regulates a metabolic response sustaining 
mitochondrial structure and function15,16.  
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Figure 2.16. NRF2 protects against heme and TNF-mediated 
cytotoxicity via a mechanism associated with reduced 
production/accumulation of mitochondrial ROS.  
(a) Percentage of cell death in primary mouse Nrf2-/- hepatocytes, treated 
(+) or not (-) with heme and/or TNF and MitoTempo (MitoT) and collected 
8h after heme treatment. Data represented as mean ± STD from 6 replicate 
wells in one out of two independent experiments with the same trend. One-
Way ANOVA. (b,d) Intracellular ROS and (c,e) Mitochondrial membrane 
potential in primary mouse Nrf2-/- hepatocytes, treated as in (a) and when 
indicated (+) with NAC. Data in (b) and (c) corresponds to the pool of three 
and two independent experiments with the same trend, respectively, and is 
represented as mean ± STD, relative to untreated (-) controls. One-Way 
ANOVA. Data in (d) and (e) displays one from the two to three independent 
experiments in (b) and (c). (f) Relative survival of Pcc-infected Nrf2-/- mice 
receiving PBS (Control) versus mice receiving MitoTEMPO (MitoT) or NAC. 
Data was pooled from three to four independent experiments with similar 
trend (n=10-23 mice per group). Log-Rank Test. (g) Mean percentage of 
infected RBC ± SEM, pooled from three to four independent experiments 
(n=10-23 mice per genotype). (h) Relative survival of Nrf2-/- mice receiving 
heme and treated with PBS (Control), MitoTEMPO (MitoT) or NAC. Data 
was pooled from two independent experiments with similar trend (n=8-10 
mice per group). Log-Rank Test. n.s.: non significant, *p< 0.05, **p< 0.01, 
***p<0.001. 
 
 
 We then asked whether NRF2 is acting as an antioxidant in vivo. 
MitoTempo administration to Nrf2-/- mice was protective against Pcc 
infection (Figure 2.16f) as well as against heme administration 
(Figure 2.16h) to a similar extent to the protection conferred by NAC 
(Figure 2.16f,h). The protective effect of both MitoTempo and NAC 
against Plasmodium infection was not associated with modulation of 
host pathogen load (Figure 2.16g). These results suggest that NRF2 
protects against heme toxicity generated during the blood stage of 
Plasmodium infection via an antioxidant mechanism protecting the 
mitochondria. 
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Figure 2.17. Heme and TNF synergize to produce 
mitochondrial ROS and mitochondrial dysfunction, leading 
to cell death.  
(a) Percentage of cell death in primary mouse Nrf2+/+ hepatocytes, treated 
(+) or not (-) with heme and/or TNF and MitoTempo (MitoT) and collected 
16h after heme treatment. Data represented as mean ± STD from 6 
replicate wells in one out of two independent experiments with the same 
trend. One-Way ANOVA. (b,d) Intracellular ROS and (c,e) Mitochondrial 
membrane potential in primary mouse Nrf2+/+ hepatocytes, treated as in (a) 
and when indicated (+) with NAC. Data in (b) and (c) corresponds to the 
pool of three and two independent experiments with the same trend, 
respectively, and is represented as mean ± STD, relative to untreated (-) 
controls. Data in (d) and (e) displays one from the two to three independent 
experiments in (b) and (c). One-Way ANOVA. *p< 0.05, **p< 0.01, 
***p<0.001. 
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2.5. Labile heme sensitizes hepatocytes to undergo TNF-
dependent necroptosis. 
 Induction of cell death in response to heme and TNF was partially 
rescued by Necrostatin-1 (Nec-1), suggesting that heme sensitizes 
hepatocytes to undergo PCD via RIPK1-dependent mechanism 
(Figure 2.18a). Primary hepatocytes from RIPK3 deficient (Ripk3-/-) 
mice were also protected against heme and TNF (Figure 2.18b).  
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Figure 2.18. Labile heme synergizes with TNF to trigger 
Ripk3-dependent necroptosis and mitochondrial dysfunction 
in hepatocytes.  
(a) Percentage of cell death in primary hepatocytes isolated from wild-type 
mice and treated (+) or not (-) with heme, TNF or heme plus TNF and, when 
indicated (+), with Nec1. Data represented as mean ± STD from 5 wells in 
one out of two independent experiments with the same trend. One-Way 
ANOVA. (b) Percentage of cell death in primary Rip3+/+ and Ripk3-/- mouse 
hepatocytes, treated (+) or not (-) with heme, TNF or heme plus TNF. Data 
represented as mean ± STD from 5 wells in one out of two independent 
experiments with the same trend. Relative induction and corresponding 
histograms of (c,d) intracellular ROS, (e,f) mitochondrial superoxide and 
(g,h) mitochondrial membrane potential. Data represented as mean ± STD 
from one out of four independent experiments with the same trend. One-
Way ANOVA. (i) Cellular ATP content in Rip3+/+ and Ripk3-/- mouse primary 
hepatocytes treated (+) or not (-) with heme, TNF or heme plus TNF. Data 
represented as mean ± STD from one out of two to four independent 
experiments with the same trend. One-Way ANOVA. *p< 0.05, **p< 0.01, 
***p<0.001. 
 
 
 Ablation of PCD in Ripk3-/- hepatocytes was associated with 
protection against intracellular ROS production/accumulation (Figure 
2.18c,d), including mitochondrial O2- (Figure 2.18e,f) as well as with 
maintenance of mitochondrial Δψm, preventing hyperpolarization 
(Figure 2.18g,h). 
 Heme and TNF reduced the intracellular ATP content of wild-type 
primary hepatocytes (Figure 2.18i), but not of Ripk3-/- cells (Figure 
2.18i). This reveals that heme and TNF interfere with mitochondrial 
function via a RIPK3-dependent mechanism, consistent with the 
notion that RIPK3 regulates cellular metabolism17. 
 Knockdown of Mlkl or Pgam5 using specific shRNAs (Figure 
2.19a) protected mouse hepatoma Hepa1-6 cells from undergoing 
PCD in response to heme and TNF (Figure 2.19b,c). This was 
associated with inhibition of intracellular ROS 
production/accumulation (Figure 2.19d,e), including mitochondrial 
O2- (Figure 19f,g) as well as with maintenance of mitochondrial Δψm 
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(Figure 2.19h,i). These results demonstrate that heme primes 
hepatocytes to undergo PCD via the canonical necroptosis signal 
transduction pathway involving RIPK1, RIPK3 and MLKL. This signal 
transduction pathway acts upstream of the outer mitochondria 
membrane PGAM518 to promote mitochondrial O2- 
production/accumulation19 and mitochondrial dysfunction leading to 
necrotic cell death20. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
ht ae
D ll e
C 
%
0
20
40
60
80
Heme
TNF
-
-
-
+
- + +
-
+
+
+
+
-
+
+
+
- -
-
-
+
+
-
-
+
+
- -
-
-
+
+
**
a b
shScr
shPgam5shScr
shMlkl
M
LK
L
PG
AM
5
Ac
tin
Ac
tin Scr.shRNA
αMlkl
Heme
TNF
-
-
-
+
- + +
-
+
+
+
+
-
+
+
+
- -
-
-
+
+
-
-
+
+
- -
-
-
+
+
0
20
40
60
80 **
Heme
TNF
Scr.shRNA
αMlkl
-
-
αPgam5 -
+
-
+
+
-
+
-
+
+
- +
+
+
-+
0
5
10
15
20
* *
e
0
10
20
30
40 ****
Heme
TNF
-
-
-
+
-
+
+
-
+
-
+
+
- +
+
+
-+
0
5
10
15
20
Heme
TNF
-
-
-
+
+
+
-
+
+
+
+
+
-+
****
d f
C
el
l D
ea
th
 (%
) 
R
O
S
 (D
C
FD
A
) 
(F
ol
d 
in
du
ct
io
n)
m
tO
2- 
(M
ito
S
ox
)
(F
ol
d 
in
du
ct
io
n)
TM
R
E
 
(F
ol
d 
in
du
ct
io
n)
- - - +
Scr.shRNA
αMlkl
αPgam5
Scr.shRNA
αMlkl
αPgam5
Scr.shRNA
αPgam5
- - - -
- -
c
% of Max
100 101 102 103 104
P
er
ce
nt
 o
f M
ax
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
shScr
shScr H+T
αMlkl
αMlkl H+T
ROS (CM-H2DCFDA)
g
100 101 102 103 104
P
er
ce
nt
 o
f M
ax
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
Mitochodrial O2
 (MitoSOX)
h i
shScr
shScr H+T
αPGAM5
αPGAM5 H+T
4
shScr
shScr H+T
αMlkl
αMlkl H+T
shScr
shScr H+T
αPGAM5
αPGAM5 H+T
100 101 102 103 10
P
er
ce
nt
 o
f M
ax
0
20
40
60
80
100
100 101 102 103 104
0
20
40
60
80
100
TMRE (Delta Phi)
shScr
shScr H+T
αMlkl
αMlkl H+T
shScr
shScr H+T
αPGAM5
αPGAM5 H+T
		 97	
Figure 2.19. Labile heme synergizes with TNF to trigger 
MLKL and PGAM5-dependent mitochondrial dysfunction and 
cell death in hepatocytes.  
(a) Detection of MLKL and PGAM5 protein expression by western blot, in 
whole cell extracts from Hepa1-6 cells transduced with a RecAd. encoding 
a control (scrambled) shRNA (Scr.shRNA) or a RecAd. encoding shRNAs 
targeting mouse Mlkl (shMlkl) or Pgam5 (shPgam5). (b, c) Percentage of 
cell death in in Hepa1-6 cells treated (+) or not (-) with heme, TNF or heme 
plus TNF and, when indicated (+), transduced with RecAd. encoding 
shRNAs targeting (b) mouse Mlkl (shMlkl) or (c)  Pgam5 (shPgam5). Data 
represented as mean ± STD from one out of two independent experiments 
with the same trend. One-Way ANOVA. Relative induction and 
representative histograms of (d,e) intracellular ROS production, (f,g) 
mitochondrial superoxide generation and (h,i) increase of mitochondrial 
membrane potential in Hepa1-6 cells treated as in (b, c). Data is 
represented as mean ± STD from two independent experiments with the 
same trend. One-Way ANOVA. *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
2.6. NRF2 regulates a cytoprotective response that inhibits 
necroptosis. 
 We reasoned that if NRF2 acts as a physiologic counter regulator 
of necroptosis, than genetic loss of function of components of the 
necroptosis signal transduction pathway should protect Nrf2-/- 
primary hepatocytes from heme sensitization to TNF-dependent 
necroptosis. Heme and TNF failed to induce primary Nrf2-/-Ripk3-/- 
hepatocytes to undergo necroptosis, as compared to primary Nrf2-/-
Ripk3+/+ hepatocytes (Figure 2.20a). Blocking PCD was associated 
with preservation of homeostatic levels of intracellular ROS 
production/accumulation (Figure 2.20b,e), including mitochondrial 
O2- (Figure 2.20c,f) as well as with maintenance of mitochondrial 
Δψm (Figure 2.20d,g) in Nrf2-/-Ripk3-/- vs Nrf2-/-Ripk3+/+ hepatocytes. 
Our data suggests that NRF2 acts as a physiologic counter regulator 
of heme and TNF-induced necroptosis in vitro. 
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Figure 2.20. NRF2 protects against Rikp3-dependent 
programmed cell death by blocking mitochondrial ROS 
production and mitochondrial dysfunction in vitro.  
(a) Percentage of cell death in primary Nrf2-/-Rip3+/+ and Nrf2-/-Ripk3-/- 
mouse hepatocytes, treated (+) or not (-) with heme, TNF or heme plus 
TNF. Data represented as mean ± STD from 6 wells in one out of two 
independent experiments with the same trend. One-Way ANOVA. Relative 
induction and corresponding representative histograms of (b,e) intracellular 
ROS, (c,f) mitochondrial superoxide and (d,g) mitochondrial membrane 
potential in Nrf2-/-Rip3+/+ and Nrf2-/-Ripk3-/- mouse primary hepatocytes 
treated (+) or not (-) with heme, TNF or heme plus TNF. Data represented 
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as mean ± STD from a pool of three independent experiments with the 
same trend. One-Way ANOVA. *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 As NRF2 acts as a physiologic counter regulator of necroptosis in 
vitro, we hypothesized that genetic loss of function of components of 
the necroptosis signal transduction pathway should bypass the 
requirement for the protective effect of NRF2 against infectious or 
sterile intravascular hemolysis in vivo. In contrast to Nrf2-/-Ripk3+/+ 
mice, Nrf2-/-Ripk3-/- mice were protected against PHZ administration 
(Figure 2.21a). Of note, deletion of the Ripk3 allele per se had no 
impact on the outcome of acute hemolysis in Nrf2+/+Ripk3-/- vs. 
Nrf2+/+Ripk3+/+ mice (Figure 2.21a). This suggests that NRF2 acts as 
a physiologic counter regulator of necroptosis to confer protection 
against sterile intravascular hemolysis.  
Genetic loss of function of components of the necroptosis signal 
transduction pathway also bypassed the requirement for NRF2 in the 
establishment of disease tolerance to sepsis, as assessed in Nrf2-/-
Ripk3-/- vs. Nrf2-/-Ripk3+/+ mice subjected to CLP (Figure 2.21b). This 
protection was not associated with modulation of pathogen load, as 
assessed for aerobic and anaerobic bacteria in different organs of 
Nrf2-/-Ripk3+/+ vs. Nrf2-/-Ripk3-/- mice (Figure 2.21c), 16h after CLP. 
Of note, deletion of the Ripk3 allele had no impact per se on the 
outcome of CLP in Nrf2+/+Ripk3-/- vs. Nrf2+/+Ripk3+/+ mice (Figure 
2.21b). Severe hepatocellular degeneration was ablated in livers 
from Nrf2-/-Ripk3-/- vs Nrf2-/-Ripk3+/+ mice, collected 16h post-CLP, as 
assessed by histological analysis (Figure 2.21d). This suggests that 
NRF2 acts as a physiologic counter regulator of necroptosis to 
confer disease tolerance to sterile hemolysis and polymicrobial 
sepsis. 
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Figure 2.21. NRF2 acts as a cytoprotective molecule against 
Ripk3-induced damage in vivo after acute hemolysis and 
sepsis.  
(a) Relative survival of Nrf2+/+Rip3+/+, Nrf2-/-Rip3+/+, Nrf2+/+Rip3-/- and Nrf2-/-
Ripk3-/- mice subjected to acute hemolysis, induced by PHZ administration, 
in two independent experiments with similar trend (n=8-11 mice per 
genotype). Log-Rank Test. (b) Relative survival of Nrf2+/+Rip3+/+, Nrf2-/-
Rip3+/+, Nrf2+/+Rip3-/- and Nrf2-/-Ripk3-/- mice subjected to CLP in two 
independent experiments with similar trend (n=6-7 mice per genotype).	Log-
Rank Test. (c) Colony forming units (CFU) of aerobic (Ae) and anaerobic 
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(An) bacteria 16h after CLP in Nrf2-/-Rip3+/+ and Nrf2-/-Ripk3-/- mice. Data 
pooled from two independent experiments (n=3-4) mice per genotype). PC: 
peritoneal cavity. Mann-Whitney U Test. (d) H&E staining of the liver of 
naïve Nrf2-/-Rip3+/+ and Nrf2-/-Ripk3-/- mice (Control) and 16h after CLP. 
Image is representative of (n=7 mice per genotype). Dotted lines indicate 
areas of hepatocellular degeneration. Scale bar = 100µm. n.s.: non 
significant, *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 We then asked whether the establishment of disease tolerance to 
the blood stage of Plasmodium infection also relies on NRF2-driven 
protection against necroptosis. Pharmacological inhibition of RIPK1 
kinase activity using Necrostatin-1 (Nec-1) restored the survival of 
Pcc-infected Nrf2-/- mice (Figure 2.22a) without interfering with 
pathogen load, as compared to vehicle treated Nrf2-/- mice (Figure 
2.22b). This demonstrates that NRF2 confers disease tolerance to 
malaria via a mechanism modulating RIPK1 activation. Deletion of 
the Ripk3 allele, however, had no impact on the survival (Figure 
2.22c) or pathogen load (Figure 2.22d) of Plasmodium-infected Nrf2-
/-Ripk3-/- vs. Nrf2-/-Ripk3+/+ mice or Nrf2+/+Ripk3-/- vs Nrf2+/+Ripk3+/+ 
mice. 
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Figure 2.22. NRF2 protects against Ripk1 but not Ripk3-
induced lethality in vivo after malaria infection.  
(a) Relative survival of Pcc infected Nrf2-/- mice treated or not (Vehicle) with 
Nec-1. Data pooled from two independent experiments (n=8-10 mice per 
group). Log-Rank Test. (b) Percentage of infected RBC in the same mice 
as (a). Data represented as ± SEM. (c) Relative survival of Pcc infected 
Nrf2-/- mice expressing (Ripk3+/+) or not Ripk3 (Ripk3-/-). Data pooled from 
four independent experiments (n=14-18 mice per genotype). Log-Rank 
Test. (d) Percentage of infected RBC in the same mice as (a). Data 
represented an as ± SEM. *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 We then questioned whether the establishment of disease 
tolerance to Plasmodium infection by NRF2 requires the inhibition of 
PCD by apoptosis. Deletion of the Caspase8 allele, however, had no 
impact on the survival (Figure 2.23a) or pathogen load (Figure 
2.23b) of Plasmodium infected Nrf2-/-Ripk3-/-Casp8-/- vs. Nrf2-/-
Ripk3+/+Casp8+/+ mice or Nrf2+/+Ripk3+/+C8+/+ vs. Nrf2+/+Ripk3-/-C8-/- 
mice.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a b
Days
S
ur
vi
va
l (
%
)
Days
P
ar
as
ite
m
ia
 (%
)
c
Control Pcc
Nrf2-/-Ripk3+/+Casp8+/+
Nrf2-/-Ripk3-/-Casp8-/-
Nrf2-/-Ripk3+/+Casp8+/+ Nrf2-/-Ripk3+/+Casp8+/+
Nrf2-/-Ripk3-/-Casp8-/- Nrf2-/-Ripk3-/-Casp8-/-
5 10 15
0
20
40
60
0 5 10 15
0
20
40
60
80
100
Nrf2+/+Ripk3+/+Casp8+/+
Nrf2+/+Ripk3-/-Casp8-/-
Nrf2-/-Ripk3+/+Casp8+/+
Nrf2-/-Ripk3-/-Casp8-/-
Nrf2+/+Ripk3+/+Casp8+/+
Nrf2+/+Ripk3-/-Casp8-/-
		 103	
Figure 2.23. NRF2 does not protect against Caspase8 
dependent apoptosis in vivo after malaria infection.  
(a) Relative survival of Pcc infected Nrf2-/- mice expressing or not Ripk3 and 
Caspase 8 (Ripk3+/+Caspase8+/+ Ripk3-/-Caspase8-/-, respectively). Data 
pooled from two independent experiments (n=4-11 mice per genotype). 
Log-Rank Test. (b) Percentage of infected RBC in the same mice as (a). 
Data represented an as ± STD. (c) H&E staining of the liver of naïve mice 
(Control) and Pcc infected Nrf2-/- mice expressing Ripk3 and Caspase 8 
(Ripk3+/+Caspase8+/+) or not (Ripk3/-/- Caspase8-/-). Images are 
representative of one experiment, n=4-5 mice per genotype. Black dotted 
lines indicate areas of hepatocyte necrosis. Scale bar = 100µm. 
 
 Histological analysis confirmed that the extent of liver necrosis in 
Plasmodium-infected Nrf2-/-Ripk3-/-Casp8-/- was similar to Nrf2-/-
Ripk3+/+Casp8+/+ mice (Figure 23c), revealing that NRF2 confers 
tissue damage control and establishes disease tolerance to malaria 
via a mechanism that does not involve Caspase8 driven apoptosis. 
 We afterwards questioned whether NRF2 confers tissue damage 
control and establishes disease tolerance to malaria via a 
mechanism involving additional signaling components in the 
necroptosis pathway. As a candidate, we decided to assess the role 
of the peptidyl-prolyl isomerase F gene (PPIF), which encodes the 
mitochondrial membrane protein Cyclophylin D (CYPD), a key 
regulator of the mitochondrial permeability transition pore (MPTP) 
and the induction of regulated necrosis21,22. Primary Ppif deficient 
(Ppif -/-) hepatocytes were refractory to heme and TNF-induced 
necroptosis (Figure 2.24a), an effect associated with maintenance of 
homeostatic levels of intracellular ROS (Figure 2.24b,e), including 
mitochondrial O2- (Figure 2.24c,f) as well as with preservation of 
mitochondrial Δψm (Figure 2.24d,g). Deletion of Ppif allele per se 
also had no apparent impact in vivo on the outcome of sterile 
hemolysis (Figure 2.24h) or Plasmodium infection (Figure 2.24i,j) in 
Nrf2+/+ or Nrf2-/- mice, as assessed in Nrf2+/+Ppif+/+ vs. Nrf2+/+Ppif -/- 
mice and Nrf2-/-Ppif+/+ vs. Nrf2-/-Ppif-/- mice.  
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 This suggests that heme primes hepatocytes to undergo TNF-
induced necroptosis in vitro but not in vivo via a CYPD-dependent 
mechanism that promotes mitochondrial O2- accumulation and Δψm 
impairment. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.24. CYPD contributes to Heme and TNF-induced 
PCD and mitochondrial dysfunction in vitro but not in vivo.  
(a) Percentage of cell death in Nrf2+/+ primary mouse hepatocytes 
expressing or not CypD (Ppif+/+ and Ppif-/-, respectively) and treated (+) or 
not (-) with heme plus TNF. Data represented as mean ± STD from 5 wells 
ba c
d
0
10
20
30
40
50
Ppif -/-
Heme
TNF -
+
- +
+
+
- -
***
0
2
4
6
8 ***
Heme
TNF -
+
- +
+
+
- -
0
10
20
30
Heme
TNF
- +
- +
+
+
-
***
Heme
TNF -
+
- +
+
+
- -
Ppif +/+
Ppif -/-
Ppif +/+
Ppif -/-
Ppif +/+
Ppif -/-
Ppif +/+
TM
R
E
 
(F
ol
d 
in
du
ct
io
n)
R
O
S
 (D
C
FD
A
) 
(F
ol
d 
in
du
ct
io
n)
m
tO
2- 
(M
ito
S
ox
)
(F
ol
d 
in
du
ct
io
n)
C
el
l D
ea
th
 (%
) 
0
2
4
6
8 ***
-
e
f
Ppif+/+
100 101 102 103 104 100 101 102 103 104
ROS (CM-H2DCFDA)
P
er
ce
nt
 o
f M
ax
0
20
40
60
80
100 Medium
Heme
TNF
Heme
+TNF
Mitochodrial O2  (MitoSOX)
100 101 102 103 104 100 101 102 103 104
0
20
40
60
80
100
Ppif-/-
Medium
Heme
TNF
Heme
+TNF
g
100 101 102 103 104 100 101 102 103 104
0
20
40
60
80
100
TMRE (Delta Phi)
Medium
Heme
TNF
Heme
+TNF
P
er
ce
nt
 o
f M
ax
0 5 10 15
0
20
40
60
80
100
h i j
Nrf2-/-Ppif+/+
Nrf2-/-Ppif-/-
Nrf2+/+Ppif+/+
Nrf2+/+Ppif-/-
Days
S
ur
vi
va
l (
%
)
5 10 15
0
20
40
60
P
ar
as
ite
m
ia
 (%
)
Days
Nrf2-/-Ppif+/+
Nrf2-/-Ppif-/-
Nrf2+/+Ppif+/+
Nrf2+/+Ppif-/-
0 2 4 6 8 10
0
20
40
60
80
100
Days
S
ur
vi
va
l (
%
)
Nrf2-/-Ppif+/+
Nrf2-/-Ppif-/-
Nrf2+/+Ppif+/+
Nrf2+/+Ppif-/-
		 105	
in one out of two independent experiments with the same trend. One-Way 
ANOVA. Relative induction of (b) intracellular ROS, (c) mitochondrial 
superoxide and (d) mitochondrial membrane potential in Nrf2+/+ mouse 
hepatocytes expressing or not CypD (Ppif+/+ and Ppif-/-, respectively) and 
treated (+) or not (-) with heme plus TNF. Data represented as mean ± STD 
from a pool of two to three independent experiments with the same trend. 
One-Way ANOVA. Histograms corresponding to (e) intracellular ROS, (f) 
mitochondrial superoxide, (g) mitochondrial membrane potential detected 
by flow cytometry in primary mouse hepatocytes treated with heme and/or 
TNF represent one out of two to three independent experiments (b,c,d). (h) 
Relative survival of PHZ treated Nrf2+/+Ppif+/+, Nrf2-/-Ppif+/+ Nrf2+/+Ppif+/+ and 
Nrf2-/-Ppif-/- mice. Data pooled from two independent experiments (n=8-11 
mice per genotype). Log-Rank Test. (i) Relative survival of Pcc infected 
Nrf2+/+Ppif+/+, Nrf2-/-Ppif+/+ Nrf2+/+Ppif+/+ and Nrf2-/-Ppif-/- mice. Data pooled 
from two independent experiments (n=7-9 mice per genotype). Log-Rank 
Test. (j) Percentage of infected RBC in the same mice as (i). Data 
represented as mean ± STD. *p< 0.05, **p< 0.01, ***p<0.001. 
 
 
 We hypothesized that, if Nrf2-/-Ripk3-/- and Nrf2-/-Ppif-/- succumb to 
Pcc similarly to the Nrf2-/- mice and if the tissue damage is 
contributing significantly to lethality after Pcc infection, than the 
extent of tissue damage should be comparable between these 
genotypes. In fact, deletion of Ppif or Ripk3 alleles in an Nrf2-/- 
background had no impact in rescuing mice from undergoing severe 
liver necrosis, as assessed in Nrf2-/-Ripk3+/+Ppif+/+ vs. Nrf2-/-Ripk3-/-
Ppif+/+ vs. Nrf2-/-Ripk3+/+Ppif-/- mice (Figure 2.25). These results show 
that there are two signal transduction pathways driving necroptosis 
in parallel that involve RIPK3 and CYPD in vivo and that NRF2 
confers tissue damage control via a mechanism that targets both 
these pathways.  
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Figure 2.25. NRF2 fails to revert RIPK3 or CYPD-mediated 
tissue damage in vivo after malaria infection.  
(a) H&E staining of liver sections from naïve mice (Control) and Pcc 
infected Nrf2-/- mice expressing Ripk3 or CypD (Ripk3+/+; Ppif+/+) or not 
(Ripk3-/-; Ppif-/-). Images are representative of one experiment, n=4 mice per 
group. Black dotted lines indicate areas of hepatocyte necrosis. Scale bar = 
100µm. 
 
 
 Combined deletion of Ppif and Ripk3 alleles (Figure 2.26a) had no 
additional impact, as compared deletion of Ripk3 alone (Figure 
2.21a), in rescuing Nrf2-/- mice from sterile hemolysis, as assessed in 
Nrf2-/-Ripk3-/-Ppif-/- vs. Nrf2+/+Ripk3-/-Ppif-/- mice. In contrast, 
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combined deletion of Ppif and Ripk3 alleles rescued Nrf2-/- mice from 
Plasmodium infection (Figure 2.26b) without interfering with 
pathogen load (Figure 2.26c), as assessed in Nrf2-/-Ripk3-/-Ppif-/- vs. 
Nrf2-/-Ripk3+/+Ppif+/+ mice. Of note, combined deletion of the Ripk3 
and Ppif alleles had no apparent impact on the outcome of 
Plasmodium infection in Nrf2+/+ mice, as assessed in Nrf2+/+Ripk3-/-
Ppif-/- vs. Nrf2+/+Ripk3+/+Ppif+/+ mice. Importantly, combined deletion 
of Ppif and Ripk3 alleles prevented the necrotic outcome of 
hepatocytes in vivo after malaria infection (Figure 2.26d). 
.  
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Figure 2.26. NRF2 protects against RIPK3 and CYPD-induced 
lethality and tissue damage in vivo after malaria infection.  
(a) Relative survival of Nrf2+/+Ripk3+/+Ppif+/+, Nrf2+/+Ripk3-/-Ppif-/-, Nrf2-/-
Ripk3+/+Ppif+/+ and Nrf2-/- Ripk3-/-Ppif-/- mice treated with PHZ. Data pooled 
from two independent experiments (n=8-11 mice per genotype). Log-Rank 
Test. (b) Relative survival of Pcc infected Nrf2-/- mice expressing or not 
Ripk3 and CypD (Ripk3+/+Ppif+/+ and Ripk3/-/-Ppif+/-, respectively). Data 
pooled from three independent experiments (n=10-14 mice per genotype). 
Log-Rank Test. (c) Percentage of infected RBC in the same mice as (b). 
Data represented as mean ± STD. (d) H&E staining liver sections from 
naïve mice (Control) and Pcc infected Nrf2-/- mice expressing Ripk3 and 
CypD (Ripk3+/+Ppif+/+) or not (Ripk3/-/- Ppif -/-). Images are representative of 
three experiments, n=12-14 mice per group. Black dotted lines indicate 
areas of hepatocyte necrosis Scale bar = 100µm. *p< 0.05, **p< 0.01, 
***p<0.001. 
 
 
Overall, these observations reveal that NRF2 confers tissue damage 
control and establishes disease tolerance to malaria via a 
mechanism that targets two signal transduction pathways driving 
necroptosis involving RIPK3 and CYPD. 
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Discussion 
 
 
 
 
 
 
 
 
 
“Anything you build on a large scale  
or with intense passion invites chaos.” 
(Francis Ford Coppola) 
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 Labile heme plays a central role in the pathogenesis of severe 
forms of disease associated with bloodstream infections, as 
demonstrated for murine experimental models of malaria1,2,3 and 
sepsis4. Detection of both extracellular hemoglobin5,6,7 and heme8,9 is 
associated with the pathophysiology of both diseases, in both 
experimental models as well as in human patients5,6,7,8,9. However, 
although the pro-oxidant nature of heme is consistently deleterious10, 
several factors like the chronicity and extent of hemolysis might 
determine the outcomes of the disease in terms of tissue damage 
and lethality. For example, increased plasma concentrations of labile 
heme and haptoglobin, the cell-free hemoglobin scavenger, are 
associated with susceptibility to malaria in human patients9, whereas 
in sepsis patients elevated plasma levels of haptoglobin correlate 
with a lower risk of mortality7. As such, the nature of the insult 
triggering hemolysis, the kinetics of hemoglobin release and 
oxidation, as well as the inflammatory milieu that accompanies this 
process is essential for a better understanding of the 
pathophyological consequences of hemolytic diseases. 
 Upon hemolysis, circulating cell-free hemoglobin and labile heme 
are recognized by the immune system as erythroid DAMPs11, 
leading to the activation of immune cells and endothelium to an 
inflammatory, pro-adhesive state that promotes vaso occlusion and 
tissue injury12. Moreover, intravascular hemolysis causes oxidative 
stress, altering redox balance and amplifying physiological 
processes that govern blood flow, hemostasis, inflammation, and 
angiogenesis12. In the presence of TNF or other by-products of 
inflammation, labile heme is highly cytotoxic to both immune13,14 and 
parenchymal15,16,17,18 cells, eventually leading to tissue damage and 
compromising disease tolerance to bloodstream infections3,4. This 
has been associated with a necrotic phenotype, which was shown to 
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be extensively linked to the additional release of DAMPs, amplifying 
the inflammatory response and promoting further tissue damage19,20.  
 The pathophysiological consequences of labile heme trigger 
adaptive stress and damage responses that counter the pathogenic 
outcomes of hemolysis12. Due to the pro-oxidant nature of labile 
heme12, the response orchestrated by NRF2 is essential in 
protecting against oxidative stress21. Perhaps the best demonstration 
that this oxidative stress response is involved in the protection 
against inflammatory hemolytic diseases is that sickle hemoglobin 
establishes disease tolerance to malaria via an NRF2-dependent 
mechanism22. The activation of this stress response was shown to 
counter the pathogenic effects of labile heme in mice2 and it is most 
likely to be the case in humans22. 
The work developed in the context of this thesis demonstrates 
that NRF2 is a critical cytoprotective molecule that counters the 
deleterious effects of labile heme and establishes disease tolerance 
to bloodstream infections (Figure 2.1e-h, Figure 2.6a,b). Additionally, 
our data shows that NRF2 protects against sterile hemolysis (Figure 
2.10a-d) and labile heme per se (Figure 2.12c-e) suggesting that, in 
the context of hemolytic infections, this transcription factor provides 
tissue damage control by specifically countering the cytotoxic effects 
of labile heme.  
Mechanistically, we were able to demonstrate that labile heme 
sensitizes hepatocytes to accumulate high levels of ROS in 
response to TNF4,23,24,10. This pro-oxidant effect is associated with 
robust Nrf2 activation, acting as a negative feedback loop, blocking 
TNF-induced necroptosis (Figure 2.15a) via the inhibition of 
mitochondrial O2- (Figure 2.15c,f) and preserving mitochondrial 
function (Figure 2.15d,g). This is consistent with the notion that 
NRF2 regulates an adaptive response to oxidative stress sustaining 
mitochondrial function25,26, which we now demonstrate to be critical 
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in the establishment of disease tolerance to bloodstream infections, 
as illustrated for malaria (Figure 2.16f,g) as well as to confer 
protection against sterile hemolysis (Figure 2.16h). In agreement 
with these findings, we have shown that Nrf2 deficient mice undergo 
hepatic necrosis upon malaria, accumulate higher levels of DAMPs 
in circulation in the different models of hemolysis and display 
increased levels of inflammatory mediators. Together, these data 
suggests that Nrf2 protects against heme-driven necrosis in vivo, 
blocking the release of DAMPs and ameliorating inflammation. 
Unfettered accumulation of mitochondrial O2- and the ensuing 
development of mitochondrial dysfunction in response to heme and 
TNF are strictly dependent on a signal transduction pathway 
involving RIPK1, RIPK3, MLKL and PGAM5, as demonstrated by 
genetic loss of function approach targeting these alleles (Figure 2.18 
and Figure 2.19). Signaling via the TNF receptor 1 (TNFR1) 
emerges from a multimeric complex comprising, among other 
components, RIPK1 and the heme-oxidized iron regulated protein 2 
(IRP2) ubiquitin ligase-1 (HOIL-1L), one of the components of the 
linear ubiquitin chain assembly complex (LUBAC)27. It is possible, 
therefore, that once transported into the cytosol via specific 
transporters such as the heme responsive gene 1 (HRG1)28, heme 
might interact with HOIL-1L to regulate TNFR1 signaling. This might 
induce signaling via the RIPK1/3 complex and/or inhibit Caspase-8 
activation, favoring the induction of necroptosis. Another possibility is 
for intracellular heme to be transported into the mitochondria, via 
specific mitochondrial transporters such as ABCB629, promoting lipid 
peroxidation, ROS accumulation, mitochondrial dysfunction and 
necrosis. Additionally, because it was shown that heme signals 
through TLR4 to induce autocrine TNF production in macrophages 
culminating in necroptosis30 and that both TNFR1 and TLR4 have 
been linked to necroptosis31, it is possible that TNF and heme 
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synergize in parenchyma cells by signaling to TNFR1 and TLR4 
respectively, leading to this explosive type of PCD. The last 
hypothesis for the mechanism of heme cytotoxicity is that heme-iron 
might signal through TLR2, a receptor involved in regulating iron 
deposition in tissues32 that have been recently shown to sensitize to 
TNFR1-dependent necroptosis33. Of note, HO-1 was shown to be 
protective to TNF-dependent PCD in primary hepatocytes34, 
suggesting that heme catabolism reverts the engagement of the 
TNF-dependent PCD pathway. Irrespectively of its molecular 
mechanism of action, labile heme appears to act as a potent 
pathophysiologic agonist of TNF-induced necroptosis, which is 
consistent with the observation that Nec1 protects macrophages 
from heme and TNF-induced PCD13. 
The mechanism via which NRF2 blocks TNF-induced necroptosis 
relies on the expression of several effector genes, which inhibits the 
RIPK1, RIPK3, MLKL and PGAM5 signal transduction pathway 
leading to the accumulation of mitochondrial O2- and ultimately to 
mitochondrial dysfunction (Figure 2.20). Whether these NRF2-
regulated effector genes modulate the RIPK1-RIPK3-MLKL-PGAM5 
signal transduction pathway or act directly to protect the 
mitochondria, remains to be established. Perhaps the best link 
between NRF2 and the pathway to necroptosis is the observation 
that PGAM5 forms a ternary complex with Keap-1 and NRF2 in the 
outer mitochondrial membrane, repressing NRF2 activation35. The 
presence of distinct pools of Keap-1 at multiple subcellular locations 
enables activation of NRF2 in response to specific insults35. In this 
particular context, placing Keap-1 and NRF2 in the mitochondria 
downstream of the engagement of the necroptosis pathway would 
justify the protective role of this cytoprotective molecule after heme 
and TNF at the level of mitochondrial ROS production/accumulation 
and loss of mitochondrial potential. It is possible, therefore, that the 
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PGAM5L/Keap-1 complex is targeted by mitochondrial ROS, 
downstream of RIPK1, RIPK3 and MLKL, to trigger NRF2 activation, 
leading to the expression of cytoprotective genes and countering 
necroptosis. An alternative hypothesis would be that the NRF2-
Keap1 complex is formed and retained in the cytoplasm through 
interactions with the cytoskeletal network36. Upon heme and TNF-
induced mitochondrial ROS production, Keap-1 would sense this 
cellular redox unbalance, leading to NRF2 nuclear translocation and 
downstream antioxidant gene expression. In keeping with the notion 
that heme and TNF induces mitochondrial ROS production 
countered by NRF2, it was shown in the context of acute bacterial 
infection that TNF production in leukocytes leads to mitochondrial 
ROS generation and kidney cell death37. Moreover, mitochondrial 
ROS inhibits GSK3b, a repressor of NRF2 activation38, presumably 
allowing the antioxidant pathway to confer tissue damage control to 
kidney cells37. Furthermore, inhibition of GSK-3β blocks the 
permeability transition pore formation, preventing necrosis39. 
Whether NRF2 provides tissue damage control by blocking 
mitochondrial ROS and necroptosis via GSK-3β inhibition in the 
context of hemolytic infections still remains to be established. 
In strong support of the notion that the inhibition of heme-driven 
necroptosis underlies the protective effect of NRF2 in vivo is the 
observation that deletion of the Ripk3 allele bypasses the 
requirement for NRF2-driven protection against sterile hemolysis 
(Figure 2.21a) or the establishment of disease tolerance to sepsis 
(Figure 2.21b,c). While pharmacologic inhibition of RIPK1 by Nec-1 
also bypasses the requirement of NRF2 for establishment of disease 
tolerance to Plasmodium infection (Figure 2.22a,b), this is not the 
case for deletion of the Ripk3 allele (Figure 2.22c,d) or even for 
combined deletion of the Ripk3 and caspase-8 alleles (Figure 
2.23a,b). This suggests that, in the case Plasmodium infection, Nrf2 
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might target an additional component of the regulated necrosis 
pathway downstream of RIPK1 but not RIPK3, presumably in the 
mitochondria. Alternatively, inhibition of RIPK1 kinase activity by 
Nec-1 might be switching its function from mediator of cell death 
towards a scaffolding function, promoting survival and suppressing 
inflammation by inhibiting FADD–caspase-8 and RIPK3-MLKL 
activation40. If this proves to be the case, this protective effect of 
Nec-1 might bypass the absence of Nrf2 by preventing both cell 
death and inflammation as a consequence of Plasmodium infection. 
 The observation that induction of necroptosis in response to 
heme and TNF relies on the expression of mitochondrial CypD 
(Figure 2.24a-g) lead to the hypothesis that CypD may be part of this 
additional component of the regulated necrosis pathway targeted by 
Nrf2. Combined deletion of the Ripk3 and Ppif alleles bypasses the 
requirement of Nrf2 for the establishment of disease tolerance to 
Plasmodium infection (Figure 2.26b,c) suggesting that, in contrast to 
sterile hemolysis or sepsis which depend solely on RIPK3, the blood 
stage of Plasmodium is associated with the induction of regulated 
necrosis via a CypD-dependent mechanism, similar to the one 
eliciting tissue damage associated with ischemia reperfusion injury41. 
Of note, activation of NRF2 in response to viral infections can 
compromise resistance to infection, therefore acting in a pathogenic 
manner42. This is illustrated for example for the Marburg virus 
infection, where viral encoded VP24 protein promotes viral 
replication via a mechanism that targets the ubiquitin ligase activity 
of the Keap1-associated Cul3–Rbx1 complex and induces NRF2 
activation43,44. This antagonistic effect of NRF2 is in keeping with the 
notion that tissue damage control mechanisms establishing disease 
tolerance to infection are tailor-made for different classes of 
pathogens45,46. This can be particularly relevant to understand the 
pathologic outcome of co-infections, such viral and bacterial co-
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infections47 where the virus can compromise resistance48 or disease 
tolerance49 to bacteria48,49. While the mechanisms via which this 
occurs are most probably multifactorial, it is tempting to speculate 
that this could involve viral inhibition of NRF2, which should impair 
disease tolerance to bacterial infections. This remains however to be 
established experimentally. 
Of note, while a protective effect of NRF2 against bloodstream 
infections was previously reported, this was attributed to a putative 
immunoregulatory effect25,50 exerted, most likely, in 
macrophages51,52. Our data suggests that such immunoregulatory 
effect may operate indirectly through the cytoprotective effect 
exerted by NRF2 limiting the release of pro-inflammatory DAMPs, 
e.g. mitochondrial DNA53,54,19, HMGB155 or labile heme12. This does 
not exclude, however, NRF2 from exerting additional 
immunoregulatory effects in innate immune cells: either by lowering 
the levels of secreted pro-inflammatory cytokines51 synergizing with 
heme and/or by regulating the sensitivity of death receptor signals56, 
NRF2 can contribute to the establishment of disease tolerance to 
hemolytic bloodstream infections. 
In conclusion, we propose that NRF2 acts as a transcriptional 
repressor of TNF-induced necroptosis and that this cytoprotective 
effect is critical to confer tissue damage control and establish 
disease tolerance to bloodstream infections. 
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“If you're not failing every now and again, it's a sign you're 
not doing anything very innovative.” 
(Woody Allen) 
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Mice 
Experimental procedures involving mice were approved by the 
Ethics Committee of the Instituto Gulbenkian de Ciência (license: 
A009/2011) and the “Direção Geral de Alimentação e Veterinária” 
(license: 0420/000/000/2012) as per Portuguese (Decreto-Lei nº 
113/2013) and European (Directive 2010/63/EU) legislations. Mice 
were bred and maintained under specific pathogen free (SPF) 
conditions at the Instituto Gulbenkian de Ciência (12h day/night; fed 
ad libidum). C57BL/6 Nrf2-/- mice (Itoh et al., 1997) were obtained 
originally from the RIKEN BioResource Center (RBRC01390; 
Koyadai, Tsukuba, Ibaraki, Japan). C57BL/6 Ripk3-/- mice (Newton 
et al., 2004) were obtained from Vishva Dixit (Genentech, USA). 
C57BL/6 Ripk3-/-Caspase8-/- mice (Oberst et al., 2011) were obtained 
from Igor Brodsky (University of Pennsylvania, Philadelphia, USA) 
with permission from Douglas Green (St. Jude Children's Research 
Hospital, Memphis, USA). C57BL/6 Ppif-/- mice (Basso et al., 2005) 
were obtained from Jackson Laboratories (022308). C57BL/6 
OKD48 reporter mice (Oikawa et al., 2012) were obtained from 
RIKEN BioResource Center (RBRC05704). Nrf2+/+ and Nrf2-/- mice 
were breed in homozygosity and offspring was co-housed 
immediately from weaning. Rip3k-/- and Ppif-/- mice were intercrossed 
with Nrf2-/- mice to obtain Nrf2-/-Rip3k-/-, Rip3k-/-Ppif-/-, Nrf2-/-Ppif-/- and 
Nrf2-/-Rip3k-/-Ppif-/- mice. Rip3k-/-Caspase8+/- mice were intercrossed 
with Nrf2-/-Rip3k-/- mice to generate Nrf2-/-Rip3k-/-Caspase8+/- mice, 
subsequently intercrossed to generate Nrf2-/-Rip3k-/-Caspase8+/+ and 
Nrf2-/-Rip3k-/-Caspase8-/- mice. Mice were genotyped by PCR using 
the following primers: Nrf2: 5’-TGGACGGGACTATTGAAGGCTG-3’, 
5’-GCGGATTGACCGTAATGGGATAGG-3’, 5’-
GCCGCCTTTTCAGTAGATGGAGG-3’; Ripk3: 5’-
CGCTTTAGAAGCCTTCAGGTTGAC-3’, 5’-
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GCCTGCCCATCAGCAACTC-3’, 5’-
CCAGAGGCCACTTGTGTAGCG-3’; Caspase 8: 5’-
CCAGGAAAAGATTTGTGTCTA-3’, 5’-
GGCCTTCCTGAGTACTGTCACCTGT-3’; Ppif: 5’-
ATTTGTCACGTCCTGCACGA CG-3’, 5’-
AGCCAGCCGACCAATAAAG-3’, 5’-AGCCAGCCGACCAATAAAG-
3’, 5’-GTTCCCGGAGGAAGAGTTC-3’; OKD48: 5’-
ATCACCAGAACACTCAGTGG-3’, 5’-TAG 
CGCTTCATAGCTTCTGC-3’, 5’-
CTAGGCCACAGAATTGAAAGATCT-3’, 5’-GTAG 
GTGGAAATTCTAGCATCATCC-3’. 
 
Reagents  
CM-H2DCFDA (Molecular Probes, C6827), MitoSox (Molecular 
Probes, M36008), Tetramethylrhodamine, Methyl Ester, Perchlorate 
(TMRM, Molecular Probes T668), Tetramethylrhodamine Ethyl Ester 
(TMRE; Molecular Probes, T669), Sytox Green (ThermoFisher, 
S7020), Giemsa (VWR; 350864X), heme (i.e. hemin; iron 
protoporphyrin; Sigma, H5533; Frontier Scientific, FSIH651-9), 
mouse recombinant TNF (mTNF, R&D System, 410-MT-010), N-
acetyl cysteine (NAC; Sigma, A9165), MitoTEMPO (Santa Cruz 
Biotechnologies, SC-221945), Necrostatin-1 (Nec-1, Enzo Life 
Sciences; BML-AP309-0020), Phenylhydrazine hydrochloride (PHZ, 
Aldrich, 114715), anti-mouse RBC polyclonal antiserum (Cedarlane, 
UK; 007CLA3840), MG132 (Calbiochem; 133407-82-6), Gelatin 
(G1393 Sigma) and Luciferin (Promega, PROME1605)  were used 
as indicated in the results section.  
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Plasmodium infection 
Mice were infected by intraperitoneal (i.p.) inoculation of 2x106 
Plasmodium chabaudi chabaudi (Pcc; AS strain) infected RBCs, 
essentially as described (Seixas et al., 2009). Host survival and 
parasitemia, i.e. percentage of infected RBCs detected in Giemsa 
stained blood smears, were monitored daily for two weeks, as 
described (Seixas et al., 2009). 
 
Cecal ligation and puncture (CLP) 
CLP was performed under isoflurane anesthesia (Anaesthesia 
AutoFlow System, EZ-AF9000, PLEXX BV), essentially as described 
(Larsen et al., 2010; Rittirsch et al., 2009). Briefly, the procedure 
consists of a 30% cecum ligation and a 23 Gauge (G) needle double 
puncture, with controlled feces extrusion. Mice received 0.9% saline 
(40 mL/kg, i.p.) immediately after the procedure and 
Imipenem/Cilastatin (25mg/kg i.p.), starting 2 hours after procedure 
and then every 12 hours for 3 days). Body weight (Compact balance 
CS-series T317.1, Roth) and temperature (Bioseb, France, Rodent 
Thermometer BIO-TK8851) were monitored daily for up to 7 days 
and survival up to 14 days. Pathogen load was quantified, essentially 
as described (Larsen et al., 2010; Rittirsch et al., 2009). Briefly, 16 
hours after CLP blood was collected through heart puncture using 
heparinized needles, peritoneal fluid was obtained by lavage (5 mL; 
sterile PBS) and organs were harvested, rinsed and homogenized in 
sterile PBS under a dounce tissue grinder (Sigma, D8938). Serial 
dilutions were plated onto Trypticase™Soy Agar II supplemented 
with 5% Sheep Blood plates (Becton Dickinson, 254053) and 
incubated (24 hours at 37°C) under aerobic (Air; 5% CO2) or 
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anaerobic conditions using a tight container equipped with the 
GasPak™ anaerobe container system (Becton Dickinson, 260678). 
Anaerobic conditions were confirmed using BBL™ Dry Anaerobic 
Indicator Strips (Becton Dickinson, 271051).  
 
In Vivo Treatments 
NAC was dissolved in PBS, pH was adjusted to 7.4 with 5M NaOH 
and administered (15 mg/kg in 200µL every 12 hour, i.p.) starting at 
4 days post-Pcc infection until day 15 or starting 2 days prior to 
heme administration and during 8 days thereafter. MitoTEMPO was 
dissolved in PBS and administered (2.5mg/kg, 200µL every 12 
hours, i.p.) as for NAC. Necrostatin-1 was dissolved in DMSO to a 
final concentration of 20mg/ml, diluted in sterile PBS and 
administered (1.25 mg/kg, 200µL every 24 hours, i.p.) starting at 4 
days post-Pcc infection until day 15. Heme was dissolved in 0.2 M 
HCl, and pH was adjusted to 7.4 with sterile 0.2 M NaOH. Stock 
solution was diluted in sterile PBS right before administration 
(20mg/Kg for Nrf2+/+ vs Nrf2-/- mice, or 40mg/Kg for reporter OKD48 
mice, i.p.). Intravascular hemolysis was induced by freshly prepared 
Phenylhydrazine (PHZ) dissolved in sterile PBS (pH adjusted to 7.4 
with sterile 0.2M NaOH) and administered (100mg/Kg and 50 mg/Kg 
14 hours thereafter, i.p.), essentially as described (Dutra et al., 
2014). Antibody-mediated hemolysis was induced by the 
administration of an anti-mouse RBC polyclonal antiserum (40µL per 
mouse, i.p) diluted in sterile PBS to a final volume of 100µL, every 
other day for 5 days (3x in total). Number of circulating RBC was 
quantified daily by flow cytometry (FACSCalibur Analyzer, Becton 
Dickinson) using coulter beads (Cytognos) and analyzed using 
FlowJo software (Tree Star Inc.). 
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Cell culture, cytotoxicity and flow cytometry based assays 
Primary mouse hepatocytes were isolated, essentially as described 
(Gonçalves et al., 2007; Gozzelino et al., 2012) and cultured (37°C; 
95% humidity, 21% O2; 5% CO2) in William’s medium (Gibco, 32551-
020), supplemented with 4% FBS, 20 U/mL penicillin and 20 U/mL 
streptomycin. Cytotoxicity was assessed by crystal violet vital 
staining, essentially as described (Gozzelino et al., 2012; Larsen et 
al., 2010). Briefly, 24h after isolation and seeding onto gelatin-coated 
(10% solution, Gelatin, Sigma, G1393) 96-well plates (Costar; 3596), 
primary hepatocytes were washed in PBS and pulsed with heme (5 
µM) in HBSS (Gibco; 24020-117) for 1 hour. Cells were 
subsequently exposed or not to mouse recombinant TNF (5ng/mL) in 
William’s medium (Life Technologies; 32551-020), supplemented 
with 4% Fetal Bovine Serum (FBS, Gibco, 10500-064), 20 U/mL 
penicillin and 20 U/mL streptomycin (Gibco; 15140-122). In 
experiments using primary Nrf2-/- hepatocytes, exposure to TNF was 
8 hours. Hepa1-6 cells (C57BL/6 mouse liver hepatoma; ATCC® 
CRL1830™) were cultured (37°C; 95% humidity, 21% O2; 5% CO2) 
in DMEM (Gibco, 21885), supplemented with 10% FBS, 20 U/mL 
penicillin and 20 U/mL streptomycin. Briefly, cells were seeded in 96-
well plates (Costar; 3596) and grown to confluence. For cytotoxicity 
assay, cells were washed in HBSS, pulsed with heme (40 µM in 
HBSS; 1 hour) and stimulated or not with mouse recombinant TNF 
(50ng/mL) in DMEM supplemented with 10% FBS, 20 U/mL penicillin 
and 20 U/mL streptomycin for 8h. Both primary cells and cell line 
were pre-treated, when indicated, 4 hours before heme and/or TNF 
treatments with N-acetyl cysteine (NAC, 10mM) or MitoTEMPO 
(25µM) in DMEM. After treatment medium was removed by a quick 
flick of the wrist and 1% Crystal Violet (Sigma, C3886) solution in 
20% EtOH (50µL) was added (1 hour) for primary hepatocytes or 30 
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minutes for Hepa1-6 cells; RT). Crystal Violet solution was removed 
by a quick flick of the wrist, plates were dried overnight (with wells 
facing down on a paper towel) and dye was dissolved in 50% acetic 
acid (50µL). Optical density was measured in a microplate reader 
(Victor3, Perkin Elmer) at λ595nm. Cell death was calculated by 
subtracting to 100 the percentage of surviving cells ((ODcells-
ODblank)/AverageODcontrol x 100). ROS accumulation was 
quantified using CM-H2DCFDA (10µM), mitochondrial superoxide 
using MitoSox (10µM) and mitochondrial membrane potential using 
TMRM (10µM) probes. Briefly, after heme and/or TNF treatment, 
cells were washed in PBS (70g, 2 minutes; RT). Cellular pellet was 
re-suspended in 200µL probe solution in PBS (15 minutes, 37oC), 
washed in PBS (70g, 2 minutes; RT) and re suspended in PBS (150 
µL). Fluorescence was quatified by flow cytometry using a low-power 
air-cooled 15mW blue (l488nm) argon laser and a band-pass filter of 
l530/30nm on FACSCalibur Analyzer (Becton Dickinson). Data analysis 
was carried out with FlowJo software (Tree Star Inc.). 
 
Recombinant adenovirus 
Recombinant adenovirus for PGAM5 and MLKL or LacZ adenovirus 
was added to Hepa1-6 cells (500pfu/per cell) at the time of seeding 
(2.4x105 cells/well) in 6-well plates (Costar; 3516) in DMEM (Gibco, 
21885). Medium was changed after 6h and experiments were carried 
out after 72h. 
 
Histopathology 
Mice were sacrificed with CO2 and perfused in toto with cold PBS 
after blood collection via heart puncture. Organs were harvested, 
		 130	
fixed in buffered 10% formalin, processed for paraffin embedding, 
sectioned at 3µm (3 sections per slide) and stained with hematoxylin 
and eosin (H&E). Slides were analyzed with a Leica DM LB2 light 
microscope. 
 
Liver Intravital Microscopy 
Confocal intravital microscopy was performed, essentially as 
described (Marques et al., 2015). Briefly, mice were anesthetized 
(i.p.) with a mixture of ketamine (125 mg/kg; Imalgene1000, Merial) 
plus Xylazine (12.5 mg/kg; Rompun, Bayer) in a final volume of 120-
160µL/mouse. The liver was surgically exposed onto an acrylic stage 
fitting an inverted Zeiss Meta microscope equipped with a 10x 
objective. Sytox Green (100µM) and Tetramethylrhodamine methyl 
ester (TMRM; 0.5mg/mL) were administered (100µL in PBS, i.v.) 10 
minutes before imaging. Image quantification was performed using 
ImageJ software. 
 
Luciferase Reporter Assays 
OKD48 reporter mice received heme (20mg/Kg in PBS, i.p.) or anti-
mouse RBC polyclonal antiserum (2x; 48 hours apart; 40µL/mouse, 
i.p.). Luciferase activity was determined 6 hours after heme and 24 
hours after anti-mouse RBC polyclonal antiserum administration, 
essentially as described (Jeney et al., 2014). Briefly, mice were 
anesthetized (Ketamine/Xylazine i.p., 120 mg/kg and 16 mg/kg, 
respectively) before luciferin administration (100mg/Kg in PBS, i.p.). 
Abdominal skin was removed 5 minutes later and luciferase activity 
was monitored by whole-mice imaging using an electron-multiplying 
charge-coupled device (EM-CCD) photon-counting camera 
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(ImagEM; Hamamatsu). Analysis was performed using Fiji software. 
In vitro luciferase reporter assays were performed in Hepa1-6 cells 
(50x103 cells/well) in 6-well plates (Costar; 3516) and transfected 
with Lipofectamine according to manufacturer’s instructions, with 5ug 
of total DNA (Nrf2 plasmid). The treatments were performed 48h 
after using heme (40uM, 1h in HBSS) and/or TNF (50ng/ml, 2h in 
DMEM) for the time indicated followed by lysis with the Luciferase 
5X buffer (Luciferase Assay System, Promega, E1501). Luciferase 
activity was measured using a microplate reader (Victor3, Perkin 
Elmer) at λ560nm. Data was normalized to LacZ, i.e. Luc/b-Gal.  
 
Immunofluorescence 
Hepa 1-6 cells were seeded onto coverslips in 24 well plates 
(Costar, 3526) and grown to confluence (37oC, 95% humidity, 21% 
O2 and 5% CO2) in DMEM supplemented with 10% FBS, 20 U/mL 
penicillin and 20 U/mL streptomycin. Cells were washed with PBS, 
fixed in 4% paraformaldehyde (5 minutes, RT), washed in PBS, 
blocked (1% BSA, 0.1% Goat Serum, 0.05% Triton in PBS, 1 
hourour, RT). Cells were incubated with rabbit anti-Nrf2 antibody 
(1:500, Cell Signaling, NRF2; D1Z9C; 12721) for 2 hours at RT or 
ON at 4oC in blocking solution in a humidified chamber. After 
washing with blocking solution (3x; 5 minutes, mild agitation), cells 
were incubated with Cy5 labeled goat anti-rabbit polyclonal antibody 
(1:1000, A10523, Life Technologies) in blocking solution (1 hour, RT) 
in a humidified chamber. Cells were washed (3x in PBS 1X) and 
then quickly rinsed in water before mounting (20µL Mowiol, 81381, 
Aldrich) containing Dabco (Dabco® 33-LV, Sigma Aldrich, 290734) 
to which 1 µL 4',6-diamidino-2-phenylindole (DAPI, Life 
Technologies, D1306) was added to stain DNA. Images were 
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acquired on a Yokogawa CSU-X Spinning Disk confocal microscope, 
with a 100x 1.4NA oil immersion objective, using the λ685nm filter 
(Cy5/Far red Filter and λ460nm  (DAPI filter) laser lines and a Andor 
iXon+ EMCCD camara. Images were processed using Fiji software 
(automated analysis for immunofluorescence). Briefly, values of 
Integrated Density per image (around 5 images per treatment with 
~20cells per image) were obtained in the Cy5 channel minus the 
DAPI channel to quantify Cy5 and DAPI co-localization. Number of 
nuclei was counted to normalize to the number of cells (IndDen/Cell). 
 
Immunoblotting 
Hepa 1-6 cells were grown to confluence in 6-well plates (Costar; 
3516), treated with heme (40 µM in HBSS; 1 hour) and/or TNF 
(50ng/mL in DMEM; 2 hours). As positive control, Hepa1-6 cells 
were treated with MG132 (10µM in DMEM; 6 hours). After scraping, 
cells were lysed in SDS Loading Buffer (50µL per well, Cell 
Signaling, 7722) and sonicated (NISONIX Sonicator XL2020) for 2x 
10 seconds on ice with a 5 second interval (intensity 5/6). After 
boiling (95°C; 5 minutes), cells were chilled on ice for 2 minutes and 
centrifuged (full speed at RT for 10 minutes). Supernatants were 
transferred to a new tube and proteins were quantified using 
NanoDrop (NanoDrop 1000, ThermoScientific - Protein 260/280).  
Cell lysates were loaded on a 10% polyacrylamide gel (50-100µg) 
and ran in a SDS-PAGE system (BioRad). Proteins were transferred 
(12V, 90 minutes) to a PVDF membrane (BioRad, 1620177) in a 
Trans-Blot® Turbo™ Transfer System (Biorad). Membranes were 
blocked for in 5% milk solution in TBST (50 mM Tris, 150 mM NaCl 
and 0.05% Tween 20 in water, pH 7.6) for 1 hour at RT. 
Subsequently, membranes were incubated with rabbit anti-Nrf2 
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monoclonal antibody (1:1000, Cell signaling, 12721) in TBST (4°C, 
overnight). For loading control, membranes were incubated with 
mouse anti-actin monoclonal antibody (1:1000, Santa Cruz 
Biotechnology, SC8432). Membranes were washed (3x in TBST) 
and incubated (1 hour; RT) with horseradish peroxidase (HRP)-
conjugated donkey anti-rabbit IgG (H+L) (1:20000, Pierce; 31458) or 
goat anti-mouse IgG (1:1000, Santa Cruz Biotechnology, Sc-2031) in 
milk solution (5% milk in TBST). Peroxidase activity was visualized 
using the ECL Western Blotting Substrate (Pierce; 32209) according 
to the manufacturer’s instructions and of the signal detected on 
photoradiographs (Super RX 18x24 500E, Fujifilm). Digital images 
were obtained with an image scanner followed by Fiji software 
analysis. 
 
Real-Time PCR 
Mice were sacrificed at day 7 and 10 after Pcc infection and at 16 
and 36h after CLP.  Control mice (Pcc day 0, CLP 0h) were not 
subjected to any infection or surgical procedure. Total RNA was 
isolated from the whole liver and kidneys using TRIzol (Invitrogen 
Life Technologies; 15596026) and the RNeasy Mini Kit (RNeasy 
Plus Mini Kit 50, QIAGEN, 50974134). RNA was quantified using 
NanoDrop (NanoDrop 1000, ThermoScientific) and used to 
synthesize cDNA for PCR with Transcriptor First Strand cDNA 
Synthesis Kit (Roche, 04897030001). cDNA samples were 
transcribed into mRNA copies by qRT-PCR using SYBR Green PCR 
mix (iTaq Universal SYBR Green Supermix, BioRad, 1725124). 
Transcript number was calculated from the threshold cycle (Ct) of 
each gene with a 2 DDCT method (relative number) and normalized 
to Arbp0 expression. The primer sequences used were: NAD(P)H 
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quinone dehydrogenase 1 (NQO1) 5’-
CCGAACACAAGAAGCTGGAAGCTG-3’, 5’-
AGGCAAATCCTGCTACGAGCAC-3’; Glutathione S-transferase 
(GST) 5’-AGCCATTCTCAACTACATCGCCAC-3’, 5’-
GGGGGACATAATACCAATTGCCCAATC-3’; Ferritin Heavy Chain 
(FtH) 5’-ATGCCGAGAAACTGATGAAGCTGC-3’, 5’-
TGCACACTCCATTGCATTCAGCC-3’; Heme oxygenase 1 (Hmox1) 
5’-AAGGAGGTACACATCCAAGCCGAG-3’, 5’-
GATATGGTACAAGGAAGCCATCACCAG-3’.  
 
Serology 
Blood samples were collected by cardiac puncture in heparinized 
tubes (Heparina LEO PHARMA 5.000 UI/ml) centrifuged (2×5 
minutes, 1600g, 4°C) and plasma was stored (-80°C). Aspartate 
aminotransferase (AST, EASTR-100), alanine aminotransferase 
(ALT, EALT-100), lactate dehydrogenase (LDH, D2DH-100), 
creatine kinase (CK, ECPK-100), creatinine (DICT-500), urea (DIUR-
100) and glutathione peroxidase (Gpx, EGPX-100) activity were 
measured by spectrophotometry (microplate reader Victor3, Perkin 
Elmer), according to the manufacturers instructions (Bioassay 
Systems). Plasma HMGB1 was measured by ELISA according to 
manufacturer instructions (IBL International; ST51011). DNA was 
isolated from plasma using DNeasy Blood & Tissue kit (Qiagen; 
69504) and DNA concentration was determined by 
spectrophotometer. Mitochondrial DNA in plasma was quantified by 
qRT-PCR using the following primers: Cytochrome b (Cytb) 5’-
CTTAGCCATACACTACACATCAG-3’ and 5’-
ATCCATAATATAAGCCTCGTCC-3’; Mitochondrial encoded 
cytochrome c oxidase III (mt-COX3) 5´- 
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ACGAAACCACATAAATCAAGCC-3´ and 5’-
TAGCCATGAAGAATGTAGAACC-3´, Mitochondrial encoded 
cytochrome c oxidase I (mt-COX1) 5’-
TTCGGAGCCTGAGCGGGAAT-3´ and 5’-
ATGCCTGCGGCTAGCACTGG-3´. NADH dehydrogenase (Nd1) 5’-
AGCCTCAAACTCCAAATACTC-3´ and 5’-
CCCTGATACTAATTCTGATTCTCC-3´. Relative DNA copy number 
in plasma was calculated using the threshold cycle (Ct) for each 
gene in Nrf2-/- mice normalized to Nrf2+/+ mice with a 2^CT method 
(Zhang et al., 2010). Plasma IL-1α, IL-1β, IL-6, TNF-α, IL-10, IL-12, 
IP-10, KC, MCP1, MIP-1α, MIP-1β, MIP2, MIG, RANTES, VEGF 
were measured by Luminex technology using the MAGPIX® system 
(Merck/Millipore) combined with the MILLIPLEX® MAP magnetic 
bead-based multi-analyte panels (Merck Millipore, MCYTOMAG-
70K). Data analysis was performed by MILLIPLEX® Analyst 5.1 
software. Total heme was quantified in plasma using the formic acid 
assay (Kuross et al., 1988). Briefly, samples were diluted in H2O in 
96 well plates (Costar, 3596) and heme concentration was 
determined by comparison to a hemin standard curve (0.5-16 µM in 
H2O). Formic acid (150 µL/well; 98-100%, Merck) was added and 
absorbance measured at λ405nm using a microplate reader (Victor3 
Multilabel Readers, Perkin Elmer). 
 
Statistical Analysis 
Survival curves were represented as Kaplan-Meier plots and 
statistical significance was evaluated with the Log Rank (Mantel-
Cox) test. Comparison of the means of three or more groups was 
performed using one-way ANOVA with a posteriori Tukey test, when 
data assumed Gaussian distribution. Otherwise, a group comparison 
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was carried out, applying the Kruskal-Wallis test, followed by 
pairwise Mann-Whitney U tests, for assessment of significance 
between every two groups with p value adjusted using Bonferroni 
correction. Weight, temperature and parasitemia (line plots) were 
compared between genotypes using pairwise T-tests. Outliers were 
identified by the Grubbs’ test from the GraphPad software, available 
online (http:// graphpad.com/quickcalcs/Grubbs1.cfm). All tests were 
performed using GraphPad v.5.0a software (Prism) and a level of 
significance was set at *p < 0.05, **p < 0.01*, ***p < 0.001, n.s. p> 
0.05. 
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Appendix 1 	
 
 
 
 
 
 
 
 
 
 
 
 
 
“The more unknowable the mystery,  
the more beautiful it is.”  
(David Lynch) 
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Introduction 
Removal of damaged red blood cells (RBC) from the circulation 
occurs through erythrophagocytosis, by tissue-resident 
macrophages in the spleen, liver and bone marrow1–4. The rapid 
removal of damaged RBC from the circulation is important for 
maintenance of iron/heme homeostasis, as the majority of iron 
required to sustain erythropoiesis is derived from senescent RBC, 
and defects in erythrophagocytosis can lead to anemia and iron 
overload4. 
 Previous work has identified receptor-ligand interactions and 
signaling pathways engaged during erythrophagocytosis. Phagocytic 
cells recognize damaged RBC by a range of senescence markers 
such as phosphatidylserine (PS), decreased levels of sialic acid, 
CD47 and binding of autologous immunoglobulins and opsonins5. 
Furthermore, some receptors involved in RBC clearance have also 
been established. Several in vitro studies have shown that the 
recognition of PS on the cell surface by stabilin-2 is important for 
RBC clearance, while others suggested that clearance of agRBC by 
macrophages is likely dependent on scavenger receptors rather than 
specific PS receptors2,6,7. However, the engulfment of RBC under 
physiological conditions is likely to involve a myriad of receptors 
including the Fc and complement-receptors. 
 Upon RBC recognition, macrophage actin cytoskeleton and 
cell surface remodeling takes place allowing the formation of a 
specialized phagosome known as the erythrophagosome. Following 
scission from the plasma membrane, phagosomes undergo a 
maturation process involving a programmed change of their 
membrane and luminal composition resulting from a highly 
coordinated series of sequential membrane fusion and fission events 
with components of the endocytic pathway. Fusion with early- 
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endosomes followed by interactions with late-endosomes and 
lysosomes culminates in conversion of the phagosome into a 
lysosome-like organelle - the phagolysosome. It is within this 
organelle that RBC undergo degradation allowing for the reutilization 
of their components4,8–10. 
 Beyond the involvement of vesicular traffic machinery, some 
autophagy players are also involved in phagolysosome biogenesis, 
including the microtubule-associated protein 1 light chain 3 (LC3), an 
autophagy effector recruited to single-membrane phagosomes in a 
process termed LC3-Associated Phagocytosis (LAP). There is strong 
evidence to suggest that LAP facilitates rapid phagosome maturation 
while contributing to the degradation of engulfed phagocytic particles 
and modulation of immune responses11–13. In contrast to canonical 
autophagy, defined by the formation of a double-membrane 
autophagosome, LAP is associated with the recruitment of LC3 to 
single-membrane phagosomes carrying different types of cargo in an 
Atg5, Atg7 and Beclin1-dependent manner, independently of the 
Mammalian Target of Rapamycin (mTor)-regulated ULK-ATG13-
FIP200 complex11,14. Rubicon, an adaptor protein, was also identified 
as being required for LAP but not for autophagy12. NADPH oxidase-2 
(NOX2) has also been identified as having a LAP-specific role12,15. It 
should be noted that this brief description of phagosomal maturation 
is a gross oversimplification of a highly complex and precisely 
choreographed process. 
 Although several studies have focused on intracellular 
mechanisms of heme trafficking during hemophagocytosis16,17, few 
have addressed the molecular mechanisms underlying maturation 
and degradation of phagosomes containing RBC. We have recently 
shown that phagosomes containing RBC cells mature slower than 
phagosomes containing IgG-opsonized particles18, which is in 
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keeping with the notion that that maturation of the phagosome in 
macrophages depends on the nature of the ingested cargo19. 
 The present study was designed to identify the molecular 
machinery involved in maturation of phagosomes containing RBC. 
Of note, while erythrophagocytosis takes place mainly in 
erythrophagocytic macrophages it can also occur in non-professional 
phagocytes such as hepatic sinusoidal endothelial cells2,20,21. The 
process has some similarities with efferocytosis that occurs in 
pathological states like atherosclerosis and in which the non-
professional phagocytes are smooth muscle cells of the arterial 
intima. In previous work we generated a smooth-muscle cell line that 
stably expressed Fcγ-RIIA receptors and described its use in studies 
of erythrophagocytosis18. Here we report mechanistic details of 
erythrophagocytosis by this non-professional phagocytic cell line as 
well as by primary bone marrow- derived mouse macrophages 
(BMDM). We show that beyond LC3, proteins associated with 
selective autophagy such as p62/SQSTM1 (Sequestosome 1), 
NBR1 (Neighbor of Braca 1 gene) and NDP52 (Nuclear dot protein 
52)22–24 are recruited to phagosomal membranes. The most striking 
phenotype was observed for p62 that associates preferentially with 
phagosomes containing RBC rather than to phagosomes containing 
IgG-opsonized particles. Moreover, we demonstrate that p62 is 
critical for RBC degradation. We also show that erythrophagocytosis 
of RBC drives the translocation of the transcription factor Nuclear 
factor E2-related factor 2 (NRF2) to the nucleus with subsequent up-
regulation of p62 expression levels. In addition, NRF2 absence 
affects RBC degradation and p62 levels suggesting a link between 
these two molecular players in RBC degradation. 
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Results 
The type of phagocytic particle determines the association of 
p62 with phagosomal membranes 
 
We started by studying LAP in the non-professional phagocytes. 
Damaged RBC were prepared by incubation in PBS (20% 
hematocrit) for 4 days at 37°C, a treatment that originates PS-
exposure on the outer leaflet of the RBC membrane, resembling 
what happens to RBC during storage
25
, or eryptosis – a programmed 
cell death mechanism similar to apoptosis in nucleated cells
26
. 
Phagocytosis of RBC was compared to phagocytosis of IgG-
opsonized particles, the most studied phagocytic model. IgG-
opsonized particles are known to be internalized via Fc-receptors. 
After exposing phagocytes to RBC or IgG-coated latex beads, LC3 
association with phagosomal membranes was assessed by confocal 
microscopy after immunostaining the endogenous protein. 
Immediately after phagocytosis, LC3B-II associated with 
phagosomes containing both particles, as evidenced by LC3 rims 
surrounding RBC and opsonized latex beads (Fig. 1A-B ́). Both types 
of phagosomes showed a rapid and transient association of LC3 with 
their membranes, with peaks reaching a maximum of about 80 % 
(78.7 ± 2.3 %) for RBC and about 70 % (71.0 ± 6.5%) for opsonized 
beads, at 0 min chase. These results are in keeping with those 
reported by other groups showing that LC3 can be detected on 
phagosomes shortly after they are formed while LC3- decorated 
autophagosomes can take hours to form
11,27
. LC3 gradually 
dissociated from both types of phagosomes, probably due to 
recycling from the phagosomal membranes (Fig. 1C). Since our 
phagocytic assays were performed in serum-free medium and 
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canonical autophagy is activated under conditions of starvation
28
, we 
tested whether nutrient deprivation was responsible for LC3 
association with phagosomes containing RBC. As shown in Suppl. 
Fig. 1, no differences in the LC3-phagosomal association pattern 
were observed when phagocytic cells were kept in the presence or 
absence of serum, suggesting that LAP machinery is independent of 
the nutritional status of the phagocytes, as previously described
11,13
. 
 Beyond LC3, phagosomal processing and autophagy share 
other players and mechanisms
12,29–32
. Therefore, we attempted to 
ascertain whether there was ubiquitination of phagosomal proteins in 
phagosomes containing both types of phagocytic particles. Indeed, 
phagosomes containing either RBC or IgG-coated beads were 
associated with poly- and/or mono-ubiquitinated membrane proteins 
(Fig. 1D-E ́). The time-course for the appearance of this tag in 
phagosomal membranes (Fig. 1F) showed that shortly after ingestion 
non-professional phagocytes presented a large fraction (around 60% 
for both particles) of phagosomes positive for ubiquitinated 
components with some differences in the kinetics of signal loss over 
the maturation time.  
 To get more insight into the autophagy-related molecular 
machinery involved in phagolysosome biogenesis, we looked at the 
phagosomal acquisition of p62, NBR1 and NDP52. These are 
receptors/adaptors which share the ability to simultaneously interact 
with the lipidated form of LC3, LC3-II, and ubiquitinated substrates
31
. 
We started by testing intracellular distribution of p62 during both 
types of phagocytosis, a universal receptor for ubiquitinated cargo 
under physiological and pathological conditions
7,23,33–35
. Pulse-chase 
experiments revealed that phagosomes containing RBC displayed a 
completely different pattern of p62 association compared to IgG-
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opsonized beads (Fig. 1G-H). Phagosomes containing RBC showed 
similar kinetics for acquisition of p62 and ubiquitinated proteins while 
phagosomes containing IgG opsonized particles showed only 
modest levels of p62 over time (compare Fig. 1I and Fig. 1F). That 
difference was not due to changes in expression levels of total p62 in 
phagocytic cells challenged with the two phagocytic particles as 
confirmed by western blot (Fig. 1J and K).  
 Next, we analyzed the association of NBR1 with phagosomal 
membranes. As seen in Fig. 1L-M’, NBR1 was recruited to both 
types of phagosomes. The time course of NBR1 dissociation from 
membranes of phagosomes that contained RBC was slightly 
different from the time course of NBR1 dissociation from 
phagosomes containing IgG-opsonized particles (Fig.1N). NBR1 
dissociation from phagosomal membranes of IgG-coated beads was 
not observed even for the longest chase time tested. This may be 
due to a compensatory mechanism for the absence of p62 on the 
phagosomal membranes of IgG-coated beads.  
 Finally, we performed immunostaining for NDP52 to assess 
its acquisition by both types of phagocytic particles (Fig. 1O-P’). 
Phagosomes containing IgG-opsonized particles showed a transient 
NDP52 association with around 69% (68.64 ± 1.19%) of positive-
phagosomes at 0 min and about 29% (28.69 ± 12.51%) at 60 min 
chase. Phagosomes containing RBC also showed a transient 
NDP52 association but this autophagy effector remained associated 
with these phagosomes for longer periods of time compared with 
those carrying IgG-opsonized beads (Fig. 1Q).  
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Figure 1. Acquisition of LC3 and autophagy adaptor proteins 
by phagosomes in non-professional phagocytes.  
Phagocytes were challenged with RBC (A, A’, D, D’, G, G’, L, L’, O and O’) 
or with IgG-opsonized particles (B, B’, E, E’, H, H’, M, M’, P and P’) and 
then immunostained for the endogenous LC3B, ubiquitin, p62, NBR1 and 
NDP52 as indicated in the different figure panels. A, B, D, E, G, H, L, M, O 
and P are immunofluorescence images. A’, B’, D’, E’, G’, H’, L’, M’, O’ and 
P’ are the composite of the immunofluorescence image with the phagocytic 
particles visualized in green (RBC stained with CFSE) or by differential 
interference contrast (DIC, IgG-opsonized particles). In A-B’ and G-H’ 
images were acquired at 0 min chase time. In D-E’, L-M’ and O-P’ the 
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images were acquired at 30 min chase time. Arrows indicate positive- and 
asterisks (*) indicate negative- phagosomes for the indicated endogenous 
protein. Bars, 10 µm. C, F, I, N and Q, Graphs showing the percentage of 
positive phagosomes for LC3, ubiquitin and the different adaptor proteins. 
Quantifications were performed in non-professional phagocytes exposed to 
the different phagocytic particles for 30 min and chased for the times 
indicated in the graph abscissa. The values are means ± SEM of, at least, 
three independent experiments. At each time point, at least, 50 
phagosomes were analyzed. *, p<0.05; ***, p<0.001 comparing differences 
between phagosomes with RBC and with IgG- opsonized particles. 
(J) p62 levels in cell lysates of non-professional phagocytes exposed for 30 
min to RBC or to IgG-opsonized particles. α-tubulin was used as loading 
control. (K) Ratio of p62/tubulin of quantified bands in cells exposed or not 
(control) to RBC or IgG-opsonized particles. Three independent 
experiments were performed. 
 
p62 and NBR1 are recruited to the phagocytic cups. 
Since LAP and the autophagy receptors/adaptors tested in this work 
were acquired by the phagosomes at very early stages of 
phagocytosis, we enquired whether they were already present when 
the phagosomes were positive for F-actin. Phagosome formation is 
preceded by a dynamic set of events that induce actin cytoskeleton 
rearrangement in order to support pseudopod extension at sites of 
particle engulfment. This reorganization leads to a localized cup-
shaped protrusion of the plasma membrane, the “phagocytic cup” 
(Figs. 2 and 3). This structure is enriched in actin filaments 
responsible for generation of the forces that alter the local shape of 
the cell surface. In the case of phagocytosis of RBC, membrane 
protrusions are formed upon actin polymerization, with particle 
sinking followed by the formation of the phagosome, through a 
process between complement-mediated phagocytosis and 
micropinocytosis
36 making the visualization of the phagocytic cups 
difficult, as can be observed in Fig. 2A (blue arrows in the XZ view 
point to F-actin). In contrast, in phagocytosis of IgG-opsonized 
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particles, the actin cups are perfectly visualized (Fig. 3).  
 To assess how early the autophagy receptors/adaptors 
associate with the phagocyte particles, phagocytes were exposed to 
RBC and IgG-opsonized beads, fixed and co-stained for F-actin with 
Phalloidin and p62, LC3B-II, NBR1 or NDP52. Notably, p62 was 
found to be present in nascent RBC-containing phagosomes, co-
localizing with F-actin as shown in Fig. 2A and absent in 
phagosomes containing IgG- opsonized particles, Fig. 3A, confirming 
the selectivity of this adaptor for RBC-containing phagosomes (Fig. 
1I). As seen in Fig. 2B and D and Fig. 3B and D, LC3 and NDP52 
were not co-localized with F-actin in any of the phagocytic particles 
incubated with phagocytes suggesting that they were acquired by 
the phagosomal membranes after actin dissociation and when 
phagosome maturation starts. NBR1 was present in the phagocytic 
cups of RBC and IgG-opsonized particles (Fig. 2C and Fig. 3C). 
Thus, during the phagocytic process, p62 and NBR1 were acquired 
earlier that NDP52 and LC3, suggesting that the former proteins 
could be involved in the recruitment of the latter.  
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Figure 2. Co-localization of LC3 and autophagy adaptor 
proteins with F-actin in phagosomes containing RBC.  
Non-professional phagocytes were fed with RBC for 30 min, fixed, and 
stained for F-actin with Phalloidin and for the endogenous LC3 or 
autophagy adaptors. A-D are representative images, obtained by confocal 
microscopy, of cells co-stained for F-actin and p62 (A), LC3 (B), NBR1 (C) 
or NDP52 (D). In A, side views (XZ) are merges of ten vertical sections of 
confocal stacks. Arrows indicate the nascent phagosome positive for F- 
actin (blue) and p62 (red). The first column represents cells stained for F-
actin. The second column represents cells stained for the endogenous p62, 
LC3, NBR1 or NDP52. The third column shows internalized RBC stained 
with CFSE. The fourth column represents merged images of F-actin with 
LC3 or autophagy adaptors and internalized RBC. The regions outlined by 
XZ
mergeA
B
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D
p62
LC3B-II
NBR1
NDP52
CFSEactin
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the boxes are nascent phagosomes. Bars, 10 µm. 
 
 
Ubiquitin is involved in the recruitment of the autophagy 
adaptors to the phagosomal membranes. 
 
Since p62, NBR1 and NDP52 have ubiquitin binding domains and 
ubiquitination occurs during phagocytosis (Fig. 1D-F), we addressed 
the role of ubiquitin in the recruitment of these adaptors to 
phagosomes. First, we determined whether ubiquitin was associating 
with phagocytic cups. As observed in Fig. 4A and B ubiquitin 
associated with phagocytic cups, visualized by F-actin staining, 
suggesting that phagosomal ubiquitination could be involved in the 
recruitment of p62, NBR1 and NDP52. An E1 ubiquitin-activating 
enzyme inhibitor, PYR-41
37 reduced the percentage of ubiquitin-
positive phagosomes containing RBC by 37.0% and by 47.0% for 
IgG-opsonized particles, when compared with control cells (Fig. 4C). 
Although inhibition of ubiquitination by PYR-41 of phagosomal 
membranes was not complete, the effect obtained was sufficient to 
affect the association of p62 (Fig. 4D), NBR1 (Fig. 4E) and NDP52 
(Fig. 4F) with phagosomes containing RBC. The inhibitory effect of 
PYR-41 in the ubiquitination of phagosomal membranes containing 
IgG-opsonized particles was only observed for NDP52 recruitment to 
the phagosomal membranes (Fig. 4E and F). Together, these results 
suggest a new and differentiating role for ubiquitin in phagocytosis.  
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Figure 3. Co-localization of LC3 and autophagy effectors in 
phagocytic cups of IgG-opsonized particles.  
Non-professional phagocytes were fed with IgG-opsonized beads for 30 
min, fixed, and co-stained for F-actin with Phalloidin and for the 
endogenous LC3 or autophagy adaptors. A-D are representative images of 
cells co-stainined for F-actin and p62 (A), LC3 (B), NBR1 (C) or NDP52 (D). 
The first column represents cells stained for F-actin. The second column 
represents cells stained for the endogenous p62, LC3, NBR1 or NDP52. 
The third column shows non-internalized beads stained with an anti-human 
IgG antibody conjugated with FITC. The fourth column represents merged 
images of F-actin with LC3 or autophagy adaptors and the opsonized latex 
beads (external and internal beads visualized by DIC). The regions outlined 
by the boxes are phagocytic cups formed upon the recognition of IgG-
opsonized particles by the Fc-receptors. Bars, 10 µm 
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Figure 4. Functional relevance of ubiquitin on the 
recruitment of autophagy effectors to phagosomes.  
Non-professional phagocytes were fed with RBC or IgG-opsonized particles 
for 30 min, fixed, and co-stained for F-actin and ubiquitin. Representative 
image of a nascent phagosome (A) and a phagocytic cup (B) positive for 
actin (first panels) and ubiquitin (second panels). The third panels show 
internalized RBC labelled with CFSE and non-internalized beads stained 
with an anti-human IgG antibody conjugated with FITC. The fourth panels 
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are composites of the 1st, 2nd and 3rd panels. Arrows and arrowheads 
indicate actin- and ubiquitin- positive phagosome, respectively. Bars, 10 
µm. (C) Effect of PYR-41 in the ubiquitination of both RBC- and IgG-
opsonized particles-containing phagosomes. Phagocytes were cultured and 
treated as described in Material and Methods section. (D) Quantification of 
PYR-41 effect on the acquisition of p62 by RBC- containing phagosomes. 
(E-F) Quantification of PYR-41 effect on the acquisition of the autophagy 
adaptor proteins, NBR1 and NDP52, respectively, by RBC- and IgG-
opsonized particles-containing phagosomes. The values are means ± SEM 
of, at least, three independent experiments. At each time point, at least, 50 
phagosomes were analyzed. *, p<0.05; **, p<0.01 comparing differences 
between adaptor-positive phagosomes containing RBC or IgG-opsonized 
particles in absence and in presence of the inhibitor PYR-41. 
 
 
The role of p62 in phagocytosis of IgG-opsonized particles and RBC 
was compared in mouse BMDM. As shown in Fig. 5A-C the results 
for wild type BMDM exhibit a pattern that is very similar to the one 
described above for non-professional phagocytes with p62 
associated mainly with RBC-containing phagosomes irrespective of 
the total p62 levels (Fig. 5D and E). Similarly, p62 associates with 
phagosomal membranes at very early stages of the phagocytic 
process in BMDM (Fig.5 F). This suggests that the role of p62 is 
conserved in professional and non-professional phagocytes. Due to 
the residual levels of p62 detected in phagosomes containing IgG-
opsonized particles we explored in further detail the role of p62, 
focusing only on RBC-containing phagosomes using mouse BMDM 
silenced for p62 or BMDM from p62 deficient mice (p62-/-). Because 
p62 recruitment to the phagosomal membranes preceded that of 
LC3 (Fig. 2A and B), we assessed the requirement of the former in 
the phagosomal association of the latter. Figure 5G compares LC3 
dissociation from phagosomal membranes of p62+/+ and p62-/- BMDM 
and shows that in p62-/- BMDM LC3 did not dissociate from these 
membranes over the periods of time examined, as compared to 
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p62+/+ BMDM. As p62 can interact with NBR1 and NDP52
38
, we also 
enquired whether recruitment of these autophagy effectors to 
phagosomes was dependent on p62. As shown in Fig. 5H and I, 
neither NBR1 nor NDP52 association with phagosomal membranes 
required p62. Interestingly, the effect of p62 absence in LAP (Fig. 
5G) delaying LC3 dissociation/degradation from the phagosomal 
membranes, seemed to have consequences in phagosome 
maturation and degradation. Phagolysosome biogenesis was 
assessed by the acquisition of the lysosomal membrane marker 
LAMP-1 in p62 silenced cells, in which p62 expression was reduced 
by 70.4 ± 0.08% assessed by qPCR and by Western blot (see Suppl. 
Fig. 2). As can be observed in Fig. 6A-C, the percentage of LAMP-1-
positive phagosomes in p62 silenced cells was lower when 
compared to the phagosomes in control cells (23.8 ± 6.3% compared 
with 50.2 ± 9.1%, respectively, at 0 min chase time). This effect on 
phagolysosome biogenesis can have an impact in the RBC 
degradation which in turn can lead to a defective uptake and 
subsequent damage. Indeed, the absence of p62 imapaired RBC 
degradation (Fig. 6D and E). Control and p62-silenced cells were 
challenged with CFSE- labeled RBC for 15 min and then followed by 
live-cell confocal microscopy for 300 min. In control cells, the 
internalized RBC underwent efficient degradation after 60 min chase 
(assessed by the loss of fluorescence and disappearance of RBC by 
DIC, Fig.6 D and E upper panels, respectively). In contrast, the 
absence of p62 led to the failure of RBC degradation showed by the 
persistence of these RBC even after 300 min chase (Fig. 6D and E 
lower panels). These results suggest that p62 is critical for 
phagosomal maturation and further degradation of RBC.  
 
 
		 155	
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5. Effect of p62 in the recruitment of LC3, NBR1 and 
NDP52 to phagosomes containing RBC cells in BMDM.  
After pulse-chase experiments with RBC or IgG-opsonized particles, WT-
BMDM cells were fixed and stained for p62. (A) WT-BMDM containing a 
p62-positive phagosome at 15 min chase time. (A’) Corresponding merged 
image showing the internalized RBC stained with CFSE. (B) WT-BMDM 
containing p62-negative phagosomes at 15 min chase time. (B’) 
Corresponding merged image showing the internalized IgG-opsonized 
particles in DIC. (C) Quantification of p62 positive-phagosomes. (D) p62 
levels in total cell lysates of WT- BMDM exposed for 15 min to RBC or IgG-
opsonized particles. GAPDH was used as loading control. (E) Ratio of 
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p62/GAPDH of quantified bands in cells exposed or not to RBC, IgG-
opsonized particles. Three independent experiments were performed. (F) 
Representative image of RBC-containing phagosome positive for actin (in 
white) and p62 (in red). Arrow and arrowhead indicate actin- and p62-
positive phagosome, respectively. Quantification of LC3- (G), NBR1- (H) 
and NDP52- (I) positive phagosomes in WT- BMDM (black bars) and p62- 
KO- BMDM (grey bars). The values are means ± SEM of, at least, three 
independent experiments. At each time point, at least, 50 phagosomes 
were analyzed. **, p<0.01; ***, p<0.001 comparing differences between 
p62-positive phagosomes containing RBC and IgG-opsonized particles or 
differences between of LC3-positive phagosomes in WT- and p62-KO-
BMDM. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. Functional relevance of p62 in RBC degradation.  
After pulse-chase experiments with RBC, control- and p62-silenced BMDM 
were fixed and stained for LAMP- 1. (A) Control-BMDM containing LAMP1-
positive and LAMP1-negative phagosomes at 0 min chase time. (B) p62-
KD-BMDM containing a LAMP-1-negative phagosome at 0 min chase time. 
(A ́, B’) Corresponding merged images showing the internalized RBC 
stained with CFSE. Arrow indicates a LAMP-1-positive phagosome and 
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asterisks (*) indicate LAMP-1-negative phagosomes. (C) Quantification of 
LAMP-1-positive phagosomes in WT-BMDM (black bars) and p62-KD-
BMDM (grey bars). The values are means ± SEM of, at least, three 
independent experiments. At each time point, at least, 50 phagosomes 
were analyzed. *, p<0.05, comparing differences between WT- and p62-
KD-BMDM. (D, E) Time-lapse experiments of WT- and p62-KD- BMDM 
challenged with CFSE labeled-RBC for 15 min (0 min chase time) and 
followed for 300 min further to assess phagosome degradation. Phagosome 
degradation (D) was measured by the disappearance of fluorescence and 
the phagosome assessed by DIC (E). Bars, 10 µm. The values are means ± 
SD of 10 different phagosomes. **, p<0.01; ***, p<0.001 comparing 
differences between WT- BMDM and p62-KD-BMDM. (E) DIC images at 0 
min and 240 min chase time of WT- BMDM and p62-KD-BMDM. Arrows 
point to RBC- containing phagosomes. 
 
 
Erythrophagocytosis is associated with p62-dependent NRF2 
activation. 
The transcription factor NRF2 that under cellular stress conditions, 
namely oxidative stress, is translocated to the nucleus and promotes 
transcription of several genes responsible for cytoprotection
39
. Under 
basal conditions NRF2 is ubiquitinated by Kelch-like ECH-associated 
protein 1 (KEAP1)-Cul3-E3 ubiquitin ligase complex and targeted to 
the 26S proteasome for degradation. Oxidative stress represses 
KEAP1 binding to the Cul3–Rbx1 complex, allowing newly 
transcribed NRF2 to undergo nuclear translocation and to trigger the 
transcription of effector genes providing metabolic adaptation to 
oxidative stress
39–41
NRF2 can also become activated via a non-
canonical mechanism: phosphorylation of Ser351 of the KIR (Keap1-
interacting 8 region, aa 346–359) of p62 causing p62's affinity for 
KEAP1 to significantly increase
42
. Once stabilized, newly transcribed 
NRF2 translocates to the nucleus where it heterodimerizes with 
other basic leucine zipper transcription factors, and it upregulates 
genes containing an antioxidant response element (ARE) in their 
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promoter
43–45
.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(Figure continues on the next page) 
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Figure 7. NRF2 is critical for RBC degradation in BMDM.  
WT and p62-KD-BMDM were fed with CFSE-stained RBC for 30 min and 
then chased for 120 min or fed for 180 min. (A) Translocation of NRF2 into 
the nucleus in WT- and in p62-KD-BMDM, assessed by immunostaining, in 
the absence (first row) or upon incubation with RBC (second and third 
rows). The second row represents NRF2-nuclear translocation in WT-
BMDM. The third row represents NRF2-nuclear translocation in p62-KD-
BMDM. NRF2 staining is represented in red, nucleus in green and 
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internalized RBC in cyan. The last panels are merged images. Bars, 10 µm. 
(B) Quantification of NRF2 nuclear translocation expressed as a ratio of the 
fluorescence intensity between the nucleus and the cytoplasm. *, p<0.05 
comparing differences between NRF2 fluorescence in WT-BMDM and p62-
KD-BMDM challenged with RBC. (C-F) WT- and NRF2-KO-BMDM were 
challenged with RBC for 15 min (0 min chase) and then chased for the 
indicated times in the figures. (C) Quantification of p62-positive 
phagosomes after fixation and immunostaining for the endogenous protein. 
(D) p62 levels in total cell lysates of WT- and NRF2-KO-BMDM, for short 
time points. GAPDH was used as loading control. (E) Ratio of p62/GAPDH 
of quantified bands in cells exposed to RBC. Three independent 
experiments were performed. (F) WT- and NRF2-KO-BMDM were 
challenged with RBC for 30 min and then chased for 120 min or fed for 180 
min. The expression of p62 gene was assessed by RT-qPCR. Data were 
normalized to the endogenous Hprt and Pgk1 genes. The values are means 
± SEM expression levels of three independent experiments, each measured 
in two technical replicates. *, p<0.05. (G) Quantification of LAMP-1-positive 
phagosomes after fixation and stained for LAMP-1. The values are means ± 
SEM expression levels of three independent experiments, each measured 
in two technical replicates. *, p<0.05. (H, I) Time-lapse experiments of WT- 
and NRF2-KO-BMDM challenged with CFSE labeled-RBC for 15 min (0 min 
chase time) and followed for 300 min further to assess phagosome 
degradation. Phagosome degradation was analyzed as described in the 
legend of Fig.6. The values are means ± SD of 10 different phagosomes. *, 
p<0.05; **, p<0.01; ***; p<0.001 comparing differences between WT- and 
NRF2-KO-BMDM. (H) DIC images at 0 min and 180 min chase time of WT- 
and NRF2-KO-BMDM. Arrows point to RBC-containing phagosomes. 
 
 
 
 To get more mechanistic insights concerning the role of p62 
in erythrophagocytosis we questioned whether erythrophagocytosis 
was associated with NRF2 nuclear translocation and whether this 
was dependent on p62. As observed in Fig. 7A and quantified in Fig. 
7B, NRF2 translocated to the nucleus only in cells that have 
internalized RBC. This occurred later in the phagocytic process, 
reaching maxima at 30 min pulse followed by 120 min chase or at 
180 min phagocytosis of RBC suggesting that the translocation of 
this transcription factor occurs only after fusion of phagosomes with 
		 161	
lysosomes and when RBC degradation was already occurring (Fig. 
6C and D). The fluorescence intensities ratio of NRF2 on nuclei and 
cytoplasm was roughly twofold in WT-BMDM exposed to RBC 
compared to unstimulated controls (Fig. 7A and B). Interestingly, in 
absence of p62, NRF2 translocation to the nucleus was reduced by 
50%, when compared with control cells (Fig. 7A and grey columns in 
B). Next, we assessed the role of NRF2 on phagosomal maturation 
and RBC degradation, using BMDM from Nrf2 deficient (Nrf2-/- mice. 
Through the entire maturation process the percentage of p62-
positive phagosomes in Nrf1-/- BMDM was reduced (Fig. 7C) when 
compared with Nrf2+/+ BMDM. This result could be attributed to the 
lower levels of p62 in Nrf2-/- BMDM when compared with Nrf2+/+ 
BMDM as shown in the Western Blot (Fig. 7D) and quantified in Fig. 
7E. Thus, in erythrophagocytosis, p62 was required for NRF2 
nuclear translocation and once there, this transcription factor 
controlled the levels of the former. Finally, we assessed whether 
NRF2 nuclear translocation during erythrophagocytosis was 
associated with p62 transcription (Fig. 7F). p62 expression increased 
after NRF2 translocation and absence of NRF2 showed a very 
significant effect on p62 levels (5.93 ± 2.23 versus 1.31 ± 1.23) at 
180 min erythrophagocytosis. Altogether, these results strongly 
suggest the existence of a positive feedback between NRF2 and 
p62.  
 Transport of RBC-containing phagosomes to the lysosomes 
was only slightly affected in Nrf2-/- BMDM when compared with 
Nrf2+/+ BMDM (Fig. 7G), while the effect on RBC degradation was 
very striking (Fig. 7H and I). These two outcomes were similar to the 
results obtained in p62 silenced BMDM (Fig. 6D and E) suggesting 
that p62 and NRF2 are involved in the same pathway.  
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Figure 8. NRF2-target genes expression upon 
erythrophagocytosis for long time points.  
WT and NRF2-KO-BMDM were challenged with RBC for 30 min and then 
chased for 120 min or fed for 180 min. The expression of HO-1 (A), SOD2 
(B) genes was assessed by RT-qPCR. Data were normalized to the 
endogenous Hprt and Pgk1 genes. The values are means ± SEM 
expression levels of three independent experiments, each measured in two 
technical replicates. *, p<0.05. (C) Working Model: Our model suggests that 
degradation of RBC by macrophages is dependent on p62/NRF2 signaling 
pathway. p62 is recruited to RBC-containing phagosomes shortly after 
erythrophagocytosis. Then, after phagolysosome formation NRF2 is 
translocated to the nucleus. This translocation leads to its activation and to 
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the increase in HO-1, p62 and SOD2 expression. These molecular 
machinery leads to an oxidative stress impairment promoting RBC 
degradation. 
 
 
Since heme is a pro-oxidant molecule, we tested the involvement of 
NRF2 in the transcription of anti-oxidant genes, including 
thioredoxin-1, ferritin, glutathione S-transferase, peroxidoxin-1, heme 
oxygenase 1 (Hmox1), catalase, superoxide dismutase (SOD) 1 and 
2. Among these, only the expression of HO-1 and SOD2 were 
increased after NRF2 translocation in BMDM challenged with RBC 
(Fig. 8A and B, black bars). As observed in Fig. 8A, in the absence 
of NRF2 (grey bars) the expression levels of Hmox1 were reduced 
compared to WT-BMDM (black bars), after erythrophagocytosis. 
Although no statistical significances were observed for SOD2 gene 
expression (Fig. 8B), it was possible to see a slight difference at 180 
min pulse time in Nrf2-/- BMDM when compared with Nrf2+/+ BMDM. 
Thus, the involvement of NRF2 on HO-1 and SOD2 expression can 
be attributed to the intracellular release of potentially pro-oxidant 
labile heme, which occurs after RBC degradation within the 
lysosomes. Accordingly, we conclude that NRF2 is both part of the 
machinery required for RBC degradation as well as for the anti-
oxidative response.		
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Supplementary Figure 1. Association of LC3 with 
phagosomal membranes in the absence of serum. 
Quantification of LC3B-II-positive phagosomes in non-professional 
phagocytes incubated in medium supplemented (black bars) or not/starved 
(grey bars) with serum, exposed to RBC and chased for the indicated times. 
The values are means ± SEM of, at least, three independent experiments. 
At each time point, at least, 100 phagosomes were analyzed. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Figure 2. Assessment of p62 silencing in 
BMDM.  
0 15 45 60
0
20
40
60
80
100
With serum Without serum
Chase time (min)
LC
3B
-II
 - 
Po
si
tiv
e 
Ph
ag
os
om
es
 (%
)
p62
GAPDH
Control p62-siRNA
A
B
Control p62-siRNA
0.0
0.5
1.0
1.5
***
p6
2 
m
R
N
A
 fo
ld
 c
ha
ng
e
(t
o 
co
nt
ro
l)
62
37
kDa
		 165	
(A) p62 mRNA fold change in knockdown versus control cells (transfected 
with scramble RNAi) was determined by RT-qPCR. Data were normalized 
to the endogenous HPRT and PGK1 genes. The values are means ± SEM 
expression levels of four independent experiments, each measured in two 
technical replicates. ***, p<0.001 comparing differences between scramble 
and knockdown cells. (B) Western Blot of p62 expression levels in 
knockdown versus control cells (transfected with scramble RNAi). GAPDH 
was used as loading control. 
 
Discussion 
While erythrophagocytosis is critical to the regulation of iron/heme 
metabolism and maintenance of homeostasis our understanding of 
the molecular processes underlying the maturation of phagosomes 
containing RBC and their subsequent degradation by 
hemophagocytic macrophages is quite rudimentary. In this work we 
provide some new insights into the biogenesis of phagolysosmes 
containing RBC, their maturation, and the ordered degradation of 
RBC in both non-professional and professional phagocytes. We 
show that the process is complex and involves a convergence of 
endocytic and autophagic processes. When RBC are phagocytosed, 
p62 and NRF2 are critical for phagolysosome biogenesis and 
degradation. Our findings also show that beyond the involvement of 
LC3, other components of the selective autophagy machinery such 
as NBR1, NDP52 and p62 are also recruited to the single membrane 
phagosomes.  
 Among the selective autophagy machinery tested, the most 
interesting outcome was observed for p62. This protein is recruited 
mostly to phagosomes carrying RBC but very weakly to phagosomes 
containing IgG-opsonized particles, suggesting not only that it has a 
negligible role in Fc-mediated phagocytosis but also the existence of 
different types of LAP. The fact that these results were observed in 
both non-professional and professional phagocytes suggests a 
conserved role of p62 in RBC-containing phagosomes maturation 
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and degradation. p62 associates with phagosomal membranes at 
very early stages of the RBC-phagocytic process, co-localizing with 
F-actin. We attempted to understand what signals the association of 
p62 with the phagocytic cups. Among other domains, p62 has a 
LC3-interacting motif (WXXL/I) called the LC3 recognition sequence 
(LRS) or the LC3-interacting region (LIR) as well as ubiquitin binding 
domains
22,46,47
. Our results indicate that p62 is not recruited to 
phagosomal membranes via interaction with LC3 since this protein 
associates with the phagosomal membranes after p62 and when F- 
actin is no longer detected on phagosomes. Using a 
pharmacological approach, we found that the recruitment of p62 
might rely, at least in part, via the interaction of its ubiquitin-binding 
domain with ubiquitinated components of the phagosomal 
membranes.  
 The absence of p62 affects phagolysosome biogenesis with 
striking effects on RBC degradation. Though p62 has been shown to 
mediate intracellular xenophagic degradation of bacteria that 
undergo ubiquitination in response to their escape from phagosomes 
and subsequent formation of a double membrane organelle33,35,48, to 
our knowledge this is the first time that the requirement of p62 for 
phagocytic cargo degradation within a single membrane organelle is 
reported. Interestingly, when RBC within the phagolysosome start to 
be degraded, NRF2 translocates to the nucleus. The translocation of 
this transcription factor is p62-dependent and in its absence RBC 
degradation is blocked suggesting that p62 and NRF2 act together to 
degrade these phagocytic particles. We enquired how and why p62 
and NRF2 interact upon erythrophagocytosis. In xenophagy, p62 is 
translocated to autophagosomes containing invasive Salmonella 
leading to Ser351 phosphorylation in the KIR motif, enhancing the 
interaction between p62-KEAP1 and consequently NRF2 
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translocation49. Furthermore, under amino acid rich conditions the 
mammalian Target of Rapamycin Complex 1 (mTORC1) has been 
identified as one of the kinases responsible for the phosphorylation 
of p6242. Interestingly, NRF2-target genes are induced at the same 
time that autophagosomes entrap the microbes49. Our data, 
however, reveal a different sequential dynamic of p62 and NRF2 in 
response to RBC engulfment. In erythrophagocytosis, p62 
associates with phagosomal membranes at very early stages while 
NRF2 is activated later. We propose that once the RBC starts to 
degrade in the phagolysosome, and their contents are imported into 
the phagocyte cytosol for storage or recycling, phosphorylation of the 
p62 residue Ser351 occurs, through an unknown mechanism, 
culminating with NRF2 translocation to the nucleus and induction of 
some of its transcriptional targets (Fig.8C). In erythrophagocytosis, 
we could detect the up-regulation of three well-known NRF2-target 
genes: p62, Hmox1 and SOD2. The results obtained for p62 confirm 
the positive feedback that exists between NRF2 and p62 that has 
been already reported for other experimental settings43–45. The up-
regulation of the other two genes could result from the products of 
RBC degradation and reactive oxygen species formation. In 
erythrophagocytic macrophages, RBC processing is followed by 
heme release from hemoglobin and its subsequent translocation 
from the phagolysosome lumen into the cytoplasm, via a mechanism 
assisted by the heme responsive gene 1 transporter (HRG1)50,16,51. 
Once in the cytosol, the heme catabolism enzyme HO-1 releases 
iron from the protoporphyrin ring for storage or reuse. Thus, the 
increase in concentration of cytosolic heme may explain the increase 
of HO-1 expression. Besides iron extraction from protoporphyrin, 
HO-1 generates equimolar amounts of biliverdin and carbon 
monoxide (CO), two anti-oxidant molecules52,53. SOD2 up-regulation 
could be explained by an attempt of the macrophages to scavenge 
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mitochondrial superoxide and thereby lower oxidative stress. 
Overproduction of reactive oxygen species has been described to be 
linked to impaired lysosomal function resulting from changes in 
cysteine residue of the Atp6v1a1 subunit of vATPase and its 
subsequent failure in acidifying the lysosomes54–56. Since lysosomal 
pH is a key determinant of lysosomal enzyme activity this could 
explain why in the absence of NRF2 or p62, RBC are not degraded. 
 Finally, some autophagy genes (such as Ndp52 and LC3B) 
as well as Lamp were demonstrated to be upregulated by the NRF2 
signaling pathway57 which in turn can contribute to the rapid 
degradation of RBC reinforcing the critical role of NRF2 in this 
process. 
 Although how the p62/NRF2 pathway modulates the 
degradation of RBC is far from being elucidated, with this work we 
reinforce the view that this non-canonical signaling pathway is 
activated in the absence of oxidative stress or under autophagic 
conditions43–45,58,59. Furthermore, we were able to identify new 
molecular machinery involved in erythrophagocytosis of RBC, 
opening new avenues for specific targeting and modulation of this 
process. This new knowledge may have a critical role in a number of 
hemolytic disorders associated with defects in RBC function that can 
lead to premature RBC senescence, such as sickle cell disease. 
Finally, as PS-exposure on the outer surface of cells is a 
characteristic of eryptosis and apoptosis, our findings will possibly 
help to understand in detail the process of apoptotic cells clearance 
and why this mechanism fails in atherosclerosis and 
neurodegenerative diseases.  
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Materials and Methods 
 
Cell culture 
 Rabbit vascular smooth muscle cells, used as a non-
professional phagocytic cell line, were from ATCC (Manassas, VA, 
USA) and maintained in RPMI-1640 medium (Invitrogen, Carlsbad, 
CA, USA) containing 10% FBS and 100 U/mL antibiotics. Cells were 
grown in a humidified incubator at 37oC under 5% CO2 atmosphere. 
Cells stably expressing Fcγ-RIIA were generated as described 
before18,60. Cells were plated in 24-multiwell plates at a density of 30   
103 cells per well and grown on glass cover slips for 24 h. For 
experiments with the E1 inhibitor PYR-41 (Calbiochem, San Diego, 
CA, USA), 20   103 cells were plated per well and 24 h after, the 
drug was added. L929 cell line (kindly provided by Prof. Ira Tabas, 
Columbia University, NY, USA) was cultured to produce L-cell 
conditioned media (LCCM) enriched in M-CSF to differentiate 
monocytes into macrophages, as previously described61. 
 Bone marrow-derived macrophages (BMDM) were obtained 
from 8-10 week old C57BL/6J wild-type (WT), p62-knockout (kindly 
provided by Prof. Herbert Virgin, Washington University School of 
Medicine, St. Louis, MO, USA) and NRF2-KO mice. Primary 
macrophages were maintained as described 62, but in RPMI- 1640 
medium, containing 10% FBS heat inactivated and 30 % LCCM. 
 Mice were bred and maintained under specific pathogen-free 
(SPF) conditions, according to protocols approved by local (Instituto 
Gulbenkian de Ciência) and national (Portuguese Official Veterinary 
Department; Direcção Geral de Veterinária) ethics committees 
according to the Portuguese (Decreto-Lei 113/2013) and European 
(Directive 2010/63/EU) legislations. C57BL/6 NRF2-/- mice were 
provided by the RIKEN BioResource Center (Koyadai, Tsukuba, 
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Ibaraki, Japan). C57BL/6J wild-type and NRF2-/- mice were co-
housed from weaning (3-4 weeks old) to the date of the experiments. 
Red blood cells (RBC) were obtained from human blood collected 
from healthy volunteers at CNC and CEDOC. Written informed 
consent was obtained from all volunteers and approved by the 
Ethical Review Board of the Faculty of Medicine of the University of 
Coimbra and NOVA Medical School. RBC were isolated and aged as 
described before18. 
 
Phagocytosis and phagosomal maturation assays 
Aged RBC (RBC) and IgG-opsonized latex beads were prepared as 
described before18 as were phagocytosis and phagosomal 
maturation assessment (pulse-chase) experiments. In pulse-chase 
experiments the pulse time was 30 min for non-professional 
phagocytes and 15 min for BMDM, followed by the chase times 
indicated in the graphs abscissa. Phagocytosis experiments with 
PYR-41 were performed as follows: the inhibitor was added to 
phagocytes at final concentrations of 5 and 10 µM, for experiments 
with RBC and IgG-opsonized particles, respectively, overnight. PYR-
41 was present throughout the pulse-chase experiments. When the 
purpose of the experiment was the visualization of phagocytic cups, 
the phagocytic cells were challenged with phagocytic particles 
without synchronization and without lysis of RBC. 
 
RNAi experiments 
 To knockdown p62 also known as (SQSTM1 or 
Sequestosome) in BMDM, a siRNA smart pool against p62 and a 
non-targeting sequence siRNA, scramble, (control) were used (GE 
Dharmacon, Lafayette, CO, USA). BMDM were transfected with 
Lipofectamine RNAiMAX (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturer’s instructions. Experiments to assess RBC 
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degradation were performed 72 h after transfection with siRNAs. 
 
Immunofluorescence and microscopy 
 Monoclonal antibodies used were: Lysosomal associated 
membrane protein-1 (LAMP-1) (1:50, Hybridoma Bank, Iowa City, IA, 
USA), Neighbor of BRCA1 gene1 [NBR1, (1:80, Abnova, Heidelberg, 
Germany)] and Nuclear factor (erythroid-derived 2)-like 2 [NRF2, 
(1:50, Cell Signaling, Danvers, MA, USA)]. Polyclonal antibodies 
used were: LC3B-II (1:100, Cell Signaling, Taipei, Neihu, Taiwan), 
p62 C-term (1:80, Abgent, San Diego, CA, USA), Nuclear dot protein 
52 [NDP52, (1:80, Abcam, Cambridge, UK)], and Ubiquitin (1:50, 
DAKO, Via Real Carpinteria, CA, USA). For immunoflourescence 
(IF), cells were fixed with 4% PFA for 30 min, permeabilized using 
0.1% Triton X-100 (with 200 nM glycine) for 30 min and blocked with 
0.5% Gelatin from cold water fish skin in PBS for 30 min. The 
exception was for LAMP-1 staining in which cells were permeabilized 
using methanol for 10 min and for NRF2 in which permeabilization 
and blocking were performed with 0.25% Triton X-100 and 1% 
BSA/10% FBS in 1X PBS/0.1% Tween-20, respectively. Then, the 
cells were incubated with the appropriate primary antibody for 90 min 
at room temperature (RT), followed by incubation with secondary 
antibody (1:800, from Jackson Immunoresearch, West Grove, PA, 
USA) for 1 h at RT. For visualization of phagocytic cups, phalloidin 
conjugated with Cy5 (1:100, Invitrogen), to stain F-actin, was added 
with the secondary antibodies. Stained samples were mounted with 
Mowiol/DABCO (Calbiochem) and analyzed by using a laser 
scanning confocal microscope (Carl Zeiss, Jena, Germany, LSM 510 
software) or a Zeiss Cell Observer with a 63× oil immersion objective 
(NA = 1.30). The images were analyzed by using LSM Image 
Browser, Image-J software or Zen software. For live-cell imaging, 
BMDM were seeded in 35 mm glass bottom microwell petri dishes 
		 172	
(MatTEK Corporation, Ashland, MA, USA) after differentiation and 
p62-silencing, BMDM were incubated for 15 min with RBC. After this 
time, non-internalized cells were lysed and the disappearance of 
Carboxyfluorescein-diacetate-Succinimidyl Ester (CFSE) 
fluorescence intensity was followed as a function of time under a 
Carl Zeiss LSM 710 META laser scanning confocal microscope 
(ZEN software) using a 63× oil immersion objective (NA = 1.30), at 
37°C in CO2-independent medium. Fluorescence intensity of RBC 
containing phagosomes at 15 min pulse was normalized to 100. 
 
Quantitative PCR 
p62, SOD2 and HO-1 were assessed by quantitative real-time PCR 
(qPCR). Total RNA was isolated using the NZY Total RNA Isolation 
kit (NZYTech, Lisbon, Portugal), and 300 ng were reverse 
transcribed with iScript® cDNA synthesis kit (Bio-Rad, Hercules, CA, 
USA), according to the manufacturer’s protocols. 
Primers sequence: p62, Forward 5 -́ 
GTCTTCTGTGCCTGTGCTGGAA -3 ́, Reverse 5 -́ 
TCTGCTCCACCAGAAGATCCCA -3 ́; HO-1, Forward 5 -́ 
AAGGAGGTACACATCCAAGCCGAG -3 ́, Reverse 5 -́ 
GATATGGTACAAGGAAGCCATCACCAG -3 ́; SOD2, Forward 5 ́ - 
TAAGGGTGGTGGAGAACCCAAAGGAG -3 ́, Reverse 5 -́ 
TTATTGAAGCCAAGCCAGCCCCAG -3 ́; Pgk1, Forward 5 -́ 
ATGGATGAGGTGGTGAAAGC -3 ́, Reverse 5 -́ 
CAGTGCTCACATGGCTGACT-3 ́. Hypoxanthine 
phosphoribosyltransferase 1, Hprt1, (QIAGEN, Hilden, Germany) 
and Pgk1 (Sigma-Aldrich, St.Louis, MO, USA) were used as 
housekeeping genes. The p62, SOD2 and HO-1 mRNA levels were 
calculated by the Pfaffl method and normalized to both Hprt1 and 
Pgk1 mRNA levels. 
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Western blot 
 For preparation of the total protein cell lysates, cells were 
lysed and blotted as described 63. The antibodies incubated in TBS 
were: mouse p62 primary antibody (Clone 2C11, Abnova, 
Heidelberg, Germany) and ECL mouse HRP-conjugated secondary 
antibody (GE Healthcare, Little Chalfont, UK); mouse α-Tubulin 
primary antibody (Sigma-Aldrich) and Goat Anti-mouse HRP-
conjugated secondary antibody (Bio- Rad, Hercules, CA, USA); and 
goat GAPDH primary antibody (Sicgene, Cantanhede, Portugal) and 
Rabbit Anti-Goat HRP-conjugated secondary antibody (Bio-Rad). 
Blots were developed with ECL (GE Healthcare). ChemiDocTM 
Touch Imaging System was used to detect fluorescence and bands 
quantification was performed using Image Lab software (Bio-Rad). 
 
Statistical analysis 
Statistical analysis (t-test or Two-way ANOVA followed by Bonferroni 
post-test) was performed using the GraphPad PRISM software 
version. 5.0. p <0.05 (*), p <0.01 (**) and p <0.001 (***) were 
considered to be statistically significant. 
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“If you can dream it, you can do it. Always remember that this 
whole thing was started with a dream and a mouse.”  
(Walt Disney) 
		 180	
Nrf2 as a master regulator of tissue damage control and 
disease tolerance to infection 
 
Miguel P. Soares*1 and Ana M. Ribeiro* 
 
Biochem. Soc. Trans. (2015) 43, 663-668; 
doi:10.1042/BST20150054 (Adapted)  	
*Instituto Gulbenkian de Ciência, Rua da Quinta Grande, 62, 6, 
2780-156 Oeiras, Portugal; 1To whom correspondence should be 
addressed: Miguel P. Soares; Inflammation group, Instituto 
Gulbenkian de Ciência, Rua da Quinta Grande, Oeiras, Portugal, 
Tel.: +351-214464520, Email: mpsoares@igc.gulbenkian.pt 
 
Key words: Disease tolerance, infection, Nrf2, oxidative stress, 
tissue damage control. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
		 181	
Resistance to infection defines a defense strategy that limits host 
disease severity via immune driven mechanisms that target 
pathogens for expulsion, containment or killing. Disease tolerance 
defines a distinct defense strategy that limits host disease severity 
without however, targeting pathogens1,2,3. Described originally in 
plants4, disease tolerance is operational in flies5,6,7 and mammals, 
including in mice8,9 as well as in humans10. The term disease 
tolerance is used hereby to refer explicitly to the defense strategy 
defined originally in the plant literature1,4, which limits host ‘damage 
to functions and structures4 imposed by infection, without interfering 
with host pathogen load1,4. 
Disease tolerance is regulated by a number of evolutionarily 
conserved stress and/or damage responses. These confer tissue 
damage control, i.e. prevent ‘damage to functions and structures’ 
imposed by infection11,4. Presumably, stress and/or damage 
responses evolved from ancestral forms of life where they provided 
cellular adaptation to environmental changes12. Much like resistance 
mechanisms, these adaptive responses evolved, most probably, 
under the selective pressure imposed by host microbe interactions. 
Resistance mechanisms can elicit, per se, varying levels of 
cellular stress and damage to the host parenchyma, as illustrated for 
innate immune responses associated with the production of reactive 
oxygen species (ROS) and/or reactive nitrogen species (RNS). This 
is coupled to a countervailing oxidative stress response regulated by 
nuclear factor-erythroid 2-related factor 2 (Nrf2), a member of the 
cap’n’collar basic leucine zipper family transcription factor 
characterized structurally by the presence of Nrf2–ECH homology 
domains13. Other members of this family include NF–E2 p45, NRF1 
and NRF313.  
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Mechanisms regulating Nrf2 activation in the context of 
infection  
Engagement of pattern recognition receptors (PRRs) by pathogen-
associated molecular patterns (PAMP) activates Nrf2 in innate 
immune cells such as monocytes/macrophages (Mø). For example, 
lipopolysaccharide (LPS) recognition by toll-like receptor 4 (TLR4) 
triggers the transcrip- tion/expression of the inducible form of nitric 
oxide synthase (iNOS/NOS2), via a mechanism involving the 
adaptor molecule Myd88 (myeloid differentiation primary response 
gene 88) and the transcription factor nuclear factor kappa B (NF-
κB)14. The TLR4–MyD88–NF-κB signal transduction pathway also 
triggers the transcription/expression of the phagocytic NADPH 
oxidase (NOX2/gp91phox)15, which generates intracellular 
superoxide (O2.−). The NO generated by iNOS reacts with O2.− and 
produces peroxinitrate (ONNO−) anions, which targets several thiol-
based (S-H) redox systems, including reactive cysteines in the 
Kelch-like ECH-associated protein 1 (Keap1)12,16,17 (Figure 1). Keap1 
is an adaptor for the cullin (Cul)3– RING (really interesting new 
gene)-box protein (Rbx)1 ubiquitin ligase complex, which targets 
Nrf2 constitutively for proteolytic degradation by the 26s 
proteasome12.  
Under oxidative stress, some of the reactive cysteines of Keap1, 
i.e. Cys151 are targeted by ONNO−, generating thiol oxidation 
products and ultimately forming disulfide bonds18. These alter the 
tertiary structure of Keap1, inhibiting its ubiquitin ligase activity and 
Nrf2 degradation12,16,17. The newly transcribed Nrf2 undergoes 
nuclear translocation and binds to small musculoaponeurotic 
fibrosarcoma (sMaf) transcription factors, including MafF, MafG and 
MafK13, driving the transcription of Nrf2-responsive genes containing 
DNA antioxidant responsive elements (AREs) in their promoter12 
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(Figure 1). In addition, NF-κB also acts directly on the Nrf2 promoter 
to induce Nrf2 transcription12, presumably required to sustain Nrf2-
dependent gene expression (Figure 2). It is now clear that other E3 
ubiquitin ligase complexes contribute to integrate Nrf2 activation 
within different forms of cellular stress12. These include the Skp1 (S- 
phase kinase-associated protein 1)–Cul1–F-box (SCF)–β-transducin 
repeats-containing proteins (β-TrCP) complex (SCFβ-TrCP)19, which 
recognizes the Neh6 (Nrf2-ECH homology 6) domain of Nrf2 when 
phophorylated by the glycogen synthase kinase 3 (GSK3)19. 
Presumably, Nrf2 phosphorylation at the Neh6 domain allows for 
coupling of different forms of stress sensed by GSK3 with Nrf2 
ubiquitination by the SCFβ-TrCP complex and its degradation by the 
26s proteasome12,19 (Figure 1). The HMG (high mobility group)-coA 
reductase degradation 1 (Hrd1) E3 ubiquitin–protein ligase involved 
in endoplasmic reticulum- associated protein degradation (ERAD) 
also controls Nrf2 activation20. Hrd1 targets the Nhe4–5 domain of 
Nrf2 for ubiquitination and degradation by the 26s proteasome20 
(Figure 1). How Hrd1 acts in the context of other components of the 
endoplasmic reticulum stress response, such as the protein kinase 
RNA-like ER kinase 1 (PERK1)21, to regulate Nrf2 is not clear. It is 
worth noting that Nrf2 activity is controlled to a large extent by its 
rate of transcription/expression (Figure 1). This is regulated by 
several transcription factors including NF-κB and Nrf2 itself, as well 
as clock components that impose a circadian control to Nrf2 activity22 
(Figure 1).  
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Figure 1. Control of Nrf2 activation by different E3 ubiquitin ligase 
complexes.  
Acronyms are defined throughout the text. When no longer targeted for 
degradation by E3 ubiquitin ligase complexes, Nrf2 activity is controlled 
mainly by its rate of transcription, with newly transcribed Nrf2 regulating 
gene expression. It is the Keap1–Cul3–Rbx1, Hrd1 E3 ubiquitin ligase and 
SCFβ-TrCP complexes, however that underlies the stress responsive 
nature of Nrf2 activity. 
 
Nrf2 and resistance to infection 
Perhaps the best demonstration that Nrf2 modulates host resistance 
to infection is provided by the observation that deletion of the Nrf2 
allele in mice enhances resistance to Marburg virus infection23. This 
effect is mediated by the Marburg virus encoded VP24 protein, which 
binds the Kelch domain of Keap1 and inhibits the ubiquitin ligase 
activity of the Keap1–Cul3–Rbx1 complex, hence inducing Nrf2 
activation23,24. Several other observations are consistent with the 
notion that viruses induce host Nrf2 activation in vitro, as suggested 
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for Kaposi’s sarcoma-associated herpes virus25, as well as for 
Influenza26,27 and dengue28 viruses. However, the pathophysiologic 
relevance of these observations remains to be elucidated. 
Conversely, other viruses such as hepatitis C virus, down-regulate 
Nrf2 activation via a mechanism impairing its nuclear import through 
delocalization of sMaf proteins29. The impact of this phenomenon to 
the outcome of hepatitis C virus infection is also not clear. 
Intracellular bacteria also modulate Nrf2 activation, as demonstrated 
for Salmonella typhimurium infection in Mø30. Activation of Nrf2 
enforces the transcription/expression of Ferroportin-1, an iron 
exporter that decreases iron cellular content30. This limits Salmonella 
access to iron, restraining the proliferation of this intracellular 
pathogen30. Whether Nrf2 acts under pathophysiologic conditions to 
promote resistance to Salmonella infection is likely, but this remains 
to be formally demonstrated30. Pharmacologic activation of Nrf2 by 
sulforaphane promotes resistance to Pseudomonas aeruginosa31 as 
well as to Plasmodium infection in mice32.  
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Figure 2. Outcomes of Nrf2 activation.  
Upon infection, activation of Nrf2 in different cellular components 
of the immune system acts in an immunoregulatory manner, 
which modulates resistance to infection. Activation of Nrf2 in 
parenchyma tissues provides tissue damage control and disease 
tolerance to infection. Control of Nrf2 activation is i l lustrated in 
the context of a generic E3 ubiquitin l igase complex, detailed 
under Figure 1. 	
Nrf2 and disease tolerance to infection  
The Nrf2 signal transduction pathway can be co-opted to confer 
tissue damage control and disease tolerance to systemic infections. 
One of the mechanisms via which this occurs involves the 
establishment of a functional crosstalk between the gasotransmitters 
nitric oxide (NO) and carbon monoxide (CO), as illustrated for 
Plasmodium infection33,34. When applied pharmacologically both 
NO34,35,36 and CO33,37,38 suppress the development of experimental 
cerebral malaria in mice, a lethal form of severe malaria that 
resembles, in many aspects, human cerebral malaria39. This 
protective effect acts via Nrf2 activation by NO40, presumably via a 
mechanism targeting Keap1 at Cys15112,41. Nrf2 activation induces 
HO-1 expression and the production of CO via heme catabolism by 
HO-1. CO acts as the gasotransmitter suppressing the onset of 
experimental cerebral malaria40. This occurs via a mechanism 
involving the binding of CO to the prosthetic heme group of cell free 
hemoglobin generated during the blood stage of Plasmodium 
infection, preventing heme from participating in the pathogenesis of 
experimental cerebral malaria40,33,37,38. The protective effect exerted 
by the NO->Nrf2->HO-1->CO signal transduction pathway is not 
associated with modulation of host pathogen load, suggesting that 
the cross talk established between these two gasotransmitters 
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confers disease tolerance to Plasmodium infection via a mechanism 
regulated by Nrf21,40. 
 Presumably, the mechanism via which Nrf2 confers tissue 
damage control and disease tolerance to malaria also involves the 
expression of Nrf2-responsive genes regulating heme/iron 
metabolism42. These include the iron storage protein Ferritin H chain 
(FtH)43,44, which confer tissue damage control and disease tolerance 
to malaria in mice10. There is further evidence that argues strongly 
for the central role of the Nrf2 signal transduction pathway in the 
establishment of disease tolerance to Plasmodium infection. In a 
similar manner to humans carrying hemizygous sickle mutations in 
the beta chain of hemoglobin, transgenic sickle mice are protected 
from cerebral malaria37. This protective effect is exerted 
irrespectively of parasite load, revealing that sickle hemoglobin can 
confer disease tolerance to Plasmodium infection1,37. Sickle 
hemoglobin induces HO 1 through Nrf2, leading to the production of 
CO, which confers disease tolerance to malaria37,38. Whether this 
mechanism explains how sickle hemoglobin protects humans from 
malaria remains to be established but is likely to be the case. It is 
probable that chronic hemolytic episodes driven by red blood cell 
mutations act as a general protective mechanism against malaria in 
human populations, such as illustrated for hemoglobin C45,46, glucose 
6 phosphate dihydrogenase (G6PD) deficiency in males47, β- or α 
thalassemia46 that confer protection against severe anemia caused 
by P. falciparum infection as well as for other red blood cell 
cytoskeleton or membrane protein defects48. Presumably, this 
protective effect is mediated via different mechanisms that converge 
at the level of Nrf2 activation. Therefore it is possible that sickle 
hemoglobin and probably other red blood cell mutations co-evolved 
with the Nrf2 signal transduction pathway to limit disease severity 
associated with these mutations while conferring protection against 
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malaria, such as illustrated for the sickle hemoglobin37. There is 
circumstantial evidence to suggest that Nrf2 confers disease 
tolerance to systemic infections, other than malaria. Namely, Nrf2 is 
protective against endotoxic shock49, severe sepsis triggered by 
polymicrobial infection49 and lung injury induced by Staphylococcus 
aureus infection50 in mice. These salutary effects have been 
associated mainly with immunoregulation but there is no clear 
evidence whether Nrf2 modulates pathogen load in these specific 
experimental settings49. We have experimental evidence confirming 
that Nrf2 prevents the lethal outcome of polymicrobial sepsis in mice, 
without, however, interfering with pathogen load (A. M. Ribeiro and 
S. Weis et al., unpublished observation). This suggests that Nrf2 can 
confer disease tolerance to infection, presumably acting as an 
immunoregulatory transcription factor in innate immune cells, but 
likely also in parenchyma cells to provide tissue damage control, 
although this remains to be fully established. 
 
Mechanisms underlying the protective effect of Nrf2 
against infection 
There is a general consensus that Nrf2 is protective against systemic 
infections, via a mechanism targeting NF-κB and modulating pro-
inflammatory gene expression in Mø49,51 (Figure 2). However, Nrf2 
activation is required to sustain interleukin (IL)-1β secretion in Mø, 
via a mechanism involving NLRP3 (NACHT, LRR and PYD domains-
containing protein 3) driven caspase 1 activation, an essential step in 
the processing of pro-IL-1β towards IL-1β secretion52. This would 
argue that Nrf2 promotes, rather than restrains, inflammation. 
Moreover, Nrf2 induces the expression of the activating transcription 
factor 3 (ATF3) in Mø, an IL-6 repressor that is protective against 
LPS but highly deleterious against bacterial infection53. This 
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suggests that Nrf2 can also act in a deleterious manner in the 
context of systemic bacterial infections (Figure 2). Oxidative stress 
can trigger parenchyma cells to undergo regulated necrosis54, 
leading to tissue damage and organ dysfunction, eventually 
compromising disease tolerance to infection11. Therefore, host 
protective mechanisms that prevent parenchyma cells from 
undergoing regulated necrosis, such as those driven by Nrf2, should 
enforce tissue damage control and disease tolerance to systemic 
infections11 (Figure 2). Presumably, this occurs via the expression of 
Nrf2 regulated effector genes, such as those controlling glutathione 
synthesis/conjugation12,17, heme metabolism, i.e. HO-155,56,57 iron 
metabolism, e.g. FtH58,59, ferroportin-130 and/or lipid peroxidation, 
e.g. biliverdin reductase60. Other mechanisms underlying the 
protective effects of Nrf2 were linked to maintenance of 
mitochondrial function50.  
Trade-off of the stress response given by Nrf2 
Disease tolerance mechanisms do not exert a negative impact on 
pathogens. As such, stress responses underlying disease tolerance 
create a situation in which the infected host, although healthy, can 
transmit the disease. This has probably major consequences on the 
natural selection of genes regulating stress responses, including 
Nrf261. Moreover, stress responses preserve core cellular functions 
at the expense of ‘accessory’ ones62,63,64 and therefore must be 
tightly regulated over time1. Nrf2 is no exception to this rule as 
illustrated by the observation that chronic Nrf2 activation promotes 
tumorigenesis65. 
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Conclusion 
The stress response regulated by Nrf2 probably plays a major role in 
conferring disease tolerance to systemic infections, such as those 
triggered by bacteria infection and leading to severe sepsis or the 
one triggered by Plasmodium infection and leading to severe forms 
of malaria. Viral infections, on the other hand, appear to thrive on 
host Nrf2 activation, as illustrated by a number of examples in which 
induction of Nrf2 activity favours virus proliferation. Given the above, 
it is not clear to what extent the Nrf2 signal transduction pathway 
may be targeted to treat infectious diseases. 
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